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Transcriptional activators play a critical role in regulating gene expression, 
precisely controlling the transcriptional response of their cognate genes in a signal-
responsive fashion. Transcriptional activation occurs when the activator localizes at a 
specific DNA sequence and facilitates the assembly of the transcriptional machinery 
(RNA polymerase II and associated transcription factors) at a gene. Malfunctioning 
transcriptional activators are associated with a significant percentage of human diseases; 
greater than 50% of all cancers, for example, are associated with mutations in the 
transcriptional activator p53. Thus, the development of activator artificial transcriptional 
factors (ATFs) that functionally replicate their natural counterparts is emerging as a 
potential therapeutic strategy.  One of the biggest hurdles to this goal is the lack of 
knowledge about the binding interactions utilized by natural transcriptional activators to 
up-regulate gene expression. The major goal of this work is to delineate the features of 
activator binding interactions in order to develop useful activator ATFs. 
 xiii 
Natural transcriptional activators exhibit a multi-partner binding profile in vitro 
and there is evidence that this is also true in vivo, although the identities of the binding 
partners are unknown. To investigate the feasibility that a single binding interaction could 
lead to transcription function, peptide ligands for the postulated activator target 
Med15(Gal11) were identified through a binding screen. Satisfyingly, localizing these 
ligands to a promoter in S. cerevisiae results in transcription activation that is 
Med15(Gal11)-specific. Activator ATFs constructed with these ligands were not, 
however, as active as natural activators. Activator ATFs with enhanced function could be 
created by incorporating ligands that were able to interact with more than one partner. 
Ligands that interact with both Med15(Gal11) and the SAGA component Tra1 
upregulated transcription to higher levels than those targeting Med15(Gal11) alone. In 
addition, the incorporation of a masking interaction into the activator ATFs led to a 
profoundly positive impact on function. Finally, towards identifying the functionally 
relevant binding partners of transcriptional activators, a nonsense suppression strategy 
was adapted to enable incorporation of photoactivatable, crosslinking amino acids into 
natural transcriptional activators in S. cerevisiae. Crosslinking experiments with Gal4 













Gene transcription is a fundamental cellular process that utilizes a cascade of 
protein-protein, small molecule-protein and protein-DNA interactions.1 Disruption of any 
number of transcription-related interactions present in healthy cells leads to aberrant gene 
expression and often to disease states as varied as cancer and diabetes.2, 3 For example, 
mutations in the transcriptional activator and tumor suppressor p53 that alter its function 
are associated with 50% of all human cancers.4, 5 Replacements of malfunctioning 
transcription factors with functional mimics and molecules that repair defects in these 
pathways will be extremely useful for biomedical applications for treatment of such 
disease states.6-8 In an early advance in this therapeutic arena, scientists at Sangamo 
Biosciences engineered a zinc finger-based transcription factor to induce angiogenesis in 
a mouse model.9 This artificial protein, when expressed in mice, was able to up regulate 
transcription of the VEGF gene leading to an acceleration of experimental wound 
healing. Approaches to develop newer generations of such therapeutic molecules that 
have advantageous stability, delivery and functional properties will have an immense 
positive impact on the feasibility of transcriptional therapies.10-13 However, as outlined in 
this Chapter, there are significant gaps in our knowledge of transcriptional regulation that 
must be filled in order for more effective transcription-targeted therapeutic agents to be 
envisioned. 
 
B. Overview of transcription 
Transcription entails the creation of RNA from a DNA template by the multi-
subunit RNA polymerase holoenzyme and its associated transcription factors.1 In 
eukaryotes, there are 3 types of RNA polymerases. RNA pol I is responsible for the 
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transcription of 28S, 18S, and 5.8S rRNA genes while RNA pol II transcribes all protein 
encoding mRNA and snRNA. The third polmerase, RNA pol III, transcribes 5S rRNA 
and tRNA genes.14-16 The studies presented here deal with regulation of RNA pol II 
transcription leading to mRNA production, which is eventually translated into protein by 
the ribosome. 
Transcription of a particular gene is initiated when, in response to internal or 
external stimuli, proteins known as transcriptional activators localize to specific DNA 
binding sites upstream of the gene.17 Subsequently, activators recruit multiple protein 
complexes that comprise the transcriptional machinery to the promoter in order to turn on 
gene expression.18, 19 
 
B.1 Transcriptional activators 
Transcriptional activators are modular proteins that are minimally constructed of a 
DNA binding domain (DBD) and a transcriptional activation domain (TAD) (Figure 1.1). 
These modules are able to function independently of each other and it is possible to swap 
the TADs and DBDs between two activators.20, 21 In other words, if the TAD of activator 
A is attached to the DBD of activator B, a new functional activator with the gene-
targeting properties of activator B will be created. 
B.1.a DNA binding domain (DBD) 
The DBD provides much of the gene-targeting specificity of the activator because 
it is responsible for localizing the protein to its cognate DNA sequence in the promoter of 
the gene that is to be transcribed. Natural DBDs consist of a wide variety of structural 
folds including zinc fingers, zinc clusters, leucine zippers and the helix-turn-helix motif 
Figure 1.1 Transcriptional activators. a) Activators function by recruiting the 
transcriptional machinery to a gene promoter. b) An activator is minimally constructed of 
two modular domains, a TAD (red) and a DBD (blue) usually linked by an unstructured 
linker region. 
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that are known to interact with DNA with high specificity and with affinities ranging 
from low to high nM.22-25 These interactions are also structurally well characterized, with 
many solid state and solution structures illuminating the details of the protein-DNA 
interactions. For example, extensive conformational and thermodynamic studies with the 
Gcn4 DBD revealed the amino acid residues involved in DNA recognition and how the 
DBD is able to use water molecules to differentially interact with the AP-1 and 
ATF/CREB DNA binding sites (Figure 1.2).26 However, there is no recognition code for 
predicting the DNA binding specificity of a natural DBD.27 Using chromatin 
immunoprecipitation (ChIP)-on-chip techniques combined with in vivo footprinting, it 
has been possible to identify the DNA binding sites of DBDs within the genome, and in 
many cases these have been correlated with gene expression profiles.28-30 From these 
experiments it has been possible to detect all of the genes that are regulated by a 
particular activator.31 However, DBDs do not generally play a role in controlling the level 
to which an activator upregulates a particular gene.17 
 
B.1.b Transcriptional activation domain (TAD) 
The TAD controls the timing and level of upregulation of a particular gene to be 
transcribed. In contrast to the DBD, much less is known about the mechanistic details of 
how this domain functions. There is also little or no sequence conservation within TADs 
across transcriptional activators, so this has limited the ability to predict the location of a 
TAD based on sequence alone.1 Thus in absence of any higher classification, TADs are 
often classified depending on their overall sequence composition as proline rich, 
glutamine/asn rich or acid rich (for examples see Figure 1.3).32-39 More recently, using 
Figure 1.2 Structure of Gcn4 bound 
to DNA.  NMR structure of Gcn4 
bZIP domain (blue) that mediates 
dimerization and DNA binding. bZIP 
consists of a coiled-coil dimerization 
domain-leucine-zipper and an 
adjoining basic region which 
mediates binding to the AP-1 half site 
(shown in gray). Water molecules 
that mediate protein-DNA 
interactions are shown as red dots 
(PDB ID: 2DGC) 
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Figure 1.3 Examples of transcriptional activation domains. TADs are often 
classified based on their sequence composition. Human CAAT box 
Transcription Factor (hCTF) contains a proline (red) rich TAD. The 
Drosophila Antennapedia protein (Antp) TAD contains several glutamine 
(green) residues.  The TAD from the Herpes simplex virus Viral Protein 16 
(VP16) is acid rich.  
the residues commonly found in known TADs, Piskacek and coworkers have developed 
an algorithm based on a 9 amino acid sequence motif that can predict the location of a 
TAD in a given protein sequence.40 Although this algorithm can successfully identify 
TADs in natural activators such as Gal4 and VP16, it also gives rise to false positives and 
further refinements in the selection criteria are required for it to be a general tool to 
predict unknown TADs. 
 
 The largest and most well studied class of TADs is the so called acid-rich class. 
As the name suggests, the name ‘acid-rich’ arose from the preponderance of glutamic and 
aspartic acids found in the domain, an unusual feature. However, mutagenesis studies 
revealed that it is the interspersed hydrophobic amino acids that play a more critical role 
in function. For example, in the acid-rich VP16 TAD it was found that the leucine and 
phenylalanine residues were critical for interactions with transcription proteins and 
cellular function, while individual acidic residues were dispensable.41-48  This has been 
more recently supported by kinetic studies of acidic TAD-target complexes that suggest 
that the overall acidity, but not individual acidic amino acids is critical for an initial 
electrostatic binding event with targets followed by a structural reorganization.49-51 In the 
final complex, the majority of the TAD-target contacts are mediated by hydrophobic 
amino acid side chains. Thus, acidic TADs have been more appropriately renamed 
amphipathic TADs.  
 One property of amphipathic TADs is that they exhibit promiscuous binding 
profiles, interacting at least in vitro with many protein binding partners within and 
 5 
outside of the transcriptional machinery. For example, the TAD of the yeast activator 
Gal4 has more than ten putative binding partners identified through biochemical and/or 
genetic means.52-63 As described in more detail in subsequent sections, it has been 
challenging to validate these interactions using traditional experimental approaches. 
There are thus a wealth of unresolved questions regarding the mechanism by which 
amphipathic TADs activate transcription. For example, it is still unclear as to what are the 
relevant functional targets of amphipathic TADs and how each individual interaction 
correlates to the overall levels of transcription obtained. To further complicate matters, 
TADs often target multiple binding sites on the same protein in vitro and it is unclear 
what the physiological relevance of each of these interactions is.64 
TADs also participate in a number of interactions with partners outside the 
transcriptional machinery that regulate the timing and levels of gene expression. These 
include post-translational modifications such as ubiquitylation, acetylation, 
phosphorylation, sumoylation, neddylation, methylation and glycosylation.65-73 
Additionally, there are also masking interactions that shield a TAD from interacting with 
cellular components until it is required for activation.4, 74 For example, the amphipathic 
yeast activator Gal4 is masked by the repressor protein Gal80.75 Addition of galactose to 
the cell stimulates a conformational change that unmasks the Gal4 TAD, enabling it to 
activate transcription of its cognate galactose-catabolism genes.76 Although the role of 
masking interactions in signaling networks is well-established, it is not clear how these 
interactions impact the level of gene activation by a given activator.  
B.1.b.i TAD Structure 
There is limited structural information on TADs, particularly in the absence of a 
binding partner; to date there are no reported structures of free TADs. The prevailing 
model is that TADs are unstructured in the absence of a binding partner but adopt a 
helical conformation when bound to a target.77, 78 More specifically, the amphipathic 
helix is proposed to be adopted by TADs when they bind targets (Figure 1.4 and 1.6).51, 
79-81 In particular, the hydrophobic face of the helix makes the important contacts while 
acidic residues don’t seem to be important for the primary interaction. A recent NMR 
study of the VP16 TAD in complex with a subunit of the general transcriptional 
machinery component TFIIH also showed that the TAD adopted a 9-residue α helix.82 
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However, there are also suggestions that amphipathic TADs such as Gal4 and Gcn4 may 
form other structures such as a β-sheet, although these investigations were performed 
with free TADs in absence of a binding partner.44, 83  
The best-characterized examples of TAD structure are from complexes with 
masking proteins. In contrast to activator-transcriptional machinery protein complexes, 
these interactions are often of higher affinity and specificity which could possibly explain 
why such complexes have been easier to characterize.75, 84 A well studied example is the 
crystal structure of the p53 TAD in complex with its masking protein mDM2, which 
shows the p53 TAD as an amphipathic helix with the three critical hydrophobic residues 
buried in a hydrophobic cleft in mDM2 (Figure 1.4).85 Notably, the three residues 
important for the masking interaction have also been shown to be important for 
transcriptional machinery interactions and in turn function.45 These findings illustrate that 
masking proteins contact an overlapping set of TAD residues that are important for 
function, perhaps suggesting a role for masking proteins in modulating the activity of 
activators. 
  
Extensive structural information for other TAD-transcriptional machinery 
complexes is still not available because the relevant targets of most TADs have not yet 
been indisputably identified. Moreover, the binding sites on the postulated targets are 
often not known, leaving researchers to structurally characterize activators in complex 
with large protein fragments which further hinders the success of obtaining crystals or 
performing solution-based methods. 
Figure 1.4 Activator-Masking 
protein interaction. Crystal 
structure of the amphipathic 
helical p53 TAD (red) in 
complex with its masking 
protein mDM2 (gray surface). 
The hydrophobic side chains 
are explicitly shown. The 
phenylalanine, leucine and 
tryptophan residues buried in 
the mDM2 cleft are important 
for mDM2 binding and for 
transcriptional activation. 
PDB ID: 1YCR. 
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B.1.b.ii TAD targets 
Over the last three decades, extensive efforts have been invested in identifying the 
targets of transcriptional activators within the transcriptional machinery. Although much 
progress has been made, the identity of the bonafide activator targets is still strongly 
debated.  For example, a new set of targets and thus a new activation mechanism has 
been postulated approximately every 5 years, completely reshaping the way the 
transcriptional community thinks about TAD function (Figure 1.5).11  
Initially, it was thought that activators would function by targeting components of 
the transcriptional machinery that were present at all promoters. Thus, researchers 
focused on components of the general transcriptional machinery and RNA pol II; an early 
candidate was the TATA binding protein (TBP).86, 87 Bolstering this hypothesis were 
studies that correlated TADs’ in vitro binding affinity for TBP with an activator’s cellular 
potency.60, 88, 89 However, it was later shown that TFIIB rather than TBP recruitment was 
important for transcriptional activation by an amphipathic activator.90, 91 Following these 
studies, TFIIB, TFIIH, TFIIA and RNA pol II were suggested as activator targets.92-95 
Nonetheless, it was shown that supplementation of these components in an in vitro 
transcription assay did not stimulate activated transcription and thus other targets were 
probably important for TAD function. 
 
Figure 1.5 A timeline of transcriptional activator targets. During the past three 
decades, many transcriptional machinery complexes and proteins with these 
complexes have been identified as key binding partners of TADs. However, 
significant debate still exists about the relevance of most of these interactions. 
  Proteasome 
 8 
Subsequently, coactivators were identified as activator targets; coactivators were 
defined as proteins or protein complexes that did not interact with DNA but served as a 
bridge between DNA-bound transcription factors and the components of the general 
transcriptional machinery. TFIID and its associated TAFs were the first candidates 
considered in this capacity.96-98 It was proposed that activators could interact with a TAF 
and thereby recruit the entire TFIID complex to the promoter. Although it was shown that 
in vitro activators can stimulate activated transcription in presence of TAFs, genetic 
experiments in yeast that inactivated individual TAFs showed that only a small fraction 
of genes were dependent on TAFs.99, 100  
Concurrently, experiments by several groups led to the identification of another 
complex of proteins that could “mediate” the function of activators in vitro, called the 
Srb/Mediator complex.101-103 Cryo-EM studies with purified yeast Mediator showed a 
modular complex, consisting of a head that interacts with RNA pol II, a middle module 
and a tail region, which was predicted to interact with TADs.104 A series of genetic and 
biochemical experiments in yeast suggested that activators interact with the Mediator 
components Med17(Srb4), CDK8(Srb10), Med15(Gal11), and Med2.57, 59, 65, 105 Further, 
it was shown using genetic experiments that Mediator was required for the function of 
several amphipathic activators such as Gal4 and Gcn4.106, 107 
Interestingly, recent work by Struhl and coworkers has indicated that Mediator 
may not be required by activators at all promoters in yeast.108 They show using ChIP that 
TFIID and not Mediator is recruited to ribosomal and glycolytic gene promoters that 
utilize activators such as Rap1. Thus, it may be that some promoters are dependent on 
TFIID, some are dependent on Mediator and others are dependent on both coactivator 
complexes. Possibly the constitutively active or housekeeping ribosomal promoters 
operate independently of Mediator (and likewise require TFIID). In contrast, tightly 
regulated promoters such as the inducible Gal1 (controlled by Gal4), developmentally 
regulated promoters and activators that respond to environmental stress or non-optimal 
growth conditions (requiring a rapid increase in gene production levels) probably utilize 
contacts with Mediator and TFIID that assist in synergistically recruiting RNA polII and 
the rest of the transcriptional machinery.  
 Finally, to rationalize how activators and other components of the general 
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transcriptional machinery efficiently bound DNA in the context of chromatin, several 
groups investigated whether chromatin-remodeling and modifying enzymes are recruited 
by TADs.109-113 In vitro experiments showed that TADs from Gcn4, Swi5, VP16, and the 
mammalian glucocorticoid receptor could interact with ATP-dependent nucleosome 
remodeling enzymes (Gcn5, SWI/SNF) and it was predicted that remodeling would 
greatly enhance stimulation of transcription from chromatinized templates.114-116 In 
support of this, it was shown that while SWI/SNF activity was not required for the 
activator Gal4 to bind to and activate transcription from nucleosome-free binding sites, 
the complex is required for Gal4 to bind to and function at low-affinity, nucleosomal 
binding sites in vivo.117 Subsequently, cell-based experiments revealed that TADs also 
interacted with components of the SAGA complex, which contains a subset of TAFs (but 
no TBP) as well as enzymes capable of covalently modifying histones.118, 119 For 
example, in vivo FRET experiments from the Green laboratory showed that Tra1, in the 
context of the chromatin modifying complex SAGA was a target of Gal4 and required for 
Mediator recruitment to the upstream activating sequence (UAS) of the endogenous Gal1 
gene.53, 54 Similarly, the mammalian homolog of Tra1, TRRAP, is required for gene 
upregulation by the activators p53 and c-Myc.120, 121 
 The examples listed above are only some of the prominent targets of TADs 
discovered in the last three decades, and there still is no general consensus among targets. 
One of the reasons for this disparity is the limitations of the methods currently used to 
discover TAD targets. Most of the approaches to date are in vitro and their cellular 
relevance is known. For example, the Gal4 TAD binds to the non-transcription protein 
lysozyme in vitro, but this interaction has no functional role in cells; thus in vitro binding 
is not necessarily a good test for identifying a relevant TAD target.122 Further, the current 
cell-based methods involving genetic and formaldehyde-based global crosslinking also 
have limitations (see Chapter 4 for a more detailed discussion).58, 123 Thus, newer 
methods are required to systematically determine activator targets. It is likely that 
strategies that determine the direct targets of activators in the native functional context 
will be particularly useful towards this end. The identification of such physiologically 
relevant protein targets of activators will have profound implications both for the general 
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Figure 1.6 Structure of the 
GACKIX domain of CBP 
bound to MLL and c-Myb. The 
amphipathic helical TADs from 
MLL (green) and c-Myb (blue) 
bind at distinct sites on the CBP 
(gray, surface rendering). The 
hydrophobic residues that make 
key contacts are shown. The 
TADs bind two distinct binding 
sites within the GACKIX 
domain. PDB ID: 2AGH 
mechanistic understanding of transcriptional regulation and for the design and discovery 
of molecules that can modulate transcription.  
B.1.b.iii TAD binding site(s)  
 An additional complicating factor in the analysis of TAD-coactivator interactions, 
is that many coactivators appear to contain multiple binding sites for transcriptional 
activators.107 For example, the mammalian coactivator CBP/p300 has multiple activator 
binding domains (GACKIX domain, CH1 and CH3) and within these domains, activators 
have been shown to target unique binding sites (Figure 1.6).124, 125 Moreover, the 
activator p53 has been shown to interact with GACKIX, CH1, CH3 and IBiD domains 
within CBP/p300 and these individual interactions have different contributions to the 
overall activator function.64 Thus, it is not only important in identifying the relevant 
coactivator targets of TADs, but also the individual binding sites that contribute to 
function.  
 
Current methods to determine coactivator binding sites involve the use of 
mutagenesis to delete portions of coactivators in vitro and in cells.126, 127 However, 
mutagenesis experiments are often difficult to interpret due to pleitropic effects resulting 
from the changes in coactivator conformation and disruption of transcriptional machinery 
complexes. For example, a single point mutant in the coactivator Med15(Gal11) (N342V) 
results is sizable conformational change that enables a new series of Med15-protein 
interactions.128, 129 On the other hand, solution and solid state structures of activators in 
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complex with coactivators are extremely useful in determining activator binding sites, 
however as discussed earlier, they are challenging to obtain.  
Thus, more straightforward approaches to map out all the activator binding sites 
and correlating them to function are required. Determination of binding sites will help in 
further understanding activator function and will also assist in the long term goal of 
developing molecules to regulate transcription by mimicking or inhibiting activator-
coactivator interactions. 
 
C. Activator ATFs 
The modular nature of activators enables the replacement of the TAD and DBD 
with natural and non-natural counterparts leading to the creation of activator artifical 
transcription factors (ATFs).10 Activator ATFs are in high demand for a variety of 
applications in medicine, industry and for mechanistic investigation of transcription (vide 
infra). 
Towards these applications, replacements for the DBDs have been successfully 
developed with protein based DBDs such as DBDs from the endogenous DNA binding 
proteins Gal4 and LexA. Further approaches using designed zinc fingers have also been 
successfully developed.130-133 Non-protein based DBDs such the polyamides, triplex-
forming oligonucleotides (TFOs) and peptide nucleic acids (PNAs) have also been 
designed and used in vitro and in vivo experiments.134-140 On the other hand, there has 
been limited development of novel TAD replacements.141 For instance, the most widely 
used TADs are short sequences derived from existing natural TADs (Table 1.1).  While 
these TADs function well in cell culture, they will have limited use in therapeutic 
applications where proteolysis and cellular delivery are a major concern. Thus, one of the 
long term goals of our research is to develop small molecule TADs that when combined 
with small molecule DBDs will lead to the creation of fully synthetic activator ATFs 
displaying advantageous stability and delivery properties. However, it has been 
challenging to develop small molecules TADs that function with the high levels of 





LexA-Gal4 and Gal4-VP16 Early examples of activator ATF20, 21 
VP2  Optimized peptide sequence from VP16142 
B42 Random E. coli fragments143 
AH peptide Designed to form amphipathic helix144 
Retinoblastoma (RB) peptide ligands Two hybrid to bind RB protein145 
Poly Q and poly P peptides Activity in vitro 36 
ATF14 Peptide sequence from VP16146 
P201  In vivo screen of random octamers peptide 
attached to Gal4(1-100)147 
LexA-GFP fusions random 15mer peptides Activity based selection148 
Gal80bp peptide Phage display against Gal80149 
6000-yeast genes fused to Gal4 DBD 150 
Mammalian cDNA fused to Gal4 DBD 151 
KIX peptide ligands Phage display against KIX152 
KIX peptide ligands  Phage display against KIX153 
RNA Activity based selection 154, 155 
Isoxazolidines (small molecules) Design (active in vitro and in vivo)156, 157 
Wrenchnolol (small molecule) Optimized hit from Screen to inhibit ESX-
Sur2 (active in vitro) 
KIX peptoids In vitro screen against KIX158 
Hydrastine (natural product) Computational screen based on LogP159 
Santonin (natural product) Computational screen based on LogP159 
 
Table 1.1 List of artificial TADs developed to date 
In particular, there are only a handful of small molecule TADs that function to 
upregulate transcription.156, 157, 160 In absence of any other design criteria, these small 
molecule TADs were designed based on the general amphipathic character seen in a 
number of natural activators. While a great advancement in the field, these molecules 
moderately activate transcription in cells and are well suited for purposes that do not need 
extremely high levels of transcriptional activation.159, 161 However, additional functional 
features are required to improve their activity to levels similar to potent natural activators 
like p53 or Hif1α to use them as analogous functional replacements. 
The primary reason for the lack of small molecules that function with high levels 
of activity is the incomplete understanding of the features natural activators use to obtain 
their cellular activity. Methods to probe the importance and determine the identity, 
thermodynamic and kinetic parameters of individual activator-target interactions will be 
particular useful for understanding the contribution of each interaction towards potency. 
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In the long term, deciphering all the features utilized by natural activators for their overall 
function will facilitate the incorporation of these features into the design of small 
molecules leading to potent activator ATFs.  
C.1 Applications of activator ATFs 
One of the most important applications of activator ATFs is for the development 
of transcription-based therapeutics to restore the proper function of malfunctioning 
endogenous transcriptional regulators.6 For example, overexpression of the 
transcriptional repressor REST/NRSF in medulloblastoma, leads to the suppression of 
genes critical for the proper differentiation of neuronal cells.162, 163 Majumder and co 
workers have shown that up-regulation of the REST/NRSF-controlled genes by an 
activator ATF consisting of the REST DBD fused to the VP16 TAD, induces tumor cell 
apoptosis, demonstrating the utility of transcription-based therapies.164 Further, activator 
ATFs could also be used in conjunction with gene therapy strategies to fine-tune the 
production of therapeutic proteins.165 
Activator ATFs are also useful in biomanufacturing, molecules that up-regulate 
transcription to prescribed levels can be used to increase the concentrations of 
biosynthetic enzymes in order to boost product yields.166, 167 Finally, in synthetic biology, 
transcriptional networks are key building blocks used to construct cell-based devices and 
networks, and molecules that function in a predictable and orthogonal fashion relative to 
natural regulators will be particularly useful.168  
 While activator ATFs have a number of practical applications, in the near term 
they are extremely useful as mechanistic tools to understand natural activator function. 
For example, in the 1980s, the Ptashne group demonstrated the modularity of 
transcriptional activators by fusing a TAD from one activator with a DBD from another 
and showed that the artificial activator created functioned using the unique characteristics 
of each individual domain.20, 21 Subsequently, they also showed that a peptide, AH, 
designed to mimic an amphipathic helix was able to activate transcription robustly, 
indicating that perhaps an amphipathic helix is an important feature found in natural 
activators.144 Further, several groups have identified random and designer peptide 
sequences that function as transcriptional activators when localized to DNA; these studies 
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have highlighted the chemical functionality that is important for activation.146, 149, 152, 153 
143 
However, there are many questions regarding the mechanism by which the 
artificial molecules and natural activators function that remain unanswered. Specifically, 
given that natural activators interact with a variety of binding partners, the use of 
activator ATFs to completely characterize each individual interaction will delineate the 
importance of each recruitment event to the overall activity of natural activators. In the 
longer term, understanding the features necessary for controlling transcriptional activity 
will lead to newer generations of activator ATFs that closely mimic endogenous 
activators.  
 
D. Overview of thesis 
The work described here focuses on probing the mechanism of natural 
transcriptional activators towards the long-term goal of designing activator ATFs for 
therapeutically and biotechnologically useful purposes. We have found that specifically 
targeting the Mediator component Med15(Gal11) gives rise to transcriptional activation 
and the level of transcription seemed to vary upon the binding site on Med15(Gal11) 
(Chapter 2). Further, we show that incorporating additional binding interactions inside 
and outside the transcriptional machinery are strategies that activators use to achieve 
potent levels of transcriptional activation (Chapter 3). Finally, we investigate the binding 
partners of transcriptional activators and the nature of the activator binding sites using 
both in vitro and cell-based photo crosslinking. We find that the activator Gal4 targets 
multiple proteins in cells and we identify a small subset of conserved binding sites on the 
coactivator Med15(Gal11) to be important for the function of endogenous activators 
(Chapter 4).  Incorporation of the features described here into future generations of 
activator ATFs (Chapter 5), leading to the design of small molecules that function in cells 
with similar activity as natural activators, will lead to the development of therapies to 
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THE DEVELOPMENT OF ACTIVATOR ATFS* 
A. Abstract 
 Malfunctioning transcriptional regulators are at the heart of many human diseases. 
For example, the transcriptional activator p53 is mutated in over half of human cancers 
preventing it from activating vital tumor suppression genes.4 Currently, gene therapy 
approaches to adenovirally deliver p53 to tumor cells are undergoing clinical trials for the 
treatment of head and neck cancer (Advexin, Introgen Therapeutics).5 However until 
further advances in gene therapy are made, these approaches have limited efficiency due 
to the problems associated with cellular delivery and immune response.6, 7 Thus, the 
discovery of synthetic molecules that functionally replace transcriptional regulators, 
artificial transcription factors or ATFs, hold great promise for mechanistic studies and 
ultimately for therapeutic applications. Historically it has been challenging to develop 
ATFs that activate transcription (activator ATFs) that function with the specificity and 
activity levels of their natural counterparts. One difficulty has been that the binding 
profile of endogenous activators is not well understood; the physiologically relevant 
targets of activators in the transcriptional machinery (so-called coactivators) have for the 
most part not yet been identified. Recently, however, several genetic and biochemical 
studies provide strong evidence for three proteins, Med15(Gal11), Tra1 and Taf12, as 
legitimate binding partners of activators, although definitive in vivo evidence is still 
lacking (discussed more completely in Chapter 4). Further, the functional relevance or the 
                                                
* Portions of this chapter were taken from Wu, Z; Belanger, G.; Brennan, B.B.; Lum, 
J.K.; Minter, A.R.; Rowe, S.P.; Plachetka, A.; Majmudar, C.Y.; Mapp, A.K. J. Am. 
Chem. Soc. 2003, 125, 12390-1 and Majumudar C.Y.; Lum, J.K.; Prasov, L.; Mapp, A.K. 
Chem. Biol. 2005, 12 313-321. Experiments in Figure 2.4 were performed by Aaron 
Minter and Annette Plaschetka. Experiments in Figure 2.5 were performed in 
collaboration with Brian Brennan. Experiments in Figures 2.7-2.10 were performed in 
collaboration with Jenifer Lum. I carried out the Experiments in Figures 2.11 and 2.12. 
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Figure 2.1. Model of 
transcription initiation. 
Activators localize on DNA 
(black line) and interact with a 
variety of protein complexes (in 
gray) including Mediator to 
recruit RNA pol II to the gene 
promoter.  
thermodynamic parameters for the interactions between activators and Med15(Gal11), 
Tra1 or Taf12 have not been completed elucidated. 
 In this Chapter, we use a synthetic peptide library to identify ligands that interact 
with the yeast Mediator protein Med15(Gal11). We find that ligands with micromolar 
dissociation constants are able to activate transcription to varying levels in yeast reporter 
gene assays. The difference in activity is attributed to the distinct binding sites that are 
targeted on Med15(Gal11) and not due to the affinity of the ligands for Med15(Gal11). In 
addition, we show that in contrast to other natural and artificial activators, the function of 
these ligands is solely dependent on the presence of Med15(Gal11), setting the stage for 
the development of cell-type and tissue-specific activator ATFs. 
 
B. Introduction 
B.1 The Mediator complex 
Mediator was originally discovered as a stable complex of proteins that could 
“mediate” the function of activators in vitro.8 It was also shown that Mediator formed a 
stable complex with RNA polymerase II, leading researchers in the late 1990s to 
hypothesize that Mediator was the bridge required for activators to interact with RNA 
polymerase II (Figure 2.1).9, 10 In support of this, several genetic and biochemical  
experiments showed that activators interacted with a subset of Mediator components 
(vide infra).11 However, the exact nature of the interaction between DNA-bound 
regulators and Mediator that results in gene upregulation was not completely understood.  
Mediator is functionally conserved from yeast through humans, consisting of 21-
25 proteins.12 Mediator was originally identified in yeast as a complex consisting of ~20 
proteins, and extensive cross-species comparisons and bioinformatics analyses have 
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Table 2.1. Components of the Mediator complex.1 Components of the 
Mediator are functionally conserved from yeast through humans. The 
Mediator is composed of three modules, the head, middle and tail. (see 
Figure 2.1). Mediator is also often associated with the CDK/Srb sub-module. 
detected metazoan counterparts for almost all yeast Mediator subunits suggesting that a 
universal “Mediator complex” appeared early during eukaryotic evolution (Table 2.1).1, 13 
Thus yeast has proven to be a great model system to investigate the functions of Mediator 
and transcription in general. It contains most of the functionally important transcriptional 
machinery components yet, a less complicated network of signaling found in metazoan 
systems. Further, due to the ease with which genes can be manipulated in yeast, S. 
cerevisiae has proven to be more tractable than human cell culture for basic research 





Although originally hotly debated, the components of Mediator are currently well 
agreed upon, but the precise function of each individual protein is still unknown. Cryo-
EM studies with purified yeast Mediator depicted a modular complex consisting of a 
head that interacted with RNA polymerase II (8 proteins), a middle module (8 proteins) 
and a tail region (5 proteins), which was predicted to interact with TADs (Figure 2.2).14 
The Mediator was also shown to associate with the CDK (cyclin-dependent kinase) 
module (4 proteins) in a few specific contexts.15 Studies by Asturias and coworkers 
revealed that Mediator undergoes conformational changes when it interacted with RNA 
polymerase II and Tijian and coworkers showed that a similar conformational change in 
the human Mediator was elicited by activators.2, 16, 17 Together these studies suggest that 
Mediator serves as a conformational relay system between DNA bound regulators and the 
transcriptional machinery. Specifically, it is in the tail module that most of the putative 
coactivators reside, with subunits Med14(Rgr1), Med3(Pgd1), Med2 and Med15(Gal11) 
identified in a number of genetic screens as effectors of positive transcriptional 
regulation.18-20 Additionally, head domain component Med17(Srb4) and components of 
the tail module including Med15(Gal11) have been implicated as direct targets of 
activators using in vitro crosslinking and pull-down assays.21-24  
  
In an elegant ‘activator by-pass’ study aimed at elucidating which Mediator 
proteins might be direct binding partners of activators, Ptashne and coworkers localized 
various components of Mediator to DNA by fusing them to DNA binding proteins and 
then evaluated their ability to activate transcription in this context.3, 25 Med15(Gal11) 
localized to DNA was not only able to activate transcription two orders of magnitude 
higher than any other Mediator component, but it was also able to activate to similar 
Figure 2.2 
The Mediator complex. 
Model of the yeast Mediator in 
complex with RNA Polymerase II 
determined from cryo-EM images.2 
Three domains have been 
identified, termed Head (H), 
Middle (M) and Tail (T).  
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levels as the potent yeast activator Gal4. DBD fusions of other components Med2, 
Med20(Srb2) also resulted in activation, although to lesser levels (Table 2.2). These 
findings illustrated the possibility that artificially localizing Med15(Gal11) to DNA by 
creating ligands for Med15(Gal11) could potentially create activator ATFs and provided 
some evidence that Med15(Gal11) is a likely target of endogenous activators. 
  
B.2 Med15(Gal11) an activator target 
 Med15(Gal11) is a 120 kDa protein that resides in the tail domain of the yeast 
Mediator complex. It was originally identified as being necessary for proper galactose 
utilization in yeast and postulated to be important in the regulation of galactose-inducible 
genes.26-28 Subsequently a number of genetic and biochemical studies have implicated it 
as a likely target of DNA-bound transcriptional activators, including the activator Gal4 
that regulates genes responsible for galactose metabolism.29 However, the function of 
Med15(Gal11) remains unknown. The N-terminus of Med15(Gal11) has been 
computationally predicted to contain a GACKIX domain with sequence homology to the 
coactivators ARC105 and CREB binding protein (CBP), leading researchers to suggest 
that ARC105 is the metazoan homolog of yeast Med15(Gal11).30 However, the rest of 
Med15(Gal11), apart from a glutamine rich region, is not homologous to ARC105, 
Table 2.2 
Activator by-pass experiments using non-
classical activators.3 Various components 
of the yeast transcriptional machinery 
were fused to the LexA DBD and the 
level of activation elicited by each fusion 
was evaluated using β-galactosidase 
assays in yeast.  
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raising questions about their functional relationship. More recently, the solution structure 
of the N-terminus (residues 2-93) of yeast Med15(Gal11) has also revealed structural 
similarity to GACKIX domains of CBP and ARC105.31 The C-terminus of 
Med15(Gal11) has been observed to associate with Tfa1 and Tfa2, subunits of the general 
transcription factor TFIIE as well as stimulate phosphorylation of the carboxy-terminal 
domain of RNA Polymerase II by TFIIH (Figure 2.3).32-34  
 
Several recent studies have implicated Med15(Gal11) as a target of both natural 
and artificial transcriptional activators. Genetic experiments show that Med15(Gal11) is 
important for transcription of GAL and MATα genes and necessary for activated 
transcription by the endogenous activators Gal4, Gcn4, Swi5, Msn2, VP16 and Met4.28, 
35-40 Further, direct binding experiments and integrated yeast reporter assays by the 
Kodadek and Kim laboratories showed that different fragments of Med15(Gal11) 
interacted with a number of natural TADs in vitro and deletions of these fragments in 
yeast caused a decrease in activation.18, 19, 29 For example, Med15(1-351) has been shown 
to interact with the Gal4 TAD in vitro.29 Med15(Gal11) has also shown to be the primary 
target of the artificial peptidic TAD XLY.41, 42 Since we initiated our studies, in vitro 
crosslinking studies by the Hahn group have identified Med15(Gal11) as one of three 
targets of the Gal4 and Gcn4 TADs from yeast whole cell extracts.21, 22 More recently, the 
Lehming group has shown using a split-ubiquitin assay in yeast that Gal4 and Gcn4 
interact with Med15(Gal11).43 
Figure 2.3 Protein interaction domains of Med15(Gal11). Med15(Gal11) is 1081 amino 
acid yeast protein that has been shown to interact with the Mediator and transcriptional 
activators. A conserved GACKIX domain similar to that found in the mammalian 
coactivator CBP is located at the N- terminus.  
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 Given the evidence suggesting that Med15(Gal11) is an activator target, we 
hypothesized that ligands for this protein would serve as tools to investigate the features 
necessary to create novel transcriptional activators with robust cellular activity. In 
particular, we hypothesized that localizing Med15(Gal11) to DNA with synthetic ligands 
would lead to the creation of activator ATFs. Further, we could use these ligands to 
investigate the affinity and orientation requirements for recruiting Med15(Gal11) and the 
relationship of these factors to transcriptional activation. For these purposes, we utilized a 
screening strategy to identify ligands that bound different surfaces of the protein.   
B.3. Synthetic peptide library screen  
In order to identify ligands for Med15(Gal11) a combinatorial peptide library was 
screened against Med15(Gal11) in vitro. The design of the library was based on the 
minimal sequences from endogenous activators that activated transcription to high levels. 
Natural TADs often contain repeats of short sequence motifs, with each motif able to 
activate transcription on its own, albeit to a lesser extent than the combination. One of the 
shortest such motifs is found in the VP16 TAD, which contains four repeats of a 
consensus eight amino acid sequence.44 It has been shown that the fusion of eight amino 
acids from this TAD (DFDLDMLG) to a DBD creates a strong activator. Thus, it was 
decided to create an octapeptide library with four residues randomized, creating a balance 
between library size and sequence coverage. While a peptide library was chosen for the 
ease of creating a library with diverse chemical functionally and detection of positive 
hits, a similar approach could be later extended to screen a nonbiopolymer-based library. 
Two libraries, AXXXXPSE and AXXXXLSE (with X=19 of the 20 natural amino acids, 
without lysine), were designed for the screen, giving a theoretical total of 260,642 unique 
sequences. In one library Leu, Ser and Glu were incorporated at the carboxy terminus. 
These amino acids are commonly found in the amphipathic class of endogenous 
transcriptional activators.45 The inclusion of proline in the second library was used to bias 
the library against peptide sequences that would form helices, to obtain sequences distinct 
from natural activators. Former students Dr. Aaron Minter and Dr. Annette Plaschetka 
used an ELISA-based screen to obtain 37 ligands from these libraries that bound to 
bacterially expressed Med15(186-619) (Figure 2.4).  
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The ligands isolated fall into 3 main sequence categories (randomized region): 
hydrophobic, amphipathic and positively charged, indicating that they might be targeting 
different surfaces of Med15(Gal11). To verify this, coworkers Dr. Zhiqian Wu and Dr. 
Brian Brennan performed fluorescence polarization-based competition binding 
experiments with the ligands identified in the screen, showing that the ligands isolated 
were binding to different surfaces of Med15(Gal11). Further, they found that these 
ligands bound Med15(Gal11) in the low micromolar range similar to other TADs such as 




B.4 Activator ATFs 
 Given the ligands target Med15(Gal11) with a similar affinity as natural and 
unnatural TADs, we hypothesized that when fused to a DBD, leading to the creation of 
activator ATFs, they should activate transcription in cells to high levels. Full length 
endogenous activators in an optimal context can upregulate gene expression 10-5000 fold 
over basal levels. In order to successfully restore the function of malfunctioning 
endogenous activators, it is likely that activator ATFs will have to activate transcription 
Figure 2.4 Synthetic peptide library screen. 
a) ELISA-based screening strategy 
b) Ligands that bound different surfaces of Med15(Gal11). Ligands fall into at 





to natural activator levels. Additionally, since the ligands were obtained based on their 
ability to bind Med15(Gal11), they could potentially function by interacting with a single 
transcriptional machinery component. Activators ATFs that function through specific 




C.1 Activity in yeast 
To assess the ability of the Med15(Gal11) ligands to function as transcriptional 
activation domains, Garrette Belanger and Dr. Jenifer Lum made yeast expression 
plasmids that encoded for fusions of these ligands to the N-terminus of the LexA DBD 
and performed qualitative X-gal plate assays in a yeast reporter assays. They identified 3 
ligands, #17, #28 and #32 that activated transcription to levels similar to the positive 
control VP2. Quantitative evaluation of ligands #17 and #28 in yeast β-galactosidase 
assays revealed that #28 activated to 60% of the activity levels seen with VP2. (Figure 
2.5) 
 
 A surprising observation from this study was that contrary to previously held 
dogma, a correlation between the affinity of each ligand to its transcriptional target 
Med15(Gal11) and its activation potential was not observed.46, 47 For example the 
artificial TAD XLY binds Med15(Gal11) with a KD of 2.2 ± 0.4 µM and activates 
transcription >500 fold over basal, however #17 with a similar affinity for Med15(Gal11) 
(KD 2.3 ± 0.4 µM) activates transcription only ~2.5 fold (Figure 2.5 and data not shown). 
We hypothesized that this could be due to the ligands targeting different surfaces of 
Figure 2.5 Med15(Gal11)Ligands 
in yeast. 
Ligands+LexA fusion were 
evaluated in β-galactosidase assays 
in yeast. Fold activation was 
determined by dividing the activity 
of the ligand+LexA fusion by the 
activity of LexA alone. Error is 
reported as SDOM from triplicate 
experiments. 
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Med15(Gal11). Specifically, some binding sites on Med15(Gal11) might be obscured in 
the context of Mediator and further some ligands might disrupt key Med15(Gal11)-
Mediator contacts; hence ligands that target those sites are unable to activate transcription 
in the context of the cell.  
Significantly, given the low micromolar Med15(Gal11) affinities observed for the 
different ligands, the endogenous activator VP2 and the potent artificial activator XLY, it 
may not be necessary to find high affinity coactivator ligands to activate transcription in 
the future. Indeed, it may be sufficient to find molecules that target a transcriptionally 
relevant site with moderate affinity. Subsequently, the Schepartz and Kodadek 
laboratories have also reported similar conclusions where they found that the affinity of 
ligands that bind different surfaces of the coactivator CBP does not correlate with the 
activity of these ligands in mammalian cell-based transcription assays.48, 49 
C.2 Optimization of ligand activity  
The cellular activity of the activator ATFs constructed from the Med15(Gal11) 
ligands and the LexA DBD was well below the 10-5000 fold levels seen with sequences 
found in endogenous activators.50 The low activity of these molecules ultimately limits 
their utility as activator ATFs and we decided to investigate different strategies to 
improve their activation potential. 
The Med15(Gal11) ligands were obtained by screening for an interaction with 
isolated Med15(Gal11) in vitro in the context of a resin-bound peptide. In the cell 
however, Med15(Gal11) is in a complex of proteins within the Mediator and certain 
binding sites might be obscured. Thus, it is conceivable that the orientation of the ligands 
is not optimal and we need to investigate different options to find favorable conditions to 
recruit Med15(Gal11). There are several factors such as the ability of the DBD to 
effectively project the ligand away from DNA and the accessibility of Med15(Gal11) 
from a particular position on the promoter that might impact how well Med15(Gal11) is 
recruited.  
C.2.a The role of the DBD 
Although natural transcriptional activators are modular proteins and 
transcriptional activation domains typically function independent of the identity of the 
DNA binding domain, the level of transcription elicited in each context varies.51-53 The 
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ability of natural TADs to interact with multiple protein targets may account for this 
functional flexibility. While changing the DBD and hence the projection of the TAD 
might affect interactions with a subset of transcription protein targets, it is unlikely to 
affect all. We hypothesized that since the ELISA-based screen was done with the ligands 
containing a free amino-terminus, a similar orientation might be required for interaction 
with Med15(Gal11) in cells. For this purpose, we fused them to the N-terminus of the 
LexA DBD. However, only a small fraction activated transcription and to only low 
levels. Modeling studies of LexA by Kaptein and coworkers indicated that the amino 
terminus of LexA is in close proximity to the DNA, raising the possibility that amino 
terminal ligand-fusions may not be optimal to project the ligand away from DNA for 
Med15(Gal11) recruitment.54, 55 To test this hypothesis ligand #28 was fused to the C-
terminus of the LexA DBD and evaluated for activation in yeast. Unfortunately, there 
was negligible improvement in the ability of this ligand to activate transcription as 
quantitated by measuring β-galactosidase activity (data not shown). Thus, in the context 
of the LexA DBD, #28 was able to activate transcription only to low levels. 
Next, we decided to investigate a different DBD derived from the S. cerevisiae 
protein Gal4, Gal4(1-147). The first 65 residues of Gal4 form a Cys6-Zn cluster that binds 
to DNA and the subsequent 30 residues mediate dimerization through helix-helix 
interactions that enhance sequence-specific DNA binding.56-58 The amino acids 97-147 
serve as a linker region of undefined structure between the TAD and the DBD (Figure 
2.6).57 A plasmid was constructed encoding ligand #28 fused to the carboxyl terminus of 
Gal4(1-147). In this context, ligand #28 is displayed in the opposite orientation (carboxy 
terminus free) relative to the original LexA fusion. 
 
 
Figure 2.6 Domains of Gal4. The yeast transcriptional activator, Gal4 has 3 major 
domains, DBD (1-65), dimerization (65-94) and two TADs (148-196 and 768-881) 
Regions 97-147 comprise a linker of unknown structure. 
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         The Gal4(1-147)-based activator was more potent than the #28+LexA fusion 
protein, with 14.5-fold activation compared to the DBD alone (Figure 2.7). The change in 
orientation from the LexA to Gal4 DBD is not the only factor contributing to the increase 
in function. Attachment of #28 to the carboxy terminus of the DBD Gal4(1-100) 
produced an activator approximately 4-fold less active than Gal4(1-147)+#28. 
Consequently, the additional linker residues present in the Gal4(1-147)+#28 fusion 
protein likely play a role in the activity increase, projecting the ligand from the DNA 
more effectively and providing more favorable conditions for the Med15(Gal11) 
interaction. A similar reliance upon linkers has been noted with natural transcriptional 
activation domains such as ATF14 and VP2, both acid-rich TADs derived from the 
potent viral coactivator VP16 as well as other nonnatural TADs. 51, 52, 59 
 
C.2.b Binding sites in promoter 
 The position of the DNA binding site relative to the transcription start site has 
also been previously shown to affect how well an activator upregulates transcription.25, 60-
62 To probe this, activator ATF #28 was tested in yeast strains bearing 2 binding sites 
either 50 bp or 191 bp upstream of the TATA box. The extent to which transcription was 
affected by the binding site position varied with the DNA binding domain employed in 
the ATF. For #28+LexA, function was better at a binding site 50 bp from the TATA box, 
with fold activity dropping by half when moved to 191 bp. The opposite trend was 
observed with Gal4(1-147) as the DBD (Figure 2.8). In that case, lower levels of 
Figure 2.7 
DNA binding domain dependence of #28. 
#28 fused to the amino terminus of LexA 
or the carboxy terminus of Gal4(1-00) and 
Gal4(1-147) was evaluated in β-
galactosidase assays in yeast. Fold 
activation was determined by dividing the 
activity of the DBD+#28 fusion by the 
activity of the DBD alone. Error is reported 
as SDOM from triplicate experiments. 
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activation were obtained when the binding sites were closer to the TATA box. These 
latter results parallel the activity of the Med15(Gal11) protein itself when it is employed 
as an activator ATF. The fusion protein Gal4(1-147)+Med15(Gal11) is a potent activator 
at the 191 bp distance; at 50 bp, however, activity drops by half.25 The results obtained 
with Gal4(1-147)+#28 are suggestive of a mechanism by which #28 specifically recruits 
Med15(Gal11) to DNA in an orientation analogous to the positioning in the Gal4(1-
147)+Med15(Gal11) fusion protein. 
 
C.2.c Increasing the activity of the other ligands 
Given the increase in activity obtained for #28, we investigated if we could apply 
these criteria to other ligands. We attached the two other ligands previously identified to 
be active when fused to LexA, ligands #17 and #32, to Gal4(1-147) and evaluated their 
activity in yeast strains bearing 2 Gal4 sites 191 bp from the TATA box. In the case of 
#17, only 2-fold activity relative to the DBD alone was observed, comparable to the 
results obtained with the LexA DBD. Similar results were obtained when #17 was fused 
to Gal4(1-100); in addition, moving the binding sites closer to the transcriptional start site 
did not provide an increase in activity (data not shown). In contrast, ligand #32 exhibited 
quite modest activity when fused to the amino terminus of LexA (1.4-fold) but the 
activity increased to 11.5-fold when it was attached to Gal4(1-147), comparable to the 
activity of #28 (Figure 2.9). Overall, these experiments provided two artificial activators 
with improved functional profiles, Gal4(1-147)+#28 and Gal4(1-147)+#32. Interestingly, 
Figure 2.8 Promoter binding site 
dependence of #28. 
#28 + LexA or Gal4(1-147) +#28 
was evaluated in β-galactosidase 
assays in yeast at different 
binding sites in the promoter. 
Fold activation was determined 
by dividing the activity of the #28 
DBD fusion by the activity of the 
DBD alone. Error is reported as 




both these ligands were from the synthetic library with proline in the third position that 
was designed to isolate molecules with sequences distinct from natural activators, 




Since the ligands were obtained based on their ability to bind Med15(Gal11) in 
vitro, we were eager to see if they indeed targeted Med15(Gal11) in the cellular context. 
Another important question we sought to answer was whether the transcriptional activity 
of the ligands was solely due to the interaction with Med15(Gal11). To explore this, β-
galactosidase assays were carried out in a yeast strain in which Med15(Gal11) had been 
deleted from the genome. This experiment is possible because Med15(Gal11) is not an 
essential protein, although yeast bearing this alteration exhibit a slow growth phenotype. 
26 Gal4(1-147)+#28 and Gal4(1-147)+#32 nearly undergo a complete loss of function in 
yeast strains bearing no Med15(Gal11) as compared to the strain containing 
Med15(Gal11) (Figure 2.10). This was in contrast to the positive control, Gal4(1-
147)+ATF14, a sequence taken from the potent viral coactivator VP16, that showed only 
a 2-fold decrease in activation levels. Although ATF14 is known to interact with Med15, 
it has several additional putative targets in the transcriptional machinery, and thus it is not 
surprising that its function is attenuated rather than abrogated in the absence of 
Med15(Gal11). 63 
Figure 2.9 Optimized 
conditions for Med15(Gal11) 
ligands. Gal4(1-147)+ligand 
fusions were evaluated in β-
galactosidase assays in yeast. 
Fold activation was determined 
by dividing the activity of the 
ligand Gal4 fusion by the 
activity of the Gal4 DBD alone. 
Error is reported as SDOM 




This point was further investigated by carrying out the same set of experiments 
using a yeast strain in which the central region of Med15(Gal11)(residues 186–619) had 
been deleted.64 This mutation minimized the deleterious phenotype of the Med15(Gal11) 
delete strain and enabled us to test if the binding sites for ligands #28 and #32 were in 
this region because the original binding screen was carried out with this fragment. 
Gratifyingly, nearly identical results were obtained, with #28 and #32 showing little or no 
activity in this strain, while the fold activation of ATF14 was similar to the strain with 
Med15(Gal11) present. Taken together, these data suggest that both #28 and #32 are 
dependent upon a binding interaction with Med15(Gal11) for upregulating transcription.  
 
We were also interested in evaluating our ligands in different cell types. In the 
long term, the development of activator ATFs that function in certain cell types will be 
therapeutically useful for specifically targeting diseased cells (for example see 65, 66). 
Intriguingly, acid-rich TADs such as Gal4 or VP16, commonly used for activator ATF 
construction, function in all eukaryotes tested, from yeast through humans.67-69 Despite 
differences in RNA polymerase II holoenzyme composition, there is evidently significant 
conservation across species with regard to activator targets. It has been challenging, 
however, to identify metazoan homologs of yeast Med15(Gal11). Recently, structural and 
computational evidence for homology between the amino terminus of Med15(Gal11) and 
the mammalian protein ARC105 was reported.30, 31 In addition, the two proteins contain a 
glutamine-rich stretch of amino acids. However, the region of Med15(Gal11) used in our 
Figure 2.10 Specificity of 
Med15(Gal11) ligands. #28 
and #32 were attached to 
Gal4(1-147) and tested for 
activity in yeast strains that 
contained Med15(Gal11) or  
Med15(Δ186-619) or 
without Med15(Gal11). 
Fold activation was 
calculated by dividing the 
activity of the particular 
construct by the DBD alone. 
Error is reported as SDOM. 
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original binding screen (residues 186–619) shares little sequence similarity with ARC105 
or any other identified metazoan protein, and we thus anticipated that activators that 
function through an interaction with this region would not be able to function in 
mammalian cells. To investigate this, a plasmid encoding the most active of the peptides 
(#28) was transiently transfected into human embryonic kidney cells (HEK293 cells) 
along with a reporter plasmid bearing five Gal4 binding sites within an E1b promoter 
upstream of a SEAP reporter gene following standard protocols. As a positive control, we 
also examined the activity of a VP16-derived transcriptional activation domain fused to 
Gal4(1-147). No activation by ligand #28 was observed while the VP16-derived TAD 
functioned well in this context (Figure 2.11). Finally, to verify that these activators were 
in fact being expressed in the HEK293 cells, we performed immunofluorescence staining 
of the cells (Figure 2.12).  Taken together, the experiments in mammalian cells reinforce 
the yeast results, indicating that #28 is dependent upon Med15(Gal11) for function. 
 
 
Figure 2.11 #28 in mammalian cells. 
AHYYYPSE (#28) was attached to 
Gal4(1-147) and tested for activity HEK 
293 using secreted alkaline phosphatase 
assay. Fold activation was calculated by 
dividing the activity of the Gal4(1-
147)+#28 by the DBD alone. Error is 
reported as SDOM. 
Figure 2.12 Immunofluorescence staining 
of HEK293 cells. HEK 293 cells 
expressing Gal4(1-147) constructs were 
probed with an α Gal4 antibody to detect 
expression of Gal4 (1-147) fusions. 
Expression of Gal4 is indicated in green. 
The nucleus is stained blue. The overlay 




D. Conclusions and future directions  
We have shown here that ligands identified using an in vitro binding screen for 
Med15(Gal11) serve as artificial TADs that function in yeast cell-based transcription 
assays. Further, low micromolar affinity for Med15(Gal11) is sufficient to recruit 
Med15(Gal11) and activate transcription. Contrary to the model in the literature, ligand-
target binding affinity did not correlate with function. However, differences in binding 
sites for activators with similar affinities for Med15(Gal11) seemed to play a role in the 
ability of the different ligands to activate transcription in yeast.  
When Med15(Gal11) itself is directly attached to LexA, localizing to it DNA, it 
results in >1000 fold levels of activation. However none of the ligands when attached to 
LexA or Gal4 DBDs displayed such high levels of activity. Perhaps, the fragment of 
Med15 we screened against did not contain the appropriate binding sites to recruit 
Med15(Gal11) in the same orientation. Additional studies aimed at discovering the 
binding sites of these and other Med15-targeting TADs in the future will provide insight 
into the relationship between binding site and potency (Chapter 4). Specifically, robust 
endogenous activators may have evolved to target privileged binding sites that recruit 
Med15(Gal11) in the optimal orientation and studies that create molecules that target 
these sites will lead to new generations of more potent activator ATFs. 
We also show that the Med15(Gal11) ligands differ from typical natural or 
artificial TADs. In contrast to natural activators, as experiments described here revealed 
that for at least two of the artificial TADs, a Med15(Gal11) interaction is required and 
sufficient for transcription function. In the future, activator ATFs engineered with the 
Med15-specific ligands combined with ligands targeting other protein targets might 
provide a simple strategy to improve potency and will be outstanding tools for probing 
the mechanistic origins of transcriptional synergy (Chapter 3). 
More practically, since the screening strategy provides TADs that function 
through binding interactions with individual transcriptional machinery proteins, targeting 
other cell-type-specific or organism-specific proteins provides a mechanism for the 
creation of activators whose functional specificity extends beyond that imposed by the 
DNA binding domain. Finally, as the screening strategy is equally applicable to 
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combinatorial libraries of small molecules, these results provide a framework for building 
tunable, uniquely specific small molecule transcriptional regulators. 
 
E. Experimental 
General methods  
All techniques used for yeast manipulations were carried out in accordance with standard 
protocols.70 All other general molecular biology techniques were carried out as described. 
The yeast strains used for testing the LexA and Gal4 fusions of ligands from the synthetic 
library screen include LS41 [JPY9::ZZ41, Matα his3Δ200 leu2Δ1 trp1Δ63 ura3-52 
lys2Δ385 gal4 gal80 URA::pZZ41] ( pZZ41 contains two LexA binding sites upstream of 
the TATA box), JPY52::JP185, Matα his3Δ200 leu2Δ1 trp1Δ63 ura3-52 lys2Δ385 
gal4Δ11 med15::LYS, URA::pJP185 (pJP185 contains two Gal4 binding sites 50bp 
upstream of the TATA box), ZL2,  Matα his3Δ200 leu2Δ1 trp1Δ63 ura3-52 lys2Δ385 
gal4Δ11 med15::TRP1, URA::pJP169 (pJP169 contains two LexA binding sites upstream 
of the TATA box) and JPY52::JP188,  Matα his3Δ200 leu2Δ1 trp1Δ63 ura3-52 lys2Δ385 
gal4Δ11 med15::LYS2, URA::pJP188 (pJP188 contains two Gal4 binding sites 191bp 
upstream of the TATA box) (Gifts from Dr. Aseem Ansari). 
For the experiments with JPY52::JP185 and JPY52::JP188 Med15(Gal11)Δ yeast strains, 
a low copy plasmid, ycplac111 Gal11WT expressing full length Med15(Gal11) from its 
native promoter was transformed into yeast (Gift from Dr. Aseem Ansari).  
 
LexA Plasmids 
The Med15 ligands were expressed as fusions to the N terminus of the LexA DBD in 
yeast. The expression of the protein was driven by the strong, constitutively active ADH 
promoter and has a His marker in yeast and ampicillin selection in E. coli. The parent 
plasmid pNLexA (high copy in yeast) used for this purpose was purchased from Origene. 
Fusions of all 37 ligands to LexA were performed by Dr. Jenifer Lum and Garrette 
Belanger. C-terminal LexA fusions were accomplished by using pHyb-Zeo from 
Invitrogen. These plasmids were prepared by Garrette Belanger and are also high copy in 
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yeast and express proteins under the control of the ADH promoter. pHyb-Zeo has a 
Zeocin marker for yeast (high copy) and an ampicillin selection in E. coli. 
 
Gal4(1-147) plasmids 
Plasmids encoding Gal4(1-147)+#17, Gal4(1-147)+#28, and Gal4(1-147)+#32 were 
generated from pGBKT7 (Clontech) by Jenifer Lum. It expresses fusions to the C-
terminus of Gal4 and is kanamycin selectable in E. coli, contains a TRP marker for yeast 
(high copy) and expresses proteins under the control of the ADH promoter.  
ATF-14 was generated from pGBKT7 by first annealing oligonucleotides encoding the 
peptide, (5′-AA TTC tgt ggt gat gct ttg gat gat ttt gat ttg gat atg ttg TAA-3′ and 5′-TC GA 
TTA caa cat atc caa atc caa atc aaa atc atc caa agc atc aga acc aca G-3′) resulting in sticky 
ends corresponding to the restriction sites EcoRI/SalI. The duplex oligonucleotides were 
phosphorylated with T4 polynucleotide kinase and ligated with T4 DNA ligase into 
pGBKT7 predigested sequentially with EcoRI and SalI and treated with calf intestinal 
phosphatase. The resulting plasmids were amplified in DH5α E. coli (Invitrogen), 
selected on LB-agar plates containing 50 µg/ml kanamycin, and isolated from cultures 
using a QIAprep Spin Miniprep Kit (Qiagen). The sequences of the isolated plasmids 
were verified by sequencing at the University of Michigan Core Facility. 
 
Gal4(1-100) plasmids 
Plasmids encoding Gal4(1-100)+#28 and Gal4(1-100)+#17 were generated from RJR217 
using homologous recombination (Gift from Dr. Aseem Ansari). These fusions were 
expressed under the control of the strong β-actin promoter and the plasmid has a His 
marker in yeast (low copy) and has an ampicillin selection in E. coli. Oligos (5’-GCA 
TTG TTA ACA  GGA TTA TTT GTA CAA GAT NNN NNN NNN NNN NNN NNN 
NNN NNN TAA AAC ATT TGA AGT TTC CAT ACT TTT GAT ACT TTT GAA G’-
3) and its complement were cotransformed into the yeast strain LS41 with the plasmid 
RJR217 which was predigested with Sal1 and treated with Mung Bean nuclease. The 
resulting plasmids incorporating #28 or #17 were amplified and subsequently extracted 
from yeast. The plasmids were amplified in DH5α E. coli (Invitrogen), selected on LB-
agar plates containing 50 µg/ml kanamycin, and isolated from cultures using a QIAprep 
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Spin Miniprep Kit (Qiagen). The sequences of the isolated plasmids were verified by 
sequencing at the University of Michigan Core Facility. 
 
Med15(Gal11)Δ(186-619) plasmid 
The YCplac111+Med15Δ(186-619) plasmid was generated from the parent YCplac111 + 
Ga11WT plasmid using site-directed mutagenesis (Gift of Dr. Aseem Ansari). This 
plasmid expresses Med15(Gal11) under the control of its native promoter, is ampicillin 
selectable in E. coli and possesses a Leu marker (low copy) for yeast selection. Briefly, 
two sets of oligonucleotides were designed to insert XhoI restriction sites either before or 
after the sequence of the region to be deleted. Site-directed mutagenesis was performed 
using the QuikChange Kit (Stratagene) according to manufacturer’s instructions. The 
methylated parent plasmid was then digested with DpnI and the nicked mutagenized 
plasmid was amplified in SMART E. coli cells (Genlantis), selected on LB-agar plates 
containing 100 µg/ml ampicillin and isolated from cultures using a QIAprep Spin 
Miniprep Kit (Qiagen). This modified plasmid was then subjected to the same 
mutagenesis procedure using the second set of oligonucleotides. After insertion of both of 
the XhoI restriction sites, the amplified plasmid was digested with XhoI and gel purified 
or religated without purification with T4 DNA ligase. The resulting 
YCplac111+Med15Δ(186-619) plasmid was amplified in SMART E. coli cells and 
selected on LB-agar plates containing 100 µg/ml ampicillin. The new 
YCplac111+Med15Δ(186-619) plasmid was subsequently isolated using a QIAprep Spin 
Miniprep Kit (Qiagen) and the sequence was verified at the University of Michigan Core 
Facility.  
 
Mammalian Gal4(1-147)+#28 plasmid 
For use in the human cell experiments, a plasmid encoding Gal4(1-147)+#28 was 
generated from pM (Clontech) by ligation of an oligonucleotide pair encoding #28 (5′-
AA TTC GGT TCT GGT GGT TCT GGT GCT CAT TAT TAT TAT CCA TCT GAA 
TAA-3′ and 5′-TCGA TTA TTC AGA TGG ATA ATA ATA ATG AGC AGA ACC 
ACC AGA ACCG-3′) into pM that had been predigested with EcoRI/SalI. The resulting 
plasmid was amplified in DH5α E. coli (Invitrogen), selected on LB-agar plates 
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containing 0.1 mg/ml ampicillin and isolated from cultures using a QIAprep Spin 
Miniprep Kit (Qiagen). The sequence of the isolated plasmids was verified by sequencing 
at the University of Michigan Core Facility. 
 
β-galactosidase assays 
The function of ligand+LexA or Gal4+ligand (peptide, artificial or natural) fusions was 
examined in yeast by a quantitative liquid β-galactosidase assay in accordance with 
established methods.70 Briefly, the plasmids encoding the peptide fusions and the DBD 
plasmid (negative control) were transformed into yeast using the LiOAc method or by 
electroporation (Med15(Gal11) delete strains), and transformed colonies were selected by 
growth on synthetic complete (SC) media containing 2% raffinose and lacking the 
appropriate amino acid(s) for selection. Freshly transformed colonies were used to 
inoculate 5 ml cultures of SC media containing 2% raffinose and lacking the appropriate 
amino acids. The cultures were incubated overnight at 30°C with agitation. Following 
incubation, these cultures were used to inoculate 5 ml cultures of SC media containing 
2% raffinose, 2% galactose and lacking the appropriate amino acids that were 
subsequently incubated overnight at 30°C with agitation to an OD660 of 3–4. The yeast 
cells were harvested and resuspended in Breaking buffer (100 mM Tris-HCl (pH 8.0), 
20% glycerol) containing the Complete Protease Inhibitors cocktail (Roche). The cells 
were lysed by vortexing with glass beads. A portion of the cell extract was used to 
measure β-galactosidase activity via incubation with o-nitrophenyl-β-D-
galactopyranoside (1 mg/ml) in Z buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM 
KCl, 1 mM MgSO4•7H2O, and 50 mM 2-mercaptoethanol [pH 7]). The reaction was 
stopped by adding 1 M Na2CO3 and the OD420 was measured on a Varian Cary 300 UV-
vis spectrometer. The activity reported was normalized to the total protein concentration 
of the extract, measured using a Bradford assay kit (Bio-Rad) with BSA as the standard.  
 
Secreted Alkaline Phosphatase Assay 
The function of Gal4(1-147)+#28 was examined in human cells using a quantitative 
secreted alkaline phosphatase (SEAP) assay in accordance with standard protocols. For 
this purpose, 4 µg of plasmid encoding Gal4(1-147)+#28, the Gal4(1-147) plasmid (pM, 
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negative control), or the Gal4(1-147)+VP16(411-455) fusion (pM3-VP16, positive 
control) were transiently transfected into an equal number of human embryonic kidney 
293 cells (ATCC) using the PolyFect reagent (Qiagen) according to the manufacturer’s 
protocol. Each transfection reaction also contained 2 µg of the SEAP reporter plasmid 
pG5SEAP. The transfected cells were cultured at 37°C in a 5% CO2 incubator in DMEM 
(Mediatech) supplemented with penicillin (100 units/ml), streptomycin (100 µg/ml), L-
glutamine (290 µg/ml) and heat-inactivated FBS (Hyclone). After 72 hr, supernatant from 
the culture was removed and assayed for SEAP activity. Briefly, 250 µl of the 
supernatant was heated to 65°C to inactivate any endogenous phosphates, after which it 
was added to an equal volume of 2× SEAP buffer (1 mM MgCl2, 20 mM L-
homoarginine, and 2 M diethanolamine [pH 9.8]) and incubated at 37°C for 10 min. 
Finally, 20 µl of 20 mM p-nitrophenol phosphate in 1× SEAP buffer was added and the 
OD405 was measured at 5 min intervals for 1.5 hr using a plate reader (Molecular 




To verify that the Gal4(1-147) peptide ligand fusions were being expressed and 
transfected in approximately equal amounts in HEK293 cells, immunofluorescence 
staining was performed. Briefly, the transiently transfected cells were fixed on glass 
slides using 2% paraformaldehyde. After multiple washes using blocking buffer (0.05% 
saponin, 5% BSA, and PBS [pH 7.2]) anti-Gal4 antibody (Covance) was added (1:2000 
dilution) and incubated for 2 hr at room temperature. After six 5 min washes, an FITC-
conjugated anti-rabbit secondary antibody (Santa Cruz Biotech) was added (1:150 
dilution) and incubated for 45 min at room temperature. The slides were then washed 
with blocking buffer 6 times for 5 min each and Hoechst (Chemicon), a nuclear stain that 
enables visualization of all cells, was added to the slides. The cells were visualized under 
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FACTORS THAT ENHANCE THE POTENCY OF TRANSCRIPTIONAL 
ACTIVATORS* 
 
A. Abstract  
Transcriptional activator proteins are major players in regulating gene expression. 
They precisely control the timing of and levels to which their cognate genes are 
transcribed.1 It is hypothesized that activators are able to achieve a desired level of 
control through an extensive network of interactions with partners inside and outside the 
transcriptional machinery.3 For example, activators can be post-translationally modified, 
undergo ligand-dependent nuclear localization, interact with masking proteins and 
proteins in the transcriptional machinery and eventually be degraded by the proteolytic 
machinery.4-14 However, it is unclear how each of these events individually contributes to 
the overall function of an activator.   
 In Chapter 2, we showed that by mimicking a single step of this cascade, specific 
recruitment of a single transcriptional machinery component Med15(Gal11), we were 
able to create activator ATFs. Unfortunately, the molecules only functioned with a 
fraction of the activity stimulated by natural activators. In this Chapter, we investigate the 
effect of incorporating additional interactions into activator ATFs in an effort to increase 
transcriptional output. First we create ligands for the SAGA complex component Tra1; 
these ligands, when attached to a DBD, are able to activate transcription to levels higher 
than the Med15(Gal11)-specific ligands. In contrast to the Med15 ligands described in 
                                                
* Portions of this Chapter were taken from Lum, J.K.; Majmudar, C.Y.; Ansari, A.Z.; 
Mapp, A.K. ACS Chem. Biol. 2006, 1, 639-643. Experiments shown in Figures 3.18, 
3.20, 3.21 and 3.22 were performed by Jenifer Lum. I performed experiments in Figures 
3.5 - 3.15, 3.19 and Tables 3.2 - 3.4. Experiments leading to the model proposed in 
Figure 3.4 were performed by Steven Rowe, Brian Brennan and members of the Ansari 
group (U. of Wisconsin). 
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Chapter 2, the Tra1 ligands interact with more than one coactivator. Evidently, the TAD 
binding site in Tra1 is similar to binding sites within other coactivators. Further, 
combination of a Med15(Gal11) ligand with a Tra1 ligand leads to a synergistic increase 
in activation. Next, we show that engineering an interaction outside the transcriptional 
machinery into activator ATFs also leads to greatly enhanced function. Specifically, we 
show that supplementing a TAD-coactivator recruitment event with an intramolecular 
masking interaction leads to higher activity, presumably through protection from 
proteolysis and/or non-specific interactions. In the future, inclusion of these design 
criteria in new generations of biopolymer-based and small molecule activators will 





B.1 Activator interactions within the transcriptional machinery 
 At a gene promoter transcriptional activation is initiated by the activator –
dependent recruitment of chromatin remodeling enzymes and formation of the 
preinitiation complex (PIC) that consists of coactivators and general transcription 
machinery components (Figure 3.1).1, 15  Activators are thought to recruit, stabilize and/or 
induce conformational changes in the preinitiation complex, signaling RNA polymerase 
II to initiate transcription.16-18 However, the identity and the relevance of the exact 
interactions activators make with these complexes in cells are ambiguous. More recently 
it was shown using chromatin immunoprecipitation at the Gal1 promoter that first Spt-
Ada-Gcn5-acetyltransferase (SAGA), a chromatin remodeling complex is recruited, 
followed by the SAGA-independent recruitment of Mediator and finally RNA 
Figure 3.1 Overview of 
transcriptional activator 
interactions. Transcriptional 
activation domains (TADs) 
undergo a variety of 
interactions with partners inside 
and outside the transcriptional 
machinery that result in RNA 




polymerase II along with the general transcriptional machinery.19 Thus, from this study it 
is likely that activators such as Gal4 directly contact components of SAGA and Mediator. 
 Subsequently, Hahn and coworkers showed using in vitro crosslinking that Gal4 
and Gcn4 interact with the SAGA component Tra1, the Mediator subunit Med15(Gal11) 
and Taf12, a shared subunit of SAGA and TFIID; remarkably, the crosslinking results 
suggest that a single peptide sequence within each activator mediates all of the binding 
contacts.20, 21 These finding are consistent with the ChIP experiments mentioned above 
and suggest that activators utilize multiple interactions for initiating gene expression. 
Further, because two distinct activators interact with the same set of targets, these results 
also hint at the possibility of a core group of conserved activator-transcriptional 
machinery contacts, possibly overlapping activator binding sites on target proteins.  
We hypothesized that if we could artificially create multiple interactions with the 
transcriptional machinery, we could probe the functional contribution of recruiting 
different complexes involved in transcriptional activation. In Chapter 2 we found that 
recruitment of Med15(Gal11) led to the activation of transcription. However, the Med15 
specific ligands only moderately activated transcription and perhaps other interactions are 
necessary to activate transcription to levels similar to natural activators. Thus we were 
interested in creating ligands for other transcriptional machinery proteins and evaluating 
their ability to activate transcription. 
B.1.a Tra1: a likely target of activators 
There is considerable evidence that Tra1 is a bonafide activator target. The 
Workman group initially showed that the activator Hap4 specifically crosslinked with 
Tra1 when incubated with reconstituted (cell-free) SAGA complex.22 Moreover, they also 
show using GST pulldown assays that the TADs of Hap4, Gal4, Gcn4 and VP16 interact 
with purified Tra1 (Figure 3.2). Subsequently, these finding were also confirmed by the 
Hahn laboratory through in vitro crosslinking studies using yeast nuclear extracts and the 
Gal4 and Gcn4 TADs, identifying Tra1 as one of three targets that these activators 
bound.20, 21 Since the crosslinking studies were performed in vitro, the cellular 
confirmation of an activator-Tra1 interaction was lacking. Since then, Green and 
coworkers, using a FRET-based approach, identified Tra1 in the context of SAGA to be 
the sole cellular target of Gal4 in yeast.23, 24 While this approach validates Tra1 as a 
 56 
bonafide activator target, it is not known if the function of Gal4 is solely dependent on a 
Tra1 interaction. Further, due to the limitations of the FRET approach, Tra1 could be one 
of many cellular targets of Gal4 (see Chapter 4); indeed, this would be more consistent 
with the preponderance of evidence showing that a variety of transcription complexes are 
recruited to a gene promoter.19, 25-28  
 
Given the evidence suggesting that Tra1 is an activator target, we wanted to 
investigate the interactions with Tra1 that contribute to function. Specifically, we wanted 
to explore if there were multiple functional activator binding sites in this protein. 
Furthermore, were these binding sites unique compared to other coactivator binding 
sites? For these purposes, we envisioned we would identify the region(s) on Tra1 that 
interact with natural activators. Next we could screen for ligands that bound this region to 
evaluate if ligands that interact with Tra1 function as transcriptional activation domains. 
Finally, we could combine the Tra1 ligands with Med15(Gal11) ligands to probe if 
multiple interactions with the transcriptional machinery would facilitate higher levels of 
activity. 
B.2 Interactions outside the transcriptional machinery 
While interactions with the transcriptional machinery are necessary for function, 
activators have also been shown to have interactions with proteins outside the 
transcriptional complex. They include interactions with enzymes that introduce covalent 
modifications such as phosphorylation and ubiquitylation as well as interactions with 
Figure 3.2 Molecular architecture of the 
SAGA complex and its component Tra1 
a) Organization of SAGA complex revealed 
by cryo-EM. SAGA is composed of 14 
subunits, including the histone acetyl 
transferase (HAT) Gcn5.2 
b) Domains of Tra1. The C terminal half of 
the protein is involved in activator contacts. 
The different conserved domains are shown 
in green.  
 
 57 
Figure 3.3 Transcriptional activator interactions inside and outside transcriptional 
machinery. In additional to interactions within the transcriptional machinery, the 
transcriptional activation domain (TAD) of an activator also interacts with masking 
proteins (mp) (shown in green). Masking interactions help prevent non-specific 
interactions such as aggregation and proteolysis that lead to non-functional activators. 
small molecules.4-14 These interactions primarily play a role in controlling the timing of 
gene expression.10 For example the transcriptional activation domain of the mammalian 
activator CREB is inactive until ser133 is phosphorylated, which then results in 
recruitment of the coactivator CBP and upregulation of gene expression.7  
 
Masking interactions also control the timing of gene expression. In a masking 
interaction overlapping residues in a TAD required for activation are concealed from the 
rest of the cellular environment, thus preventing activation until the residues are revealed 
to the transcriptional machinery. An excellent example of this is the mouse homolog of 
double minute 2 (hDM2), a masking protein that regulates p53 function by discriminating 
p53-coactivator interactions and playing a role in p53 turnover.29-32 An instance of an 
intramolecular masking interaction is found in the activator Put3, which in normal cells is 
unable to activate transcription due to concealment of its activating region. On the 
addition of a specific metabolite (proline) it undergoes a conformational change that frees 
the transcriptional activation domain, thus enabling it to stimulate expression of its 
cognate genes  (for additional examples see Table 3.1). 8, 33, 34 
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Recent work from our group demonstrated that masking interactions also play a 
role in the overall activity of an activator through preventing aggregation, non-specific 
binding interactions and/or increasing the stability of the activator. For example, XLY (an 




Role of interaction 
p53 mDM232, 36 Shields TAD from interactions, also controls degradation 
E2F RB37 Phosphorylation of RB releases E2F and stimulates cell proliferation 
Gal4 Gal805, 38-41 In the presence of glucose, Gal80 masks the TAD from interactions; 
addition of galactose stimulates a conformation change that exposes the 
TAD to the transcriptional machinery  
Leu3 Intramolecular42, 
43 
Leu3 acts as a repressor protein. On the addition of a Isopropylmalate (α 




Addition of proline results in a conformation change that releases the TAD 
from interacting with an intramolecular inhibitory region and permits 
activation 
PC4 Intramolecular44  Depending of the phosphorylation state of PC4, it undergoes 
conformational changes in a lysine rich region, which gradually effects 
DNA binding and transcriptional cofactor recruitment 
IRF-7 IRF-545 IRF-5 binds to the IRF-7 and masks its DNA binding domain, preventing 
activation 
Hap1 Hsp70-Ydj146 In absence of heme, Hap1 is bound by at least four cellular proteins 
including Hsp70 and Ydj1 which represses its activity. On the addition of 
heme these proteins dissociate from Hap1 and high levels of transcription 
are observed 
NorR Intramolecular47 Binding of Nitric oxide to the non heme iron center in the GAF domain of 
NorR results in the formation of a mononitrosyl iron complex and relieves 
intramolecular repression, enabling NorR to activate transcription 
Pit-1 Pit-1β48, 49 Heterodimerization of Pit-1 with Pit-1β results in masking of the Pit1 TAD 
preventing it from interacting with its coactivator CBP 
Ino2 Opi150 In the presence of inositol and choline, the basic leucine zipper motif 
containing protein Opi1 binds the TAD of Ino2 preventing activation 
Vnd Intramolecular51 Vnd contains two TADs that are masked intramolecularly. When Dichaete 
binds Vnd, the TADs are unmasked and gene expression is initiated. 
Further, Vnd also acts as a repressor when it interacts the co-repressor 
Groucho 
TAK1 TIP2752 TIP27 containing two zinc finger motifs represses TAK1 by interacting with 
the TAK1 TAD and it is suggested to affect coactivator recruitment 
p65 GR53 Glucocorticoid receptor (GR) represses the activity of NF-kB activation 
domain p65 by competing with the  p65-CBP interaction  
Smad3 GR LBD54 The function of Smad3 involved in TGF-β signaling is repressed by an 
interaction with the GR ligand binding domain (LBD) 
Mac1 Intramolecular55 Copper binding to two cys-rich motifs results in a conformational change 
that creates an intramolecular interaction in Mac1 between the DBD and 
the TAD, inhibiting both DNA and coactivator binding  
EWS and 
SSAP  
ZFM156 Binding of the ZFM1 to the TADs of EWS and SSAP prevents them from 
activating transcription  
ELF3 
(ESX) 
Intramolecular57 In absence of a binding partner, the ELF3 TAD interacts with the DBD 
preventing DNA binding. On association with a coactivator, ELF3 
undergoes a conformational change that enhances DNA binding and in 
turn activation 




In contrast to natural TADs, artificial TADs generally operate outside of the 
endogenous regulatory pathways and lack masking partners or interactions. Therefore, 
artificial TADs are typically unable to utilize all of the resources of the cellular 
machinery that contribute to functional potency and this could possibly explain why they 
do not activate transcription to high levels in vivo or in cell culture.10, 29, 38, 58 
There is one exception to the trend of modestly active artificial TADs: the 16 
amino acid artificial TAD XLY activates transcription to levels seen with full length Gal4, 
a potent yeast activator.59, 60 Drs. Brian Brennan and Steven Rowe (former graduate 
students) in collaboration with Prof. Aseem Ansari (U. of Wisconsin) performed a series 
of biochemical and genetic experiments that probed the mechanism by which this 
activator achieved high activity levels. Using fluorescence polarization-based binding 
assays, they found that XLY interacted with low micromolar affinity with its 
transcriptional machinery target, Med15(Gal11). Surprisingly, they also found that XLY 
had similar affinity to part of its own DBD, Gal4(1-100). Moreover, disruption of either 
interaction in Med15(Gal11) mutant strains or attachment of XLY to a different DBD 
resulted in loss of activity. Further investigation identified the hydrophobic loop in the 
dimerization domain comprising residues (52-100) of Gal4 to be critical for XLY 
function.  
From these results, it was hypothesized that the secondary contact with the Gal4 
dimerization domain likely serves as a masking interaction, preventing XLY from 
participating in non-productive interactions (for example with chaperones) or proteolysis 
until it is exposed to its target protein Med15(Gal11), at which point XLY can recruit the 
transcriptional machinery and robustly activate transcription (Figure 3.4).35  
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Figure 3.4 Model for XLY function. XLY can only activate transcription when it 
can perform two interactions, one with part of its own DNA binding domain 
Gal4dd and the other with its transcriptional machinery target Med15 (middle 
pathway). Disruption of either interaction leads to loss of function; top pathway 
does not permit coactivator binding, bottom pathway does not allow interaction 
with Gal4dd. XLY binding sites are indicated in red and their absence is indicated 




Given that a masking interaction is essential for the function of XLY, it is likely 
that masking interactions play a general role in controlling not only the timing of 
endogenous activator function but also in assisting the level of upregulation. To directly 
probe this, we hypothesized that engineering a masking interaction into TADs that 




C.1 Creating an additional interaction within the transcriptional machinery 
 Given the importance of chromatin remodeling in transcriptional activation and 
that endogenous activators target Tra1, a component of these complexes, we 
hypothesized that ligands for this protein would be useful tools for investigating the 
importance of recruiting chromatin remodeling complexes in transcription initiation as 
they could be used to either specifically block or recruit such complexes. More 
importantly, we previously created ligands for the Mediator component Med15(Gal11) 
(Chapter 2) that were only able to moderately activate transcription in a Med15(Gal11)-
dependent manner at a synthetic Gal1 promoter. Thus, it would be of interest to probe the 
functional effect upon recruitment of the SAGA complex to a gene promoter in 
combination with Mediator recruitment. One of the central models of transcription 
initiation is that multiple activators residing at a promoter work cooperatively to recruit 
various complexes, and our strategy would be a means to replicate this with, presumably, 
with greatly enhanced function.28, 61 
C.1.a Identification of activator binding region of Tra1 
 In order to screen for ligands that bind Tra1, it was first necessary to identify the 
endogenous activator-binding module of the 433 kDa protein. We hypothesized that we 
could better mimic activator function by creating ligands that bound similar surfaces on 
Tra1 as natural activators. Presumably, endogenous activators target binding sites on 
Tra1 that are accessible in the cell, in context of the various proteins Tra1 associates with 
and ligands that target these regions should be able to interact with Tra1 in vivo. 
Workman and coworkers provide some insight into the region of Tra1 important for 
activator function; a temperature-sensitive Tra1 mutant with amino acid substitutions in 
the C-terminal half of Tra1 (amino acids 2226 to 3744) abolished VP16 binding in vitro 
and yeast containing this mutant displayed phenotypes consistent with compromised 
Gcn4-dependent activation.22  
To further pinpoint a region on Tra1 targeted by the activators Gcn4, Gal4 and 
VP2, we created ~50 kDa fragments of Tra1 spanning amino acids 1900-3500 (Figure 
3.5a). These fragments were initially expressed as GST fusions in E. coli to facilitate 
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Figure 3.5 Tra1 E. coli 
expression constructs 
a) Different constructs 
spanning the C- 
terminal half of Tra1 
were constructed as 
fusions to MBP 
b) Expression of 
MBP-Tra1 constructs 
in Rosetta (DE3) 
pLysS cells.   
c) Sequences of TADs 
used to identify 
activator binding 
region(s) within Tra1. 
isolation. However, an extremely low level of soluble protein was obtained, with the 
majority of the GST-Tra1 fusions residing in the cell pellet. Thus we decided to express 
and purify the Tra1 fragments as fusions to the maltose binding protein (MBP) in E. coli 
to assist in solubility and purification (Figure 3.5b), leading to ~2 mg/L of protein that 
was soluble up to 50-100 µM concentrations. The TADs Gcn4 (105-134), Gal4 (840-881) 
and VP2 were synthesized using solid phase synthesis methods and fluorescein labeled 
(Figure 3.5c). Using fluorescence polarization, the affinity of Gal4, Gcn4 and VP2 was 
assessed for each Tra1 fragment. It was found that only Tra1(3092-3524) had any 
measurable affinity for these TADs (Table 3.2). It is also possible that the other 
fragments are not fold properly when expressed in E. coli and thus do not bind TADs.  
The binding results were quite different than those seen with the coactivator 
Med15(Gal11). Firstly, the TADs bind Tra1 5-10 fold weaker than they bind 
Med15(Gal11). Perhaps activators recruit SAGA using interactions with Tra1 and Taf12, 
a component of SAGA also postulated to be a target of activators.20 Also, in the case of 
Tra1 only one region was found to interact with activators, while Med15 has many 
functional binding sites (see Chapter 4). Furthermore, consistent with the hypothesis of 
the existence of a subset of functionally conserved binding sites, the three endogenous 
TADs target the same Tra1 fragment, possibly targeting a similar binding site(s).62, 63 
However, competition experiments to verify this could not be performed conclusively 
since at concentrations above 500 µM the TADs showed significant aggregation. 
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Table 3.2 Natural 
activator binding 
affinities for Tra1 
fragments. The 
dissociation constant 
for different fragments 
of Tra1 was 
determined using FP. 
The data reported is an 
average of 3 
experiments with error 




C.1.b Screening for ligands 
In order to identify ligands for Tra1, we first screened an 8 amino acid synthetic 
peptide library (AXXXXPSE) against Tra1(3092-3524) (Figure 3.6). The library was 
synthesized on solid phase on PEGA resin and had 4 variable positions giving a total 
possible 130,321 unique sequences. The same library was successfully used previously to 
yield ligands that targeted Med15(Gal11) and activated transcription (Chapter 2). Ligands 
for Tra1 were obtained using an ELISA-based screen and they were selected on a 
colorimetric basis relative to the positive control VP2, an endogenous activator that binds 
Tra1 and the negative control, which was the acetylated resin (Figure 3.7). The sequences 




Figure 3.6 ELISA-based screen for Tra1 ligands. An 8 amino acid combinatorial 
library with 4 randomized positions (130,321 unique sequences) synthesized on 
PEGA resin was screened to obtain ligands for Tra1(3092-3534). 
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In contrast to the ligands obtained that bound Med15(Gal11), the Tra1 ligands 
bore significant sequence homology, perhaps indicating that they target the same binding 
site; all the ligands were acid rich (Figure 3.8).64 However, compared to endogenous 
TADs such as Gal4 that also contain a preponderance of acidic residues, a majority of 
these ligands did not contain interspersed hydrophobic residues. The presence of 
hydrophobic residues in endogenous TADs has been well documented to be important for 
interaction with target proteins and the dearth of hydrophobic residues was therefore 
somewhat surprising.30, 62, 65-67 In order to measure the affinity of the ligands for Tra1, 
several ligands were synthesized and labeled with fluorescein. Using fluorescence 
polarization-based binding assays it was found that the ligands only weakly interacted 
with Tra1; a measurable dissociation constant could not be calculated due to the 
propensity of Tra1 to precipitate/aggregate at higher concentrations (Figure 3.9a). 
Nonetheless, when these ligands were fused to a DBD they activated transcription to 20-
30 fold (Figure 3.9b). Given that the positive control VP2 itself binds Tra1 with a 
moderate affinity (30 ±4 µM), perhaps a high affinity interaction with Tra1 in vitro is not 
required for activator function. 
 
 
Figure 3.7 Positive hit from 
ELISA-based screen against Tra1. 
The synthetic library was incubated 
with MBP-Tra1 and subsequently 
with anti MBP-HRP antibody. The 
beads that bound Tra1 are indicated 
with the observance of blue color 
due to the cleavage of the TMB 
substrate. 
Figure 3.8 Sequences of ligands that bound Tra1 in the synthetic peptide library 
screen. Sequences of ligands obtained by Edman degradation sequencing of 
beads that turned blue in ELISA-based screen with Tra1. Variable positions in 




C.1.c Phage display selection 
 As outlined above, the screen against Tra1 provided quite different results than 
the Med15(Gal11) screen described in Chapter 2. In the Med15(Gal11) screen, ligands 
that activated transcription and that did so by interacting with at least three distinct 
binding surfaces were identified. In contrast, the Tra1 ligands shared significant sequence 
similarities, suggesting that they were likely targeting a shared binding site. This was 
somewhat surprising since the use of a screen typically facilitates the identification of 
ligands that bind to different surfaces and the results may indicate that the peptide library 
used was not sufficiently diverse in sequence composition.64  Further both native TADs 
and the Tra1-selected TADs bound to Tra1 more weakly than the Med15(Gal11) ligands 
interacted with their target protein. Ultimately the poor binding affinity of the Tra1 
ligands limits their utility as mechanistic tools.   
To address the limitations of the previous experiment, we chose to carry out a 
phage display selection with a commercially available phage-displayed dodecamer 
Figure 3.9 Functional evaluation of synthetic library ligands for Tra1. 
a) Fluorescence polarization was used to determine the affinity of the ligands for Mbp-
Tra1 or MBP. The ligands interact with Tra1 but, a dissociation constant could not be 
measured due to the aggregation of Tra1 at higher concentrations 
b) Gal4+ligand fusions were evaluated in β-galactosidase assays in yeast. Fold 
activation was determined by dividing the activity of the Gal4+ligand fusion by the 




Table 3.3 Ligands for Tra1 
determined by phage display. A 
subset of ligands isolated after 2 and 
3 rounds of positive selection against 
Tra1. 500 µM VP2 was used in the 
binding buffer to isolate ligands that 
target different binding sites than 
those targeted by VP2. 
library. By using a longer peptide (twelve versus eight residues) and carrying out multiple 
rounds of selection, affinity enhancement is often realized.68-70 Each phage displays 
dodecamer peptides on the surface of the coat protein PIII and it contains five copies of 
the peptide. In addition, the phage library has ~109 different sequences, several orders of 




Since the ELISA screen against Tra1 yielded ligands with similar sequence 
compositions, suggesting the ligands target a similar binding site on Tra1, we attempted 
to obtain ligands that targeted different binding sites on Tra1. For this purpose, the phage 
display was performed using two different conditions: phage incubated with Tra1, and 
phage incubated with Tra1 in a buffer containing the endogenous TAD VP2 (500 µM). 
We hypothesized that inclusion of VP2 would bias the selection against ligands that 
interact with the same surface(s) as VP2 and would enable investigation of the 
significance of endogenous activator binding site(s). Three rounds of positive selection 
were performed against Tra1 and one round of negative selection against maltose binding 
protein (MBP) after the first positive selection, since Tra1 was fused to MBP. DNA was 
extracted from the phage that were isolated under the various conditions and sequenced 
to obtain the encoding peptides (Table 3.3). In order to verify that the sequences obtained 
do in fact target Tra1, a phage-based ELISA was performed and the sequences that 
preferentially bound Tra1 were carried forward for activity assays in yeast (Figure 3.10). 
To test the ability of the ligands to activate transcription, they were fused to the Gal4 (1-




One ligand (ENSPLWWPQPLA) in particular was able to activate transcription to 
high levels. This ligand was obtained under the condition where no competing VP2 was 
used when the phage were selected to bind Tra1. Another active ligand, 
ALQQTPFPSFPS, was also obtained under these conditions. However, none of the 
ligands tested that were biased to bind sites other than VP2 activated transcription to high 
levels (Figure 3.11). The KD for ENSPLWWPQPLA was, in contrast to the earlier Tra1 
ligands, measurable (98 ± 8 µM) but is still >3-fold higher than that of VP2. Competitive 
ELISA experiments with phage-ENSPLWWPQPLA and VP2 showed that increasing 
concentrations of VP2 inhibited the binding of phage-ENSPLWWPQPLA to Tra1, 
suggesting that VP2 and ENSPLWWPQPLA target an overlapping site on Tra1 (Figure 
3.13). 
Figure 3.10 ELISA of ligands isolated from phage display. 1010 phage expressing 
select ligands isolated after 3 rounds of positive phage display selection against 
Tra1 were probed in an ELISA to determine if they bound Tra1 selectively over 
maltose binding protein (MBP) or buffer without protein. The bound phage were 




A distinctive feature of molecules that function using a mechanism similar to 
endogenous TADs is that increasing their local concentration at the promoter, for 
example, by oligomerization, leads to transcriptional levels greater than the sum of those 
observed with the individual activators.68, 71 Given the amphipathic nature of 
ENSPLWWPQPLA, it seemed possible that, similar to the natural amphipathic TADs 
that it resembles, it would function in a similar manner. To investigate this possibility, a 
dimer of ENSPLWWPQPLA was synthesized and found to bind Tra1 three-fold better 
(28 ± 1 µM) and correspondingly was able to activate transcription synergistically with 
greater than 95% confidence (four fold increase relative to the monomer) (Table 3.4 and 
Figure 3.12). In contrast the Med15(Gal11) ligands described in Chapter 2 did not display 
synergistic levels of transcription when multimerized (data not shown).72 We attributed 
the lack of synergy with the Med15(Gal11) ligands to their Med15(Gal11)-specific 
mechanism of function. Thus, these finding are indicative of ENSPLWWPQPLA 
functioning in a manner similar to natural activators but distinct from the Med15(Gal11)-
specific ligands. 
Figure 3.11 
Evaluation of Tra1 ligands from phage 
display. Gal4+ligand fusions were 
evaluated in β-galactosidase assays in 
yeast. Fold activation was determined by 
dividing the activity of the Gal4+ligand 
fusion by the activity of the Gal4 DBD 
alone. Error is reported as SDOM from at 
least triplicate experiments. 
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The natural activator VP2, whose function the Tra1 ligand resembles, has been 
shown to interact with several coactivators in vitro. To investigate if the Tra1 ligand 
would interact with coactivators in addition to Tra1, the in vitro binding affinity for 
Med15(Gal11) (1-357), a protein fragment that interacts with several natural and 
unnatural TADs, was measured. It was found that ENSPLWWPQPLA bound 
Med15(Gal11) with a 81 ± 3 µM dissociation constant. The endogenous activator VP2 
also targets this region of Med15(Gal11), although with a stronger affinity (3.8 ± 0.5 µM) 
(Table 3.4). Satisfyingly, competitive ELISA experiments with Med15(Gal11),  phage-
ENSPLWWPQPLA and VP2 indicated that VP2 and ENSPLWWPQPLA compete for 
the same binding site on Med15(Gal11) (Figure 3.13), although a VP2-induced 
conformational change in Med15(Gal11) that prevents ENSPLWWPQPLA from binding 




Dimerization of Tra1 ligand. Gal4+ligand 
fusions were evaluated in β-galactosidase 
assays in yeast. Fold activation was 
determined by dividing the activity of the 
Gal4+ligand fusion by the activity of the 
Gal4 DBD alone. Error is reported as 
SDOM from at least triplicate experiments. 
 
Table 3.4. Dissociation constants for Tra1 ligands. Fluorescence polarization was 
used to measure the dissociation constants for the fluorescein labeled ligands and 




To investigate the functional importance of the Med15(Gal11) interaction for the 
ability of ENSPLWWPQPLA to activate transcription in yeast, transcriptional assays 
were performed in yeast deleted for parts of Med15(Gal11). It was found that deletion of 
Med15(2-345) results in a reduction in the activity of ENSPLWWPQPLA, but as seen 
with the partially retained activity of the dimer, other interactions between the ligand and 
the transcriptional machinery, most likely with Tra1, are important for function (Figure 
3.14). A similar functional dependence for Tra1 could not be performed in a 
straightforward manner due to the importance of Tra1 for yeast viability. Further, the 
functional reliance of ENSPLWWPQPLA on Med15(Gal11) is consistent with the 
Med15(Gal11) dependence of VP2, whose activity is also reduced in yeast deleted for 
Med15(2-345) (Chapter 4). 
Figure 3.13 Competitive ELISA experiments with VP2 (DFDDMLGDFDLDMLG) 
and ENSPLWWPQPLA. 
a) 1010 phage expressing ENSPLWWPQPLA with varying amount of VP2 were 
incubated with 96 well plates pre-bound with Med15(Gal11). The bound phage were 
detected using an anti-phage antibody and visualized by colorimetric detection. The 
values reported are an average of triplicate experiments and error is reported as SD  
b) similar experiment as a) with Tra1 pre-bound on the plate. 
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C.1.d Combinations with Med15(Gal11) ligands 
 In order to investigate the functional consequence of combining a Tra1 ligand 
with a Med15(Gal11)-specific ligand we decided to simultaneously introduce activator 
ATFs constructed from the Med15(Gal11) ligand AHYYYPSE and the Tra1 ligand 
ENSPLWWPQPLA into yeast. For this purpose, we used a yeast strain that had binding 
sites for the LexA and Gal4 DBDs upstream of the LacZ reporter gene. We attached the 
Med15(Gal11) specific ligand AHYYYPSE to Gal4(1-147) and ENSPLWWPQPLA to 
the LexA DBD (Figure 3.15a). To see a more pronounced effect, we also performed a 
similar experiment where we combined the AHYYYPSE dimer with the 
ENSPLWWPQPLA dimer. (Figure 3.15b) Satisfyingly, we found that the combination of 
these two ligands gave a statistically significant synergistic increase in transcription in 
yeast compared to either construct by itself.  
While the mechanistic origin of synergy is still debated, two limiting models 
postulate that synergy could appear by simultaneously targeting multiple binding sites on 
the same transcriptional machinery target or due to the recruitment of multiple 
transcription proteins.61, 73-77 Although, ENSPLWWPQPLA and AHYYYPSE target 
Med15(Gal11), they target distinct binding sites on Med15(Gal11) (data not shown). 
Previously, Lev Prasov in our group has shown that combination of ligands that target 
distinct surfaces of Med15(Gal11) leads to only additive levels of transcription.72 Thus, it 
is likely that the synergy between AHYYYPSE and ENSPLWWPQPLA appears due to 
Figure 3.14 Med15(Gal11) 
dependence of Tra1 ligands. 
Tra1 ligands were evaluated 
for function in yeast strains 
with Med15Δ(2-345) or 
Med15 WT using 
quantitative β-galactosidase 
assays. Fold activation was 
determined by dividing the 
activity of the Gal4+ligand 
fusion by the activity of the 
Gal4 DBD alone. Error is 
reported as SDOM from at 
least triplicate experiments. 
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the recruitment of Med15(Gal11) and Tra1. However, additional experiments will be 




C.2 Engineering interactions outside the transcriptional machinery: incorporation of 
masking   
The screen for Med15(Gal11) described in Chapter 2 resulted in peptides with 
several different sequence compositions that bound Med15(Gal11) with similar affinities. 
In terms of their ability to activate transcription, however, we found that only ligands 
with a moderately hydrophobic or amphipathic sequence were able to function as TADs. 
Interestingly, there were several hydrophobic ligands that bound Med15(Gal11) with low 
micromolar affinities, but were unable to activate transcription when fused to the LexA 
Figure 3.15 Synergistic activation of Med15(Gal11) and Tra1 Ligands. a) 
Monomers of Med15(Gal11) ligand (AHYYYPSE) fused to Gal4(1-147) and the 
Tra1 ligand (ENSPLWWPQPLA) fused to LexA were evaluated β-galactosidase 
assays in yeast. Relative fold is calculated by normalizing the activity of the first bar 
in each graph to 1. Error is reported as SDOM from at least triplicate experiments. 
b) same as a) expect dimers of ligands were used.  
 73 
DBD. Given the probable unstructured nature of these ligands in absence of a binding 
partner, coupled with their hydrophobicity, it appeared that proteolysis and non-specific 
interactions might be compromising their ability to activate transcription (Figure 3.16).58, 
78-80 We hypothesized that in a manner analogous to the artificial TAD XLY, 
incorporation of an intramolecular interaction into these ligands would provide structure 
to and/or mask the hydrophobic surfaces, converting them from inactivate peptides into 






To test this hypothesis, we chose Gal4(1-100), a DBD that could provide an 
intramolecular binding surface(s) for at least a subset of the ligands. This region 
comprises a binuclear zinc cluster DNA binding domain (1-40) as well as a dimerization 
domain (40-100) that contains at least three binding surfaces that are known to interact 
with hydrophobic partners (Figure 3.17).35, 81, 82 Residues in helices 1 and 2 are critical 
for dimerization of Gal4 and for DNA binding. The two other surfaces facilitate contacts 
that mediate transcriptional activation. Specifically, in the presence of a point mutation in 
the transcription protein Med15(Gal11)(N342V) termed Gal11P, residues in loop 1 and 
helix 3 of Gal4 are able to recruit Gal11P, converting this surface into a potent 
transcriptional activator.83 The third surface primarily consisting of residues in loop 1 
was found to be critical for the interaction with XLY. Of the three binding partners, the 
ligands bear most similarity to XLY in terms of hydrophobic content 
Figure 3.16 Mean hydrophobicity of Med15(Gal11) ligands. Mean 
hydrophobicity was determined for each peptide in library 2 (see Chapter 
2 for screening details) using a hydrophobicity calculator (CCS scale). 
http://www.bbcm.univ.trieste.it/~tossi/HydroCalc/HydroMCalc.html 
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(LTGFVQDYLLPTCIP, calculated mean hydrophobicity 1.82) and size (8 amino acid 
residues versus 16). Thus, Gal4(1-100) seemed an ideal choice to implement our strategy 







Dr. Jenifer Lum, a former graduate student in the laboratory, made yeast 
expression plasmids for all 37 Med15(Gal11) ligands described in Chapter 2, fused to the 
Gal4(1-100) DBD. She initially screened the Gal4(1-100)+ligand fusions in an X-gal 
filter plate assay versus the positive control Gal4(1-100)+VP2, a reiteration of a 
transcriptionally active segment of the viral coactivator VP16 that is commonly used in 
activator ATFs and the negative control, Gal4(1-100). Qualitatively, ligands #23, #31, 
#34, #35, #36 and #37 displayed significant levels of activity. A more quantitative o-
nitrophenol-galactoside (ONPG) liquid assay revealed a dramatic increase in activity for 
several of the ligands from library 2 (AXXXXPSE) that appeared active in the plate 
assay. Ligand #36, for example, only showed 1.2-fold levels of activity when attached to 
the LexA DBD, but upon attachment to Gal4(1-100) displayed a 600-fold increase in 
activity relative to the Gal4 DBD alone. The enhancement in activity correlates well with 
the mean hydrophobicity of the variable region within the ligands, where the most active 
ligands also have the highest mean hydrophobicity (Figures 3.16 and 3.18). 
Figure 3.17 Crystal Structure of the Gal4 DNA binding and dimerization domains. 
Gal4(1-96) bound to its cognate DNA (blue). Surface rendering and ribbon cartoons 
of the structure showing the hydrophobic residues in green. The different structural 
features are indicated. PDB ID: 3COQ 
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Not surprisingly, it was found that the dimerization domain of Gal4 played a role 
in the activity of the ligands; close proximity of the ligands to this domain is important to 
maintain the increased activity observed with #23, #31, #36 and #37 (Figure 3.18). We 
made fusions of these ligands to the Gal4(1–147) DBD and this negates the activity 
enhancement seen when they are attached to Gal4(1-100). Probably the structure of 
Gal4(1–147) differs from Gal4(1–100), with a portion of the hydrophobic binding 
surfaces in the Gal4(52–100) region obscured.84  
C.2.a Unmasking the masking interaction 
The enhancement in activity of the ligands when attached to Gal4(1-100) and its 
correlation to ligand hydrophobicity was suggestive of an interaction between the 
hydrophobic dimerization domain of Gal4 and the ligands. To directly probe this, we 
used fluorescence polarization to assess the affinities of the different ligands for Gal4(1–
100). Initially, we decided to focus the binding studies within the hydrophobic 
dimerization domain of Gal4. Towards this end, the ligands were synthesized using 
standard FMOC solid phase synthesis protocols and labeled with fluorescein at the 
amino-terminus in solution. The affinity for bacterially expressed GST-Gal4(52-100) was 
measured and observed to correlate with the activity enhancement (data not shown). 
Further, the ligands were labeled at the C-terminus via a thiol linkage from a cysteine 
residue. The trends in binding affinity were similar to the amino-terminal labeled ligands, 
Figure 3.18 Activity of 
Med15(Gal11) ligands on Gal4(1-
100) vs Gal4(1-147). Ligand+Gal4 
fusion were evaluated in β-
galactosidase assays in yeast. Fold 
activation was determined by 
dividing the activity of the 
ligand+Gal4 fusion by the activity of 
Gal4 alone. Error is reported as 
SDOM from triplicate experiments. 
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with the ligands that bound the best showing the highest activity enhancement. 
Nonetheless, the affinities were slightly weaker, indicating the importance of a more 
accessible carboxy-terminus. To our dismay, control experiments with the fluorescein 
labeled ligands and GST alone showed similar binding affinities as the GST-Gal4(52-
100) fusion. 
To eliminate the interaction with GST, GST-Gal4(1-100) was bacterially 
expressed, and the GST tag was cleaved off using precision protease. The resulting free 
Gal4(1-100) was then purified by gel filtration chromatography. The binding affinity of 
the ligands for Gal4(1-100) was measured and gratifyingly, the ligands bound with low 
micromolar affinities, with a trend that followed the activity enhancement (Figure 3.19). 
Ligands #36 and #23 which show the greatest activity enhancement when attached to 
Gal4(1–100) also interact most tightly (KDs of 2.6 ± 0.1 and 3.1 ± 0.1 µM, respectively), 
ligand #31 exhibits a 2- to 3-fold higher KD corresponding to its smaller activity 
enhancement (7.3 ± 0.2 µM). Ligand #37, which shows the smallest activity 
enhancement of the four, also binds, but as a result of the propensity of Gal4(1–100) to 
aggregate at concentrations above 15–20 µM, a complete binding curve could not be 
obtained. Interestingly, ligand #28 and VP2, TADs that activate transcription but do not 
show enhancement when attached to Gal4(1-100) do not detectably bind. Another 
noteworthy result showed that the ligands bound Gal4(1-100) with a similar affinity  
irrespective of the presence of its cognate DNA, indicating that the ligands can bind 
Gal4(1-100) in its DNA-bound and unbound conformations (data not shown). These 
results indicate that the interaction with Gal4(1-100) can potentially take place when the 
activator is free in the cellular environment, when in absence of a masking interaction it 
is most likely to undergo non-specific interactions and/or proteolysis.58, 78, 85 
 
Figure 3.19 Dissociation constants of 
Med15(Gal11) ligands with Gal4(1-
100). Each ligand was incubated with a 
range of concentrations of DNA-bound 
Gal4(1-100) and fluorescence 
polarization was monitored. mP is 
millipolarization units and errors are 
reported as SD. N.D. = not detected. 
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The in vitro binding studies between Gal4(1-100) and the ligands are consistent 
with a masking interaction between the ligands and the DBD. It is only when the ligands 
are in close proximity to Gal4(1-100), that they are able to activate transcription to high 
levels. To confirm an interaction in a cellular context, Jenifer Lum carried out alanine 
scanning mutagenesis of the dimerization domain Gal4(52-100) and measured the 
activity of #36, the most potent ligand, using quantitative β-galactosidase assays in each 
case. Alanine substitution at three residues (76, 77, and 84) resulted in a dramatic 
decrease (≥80%) in activity. Other residues (81, 82, and 90) had a more moderate effect 
on function (Figure 3.20). Residues 76, 77 and 84 define a binding interface at the second 
helix and first loop of the dimerization domain, a conformationally mobile and solvent-
exposed region of the structure. Notably, these mutations had no effect on the activity of 
a control TAD, VP2, that shows no enhanced activity when attached to Gal4(1–100). 
Substitution at residues 69, 70, and 75 increased activity 3- to 9-fold; given their position 
relative to the binding site, these alanine substitutions likely increase the accessibility of 
the binding site. Substitution of residues 97 and 89 similarly produced an increase in 
activity. In this instance, attenuated dimerization of helix 3 may facilitate interaction of 
the activation peptide with the loop 1 binding site. In addition, the NMR structure of 
Gal4dd reveals that residues 97–100 are largely unstructured and thus may provide needed 
flexibility such that key residues of the activation peptide can reach the binding site.82 
Based on the NMR and crystal structures, Leu77 is ~15-25 Å from Phe97, and when 
extended, Gal4(97–100)+SS+ALWFFPSE is estimated to be ~35 Å long, within range of 
the proposed binding site. The mutagenesis studies together with the binding experiments 
reinforce the importance of Gal4(1-100) in the activity enhancement of these ligands and 
is consistent with the hypothesis that it mimics a masking interaction. 
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C.2.b Expanding the scope 
Hydrophobicity of the Med15(Gal11) ligands is an important factor in the 
enhancement of function when attached to Gal4(1-100) (Figure 3.16 and 3.18). Natural 
and artificial TADs also possess a preponderance of hydrophobic residues critical for 
function and are often unstructured in the absence of a protein binding partner. Thus, it 
might be possible to incorporate the masking interaction into other TADs to enhance their 
function. To test this idea, Jenifer Lum made yeast expression plasmids for several 
relatively short, non-natural peptide TADs fused to Gal4(1-100) or Gal4(1-147) and 
evaluated their ability to activate transcription (Figure 3.21a). KBP1.66 and KBP2.20 
were isolated from a phage display screen against the mammalian coactivator CREB 
binding protein, CBP.70 AH was designed to generally mimic the amphipathic helix (AH) 
motif found in most natural activators.86 These ligands show no direct sequence overlap 
with natural yeast activators and thus are unlikely to interact with endogenous masking 
proteins that regulate stability and activity. G80bpA arose from a phage display screen 
from binding to the yeast repressor Gal80, nonetheless, it is not known to be regulated by 
Gal80.68, 87 KBP1.66, KBP2.20 and Gal80bpA display a significant increase in activity 
upon attachment to Gal4(1-100) compared with Gal4(1-147) (49-, 49-, and 79-fold 
enhancement, respectively). In contrast, AH did not display a significant difference when 
attached to either Gal4(1-100) or Gal4(1-147). It is possible that the hydrophobic residues 
in AH are not well placed for an interaction with the DBD, perhaps as a result of a 
significant secondary structure assumed by the TAD (Figure 3.21b). 
Figure 3.20 Gal4dd residues 
that alter activation. Surface 
rendering of the crystal 
structure of the Gal4(1–96) 
dimer. The residues in Gal4 
that upon replacement with 
alanine increase the activity 
of Lex(1-202)+Gal4(40-
100)+ALWFFPSE (#36) are 
shaded in green, while the 
residues that significantly 
decrease the activity are 
indicated in red.  
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Jenifer Lum also evaluated the natural activation domains of VP16, Gal4, Gcn4, 
and p53. These TADs also contain an excess of hydrophobic residues and the importance 
of these residues in mediating up-regulation has been well documented.5, 30, 66, 67, 88, 89 
Interestingly, ATF11, Gcn4 and p53 showed an activity enhancement. In contrast, VP2 
and Gal4 did not increase in activity upon attachment to Gal4(1–100) (Figure 3.20c).  
Correspondingly, we did not see a significant interaction between VP2 and Gal4(1-100) 
in vitro (Figure 3.19). 
 
Figure 3.21 Enhancing the function of natural and unnatural TADs.  
a) Sequences of unnatural and natural TADs investigated. b) Unnatural TADs fused 
to Gal4(1-100) or Gal4(1-147). c) Natural TADs fused to Gal4(1-100) or Gal4(1-
147).Ligand+Gal4 fusions were evaluated in β-galactosidase assays in yeast. Fold 
activation was determined by dividing the activity of the ligand+Gal4 fusion by the 
activity of Gal4 alone. Error is reported as SDOM from triplicate experiments. 
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The Tra1 ligand ENSPLWWPQPLA also contains a number of hydrophobic 
residues. To probe if attachment to Gal4(1-100) would also assist its activity, we 
compared its activity on Gal4(1-100) versus Gal4(1-147) (Figure 3.22). In this instance 
also we observed an activity increase on attachment to Gal4(1-100), suggesting that the 
function of a wide variety of hydrophobic TADs can be enhanced in this context. 
 
D. Conclusions and future directions 
We have shown that natural activators interact with the C-terminus of Tra1 and 
ligands that target this region when used fused to a DBD activated transcription to levels 
higher than the Med15(Gal11)-specific ligands. In particular, we found that a ligand that 
targets an overlapping binding site with the endogenous activator VP2 activated 
transcription to the highest level. Further this ligand was found to interact with another 
coactivator Med15(Gal11) at a shared binding site with VP2. These findings suggest that 
activator binding site(s) on different coactivators are similar. Thus, in the future, 
strategies aimed at deciphering endogenous activator binding sites will be extremely 
useful for activator ATF development; possibly targeting one such site would lead to 
molecules capable of activating transcription to high levels, as they potentially will be 
able to interact with similar sites on multiple coactivators (Chapter 4). 
We were also able to enhance the function of the Tra1 ligands. Combination of 
the Tra1 and Med15(Gal11) ligands creating multiple interactions with the transcriptional 
machinery at the activator-relevant targets Med15(Gal11) and Tra1 led to synergistic 
levels of gene expression. Thus, it seems likely that endogenous activators attain high 
Figure 3.22 Enhancement of the function 
of the Tra1 ligand. 
ENSPLWWPQPLA was fused to Gal4(1-
100) or Gal4(1-147) and evaluated in β-
galactosidase assays in yeast. Fold 
activation was determined by dividing 
the activity of the ligand+Gal4 fusion by 
the activity of Gal4 alone. Error is 




levels of activity by interacting with more than one protein in the transcriptional 
machinery. Approaches to identify all the functionally relevant targets of natural 
activators will assist in creating robust synthetic activators by incorporating all these 
interactions (Chapter 4). 
Interaction(s) outside of the transcriptional machinery also have a profoundly 
positive effect on transcription function. Micromolar ligands for the transcriptional 
machinery, for example, only function as robust transcription activators when such a 
secondary binding interaction is available. Given the hydrophobic nature of these ligands, 
it is likely that the secondary interaction alters the binding and stability profile of the 
ligands, decreasing non-specific binding and premature proteolysis that would reduce the 
effective functional concentration of the ligands available for transcriptional activation. 
Consistent with this notion, we have found using western blots that the stability of the 
ligands is altered when fused to Gal4(1-100) versus Gal4(1-147).90 Moreover, this 
strategy of incorporating a secondary "masking" interaction appears general; several 
natural and artificial TADs had their activity significantly enhanced in vivo via this 
mechanism. Inclusion of such a strategy in future generations for small molecule and 
non-biopolymer-based TADs could assist in limiting non-productive interactions, 
facilitating their delivery to their transcriptional machinery targets and greatly elevating 




Peptide synthesis of TADs 
FMOC-based solid phase peptide synthesis was used to synthesize the VP2, Gal4(840-
881) and Gcn4(105-134) peptides.  For this purpose, an ABI 433A peptide synthesizer 
was used and the peptides were prepared using clear amide resin (0.40 mmol/g, Peptides 
International) at 0.1 mmole scale using manufacturer recommended conditions, except 
for forced double coupling of all residues in the synthesis of Gal4 and Gcn4. The Med15 
and Tra1 ligands were synthesized using a ATT 90 peptide synthesizer (Advanced 
ChemTech). A cysteine was added to the C-terminus of Gal4, Gcn4 to facilitate labeling 
with fluorescein.  
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After completion of automated synthesis, all the peptides were fully deprotected 
and cleaved off the resin using 95% TFA, 2.5% Triisopropylsilane (TIS), and 2.5% water 
(5mL, 2 h). Subsequently, the solution was evaporated by blowing nitrogen to <1 mL and 
precipitated with cold ether (3x10 mL). Without further purification, the Tra1, Med15 
ligands and the VP2 peptide were labeled at the N terminus using fluorescein 5,6 
succinimidyl ester (Pierce). For this purpose, ~1 mg of crude peptide was dissolved in 
20µL of DMF and 50µL CH3CN followed by 500µL of 100mM NaHCO3 pH 8.6. 
Approximately 10 fold excess of fluorescein 5,6 succinimidyl ester dissolved in 10µL 
DMF and 50µL CH3CN was added to the peptide solution and the coupling was carried 
out at 37 ºC overnight. The product was characterized by electrospray mass spectrometry 
and purified to homogeneity using reversed-phase HPLC on a C18 column with a 
gradient solvent system (Buffer A: 0.1% TFA, Buffer B: CH3CN) and stored dry at -20 
ºC.  
To facilitate the labeling of the Gal4, Gcn4 TADs, ~1 mg of TAD was dissolved 
in 50µL DMF and 50µL CH3CN followed by 500µL 0.1% TFA. To this ~10 fold excess 
of fluorescein maleimide (Pierce) dissolved in 50µL DMF was added and the reaction 
was carried out at 37 ºC overnight. The products were characterized and purified as 
described above.  
 For competition binding studies, unlabeled peptides were purified to homogeneity 
using reversed-phase HPLC as described above. 
 
Synthesis of peptide library 
The AXXXXPSE peptide library was synthesized using split-pool synthesis. 0.5 mmole 
of PEGA-NH2 resin (Novabiochem, 0.4 mmol/g) was manually coupled with 5 
equivalents of HOBT, HBTU, diisopropyl ethyl amine and each amino acid. The PEGA 
resin was chosen due to its hydrophilicity relative to more commonly used 
PEG-grafted polystyrene resins and because it has a long PEG chain tethering the peptide 
to the solid support, facilitating interaction with large proteins. After the addition of the 
residues PSE, the resin was split into 19 reaction tubes and one of 19 endogenous amino 
acids was added to each tube (no lysine). After the coupling proceeded for ~12 h, the 
resin from all the reactions was pooled, FMOC deprotected (3x10mL 20% piperidine in 
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DMF, 10 min) and again split into 19 reactions to repeat the same process, 3 more times. 
Finally, the resin was pooled and alanine was added to complete the synthesis of the 
library. After removal of all protecting group using 95% TFA, 2.5% TIS, 2.5% water for 
4 h, the library was washed extensively with MeOH and stored dry at -20 °C. 
 
Plasmid Construction 
DNA Oligos for plasmid construction were purchased from Invitrogen or Integrated 
DNA Technologies (IDT).  
 
Tra1 expression plasmids 
Plasmids for bacterially expressing Tra1 were generated from pMal-c2g (New England 
Biolabs) or pGEX6p-1 (GE healthcare). This plasmids express proteins as fusions to 
MBP or GST respectively and are ampilcillin selectable in E. coli.  
Primers   1905 Fwd (5' - CTG GTC GTG AAT GGA TCC GCG TAC CTG GTT ACA 
TCA TAT - 3') and 2358 rev (5' - GTA GGC TTG GAC CTC GAG CTA GCT TCT 
GGA CAT ATT GAC ATT - 3'); 2162 Fwd (5' - CTG GTC GTG AGC GGA TCC ATG 
AAT GCT TTG GAT GTC G - 3') and 2588 rev (5' - GTA TGC ATG TAA CTC GAG 
CTA AGA AAG CAA TGT AAT GAT AGA TCG - 3'); 2478 Fwd 5' - CTG GTC GTG 
AAT GGA TCC GGT TCT TTT AAT AGA GAG AGA - 3' and  2902 rev (5' - GTA 
GGC TTG TCA CTC GAG CTA TAC TAG GTC ATT CCA CAT ATT - 3'); 2693 Fwd 
(5' - CTG GTC GTG AAT GGA TCC TCA TAT GAA CAA ATT GGC CTT - 3') and 
3140 Rev (5' - GTA GGC CTG CCA CTC GAG CTA TAG TTG AGG AAT GAA AGT 
AAT - 3'); 3092 Fwd (5' - CTG GTC GTG AAT GGA TCC TAT AAG AAC TCG AAG 
ATT AGG - 3') and 3524 rev (5' - GTA GGC CTG CCA CTC GAG CTA TGA TGG 
TAC AAA CAT TGT TTG - 3') were used to amplify Tra1 fragments from yeast 
genomic DNA for incorporation in pGEX6p-1. Expand high fidelity DNA polymerase 
(Roche) was used to amplify the products with 400 nM of each primer and 4.5mM MgCl2 
and 1µL of yeast genome DNA template per 50 µL reaction. The amplification 
conditions are [94 °C 2’, 9x (94 °C 15”, 52 °C 30”, 68 °C 2’), 24x (94 °C 15”, 59 °C 30”, 
68 ° C 2’), 68 °C 7’, 4 °C hold]. A total of 4, 50 µL PCRs were performed for each Tra1 
fragment. The PCR products were purified using a Qiagen PCR purification kit and 
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subsequently double digested with BamHI and EcoRI. The digestion reaction was 
purified using the Qiagen PCR purification kit and ligated with T4 DNA ligase into 
pGEX6p-1 predigested sequentially with BamHI/EcoRI and treated with calf intestinal 
phosphatase. The resulting plasmids were amplified in Smart E. coli cells (Genlantis), 
selected on LB-agar plates containing 100 µg/ml ampicillin, and isolated from cultures 
using a QIAprep Spin Miniprep Kit (Qiagen). The sequences of the isolated plasmids 
were verified by sequencing at the University of Michigan Core Facility.  
 MBP-Tra1 constructs were created using the same fwd primers as used for GST-
Tra1. The reverse primers used are 2358 Rev (5’- GTA CGC ATG GAC GTC GAC CTA 
GCT TCT GGA CAT ATT GAC AAT - 3’) 2588 Rev (5’ - GCA CGC AGG GAC GTC 
GAC CTA AGA AAG CAA TGT AAT GAT AGA - 3’) 2902 rev (5’ - GTA CGC AGG 
GAC GTC GAC CTA TAC TAG GTC ATT CCA CAT ATT - 3’) 3140 rev (5’ - GTA 
CGC AGG GAC GTC GAC CTA TAG TTG AGG AAT GAA AGT AAT - 3’) 3524 rev 
(5’ - GCA CGC AGG GAC GTC GAC CTA TGA TGG TAC AAA CAT TGT TTG - 
3’). The GST Tra1 fusions were used as a template to create the MBP fusions. Pfu turbo 
(Stratagene) was used in these PCRs to improve fidelity. 10 ng of template, 3.5mM 
MgCl2 and 200 nM of each primer was used in each 50 µL amplification reaction using 
the same PCR protocol as described above. The PCR products were purified using a 
Qiagen PCR purification kit and subsequently double digested with BamHI and SalI. The 
digestion reaction was purified using the Qiagen PCR purification kit and ligated with T4 
DNA ligase into pMal-c2g sequentially predigested with BamHI/SalI and treated with 
calf intestinal phosphatase. The resulting plasmids were amplified in Smart E. coli cells 
(Genlantis), selected on LB-agar plates containing 100 µg/ml ampicillin, and isolated 
from cultures using a QIAprep Spin Miniprep Kit (Qiagen). The sequences of the isolated 
plasmids were verified by sequencing at the University of Michigan Core Facility. 
 
MBP plasmid 
To create MBP-stop, a plasmid that only expressed MBP, a stop codon was inserted after 
MBP in pMal-c2g. Oligos (5’- GAT CCT AGT GAT GGC CAG -3’)and (5’ TCG ACT 
GGC CAT CAC TAG -3’) were annealed, phosphorylated and ligated into BamHI/XbaI 
sequentially digested pMal-C2g and CIP treated as described in Chapter 2. 
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Expression Plasmid for GST-Gal4(52-100) and Gal4(1-100) 
The plasmid expressing GST-Gal4(52-100) was a gift from Dr. Aseem Ansari. 
Gal4(1-100) was amplified from yeast genomic DNA using primers (5’- cat gga tcc atg 
aag cta ctg tct tc -3’) and (5’- cat gaa ttc tta atc ttg tac aaa taa tcc tg - 3’) containing 
BamH1 and EcoR1 restriction sites. The plasmid was constructed as described above by 
inserting into pGEX6p-1. 
 
Med15(Gal11)(2-345) delete  
Ycplac111 Med15Δ(2-345) expressing Med15(Gal11) on a low copy plasmid under the 
control of the native Med15(Gal11) promoter in yeast was generated by Jenifer Lum by 
performing site-directed mutagenesis to introduce XhoI restriction sites at amino acids 2 
and 345 in Ycplac11 Med15 WT. Subsequently, the plasmid was digested with XhoI and 
re-ligated to form ycplac111 Med15Δ(2-345). 
 
Tra1 ligand plasmids 
Plasmids expressing the Tra1 ligands on Gal4(1-147) were constructed by insertion of 
DNA oligos encoding the ligands into pGBKT7 as described in Chapter 2. pGBKT7 is 
high copy in yeast, contains a tryptophan marker and expresses Gal4 fusions under the 
control of the ADH1 promoter. 
 
Plasmids used for masking experiments 
Plasmids expressing the Med15 ligands or the Tra1 ligand on Gal4(1-100) or Gal4(1-147) 
were constructed by insertion of DNA oligos encoding the ligands into XbaI/SalI 
digested NYC317 (Gift from Dr. Aseem Ansari) or NYC317-147 (constructed by Jenifer 
Lum) as described in Chapter 2. These plasmids are low copy in yeast, contains a 
histadine marker and expresses Gal4 fusions under the control of the β-actin promoter. 
 
Expression of Tra1 constructs 
Plasmids for the expression of each Tra1 fragment fused to GST or MBP are described 
above. The appropriate plasmid was transformed into chemically competent 
 86 
Rosetta2(DE3) pLysS E. coli (Novagen) and cells were plated onto LB-agar plates 
supplemented with ampicillin (100 µg/mL) and chloramphenicol (34µg/mL). Cultures 
(50 mL) from single colonies were grown overnight at 37 °C (300 rpm) in Select APS 
Super Broth (Difco) supplemented with ampicillin (100µg/mL) and chloramphenicol 
(34µg/mL) before addition to 1L of Select APS Super Broth supplemented with 
ampicillin (100µg/mL) and chloramphenicol (34 µg/mL). After an OD600 of 0.3 was 
reached (37 °C, 300 rpm), the cultures were cooled to 16 °C for 1 h (100 rpm), and 
expression was induced with IPTG (final concentration 0.1 mM) for 12 h (250 rpm). The 
frozen cell pellet was resuspended in Buffer A (100 mM PBS pH 7.4, 10% glycerol (v/v), 
1 mM DTT, 0.2% NP-40 (w/v) and Roche Complete Protease Inhibitor Cocktail) lysed 
using sonication, and the GST-tagged protein was isolated using glutathione-sepharose 
beads (GE Healthcare) The MBP-tagged protein was isolated using amylose resin (New 
England Biolabs). The protein was eluted from the beads overnight at 4 ºC using Elution 
buffer (50mM Tris pH 8.0 0.1%, NP-40 and 15mM Glutathione) for GST tagged proteins 
or (100 mM PBS pH 7.4, 10% glycerol (v/v), 1 mM DTT, 0.2% NP-40 (w/v) and 10 mM 
maltose) for MBP fusions. The protein solution was then buffer exchanged to Storage 
buffer (10 mM PBS, pH 7.4, 1 mM DTT, 10% glycerol (v/v), and 0.01% NP-40) using a 
PD-10 column (GE Healthcare). Finally, the protein was concentrated to 20-200 µM 
using a Vivascience 30K centrifugal filter device (polyethersulfone membrance). The 
protein concentration was measured using a Bradford assay (Bio-Rad) with BSA as the 
standard. The identity and purity of the fusion protein was verified by reducing SDS-
PAGE with appropriate molecular weight standards. The protein solution was stored at –
80 °C until needed.  
For use in the ELISA screen and phage display selection, MBP-Tra1(3092-3524) 
was further purified using size exclusion chromatography. For this purpose, after elution 
from the amylose resin, the protein was concentrated to ~3 mL using a Vivascience  30K 
centrifugal filter device (polyethersulfone membrane) and then loaded onto a gel 
filtration column (16/60 Superdex 200, GE Healthcare) pre-equilibrated with (10 mM 
PBS, pH 7.0, 1 mM DTT, 10% glycerol (v/v), and 0.01% NP-40). Fractions containing 
MBP-Tra1(3092-3524) were pooled and concentrated using a Vivascience  30K 
centrifugal filter device. MBP was expressed and purified using the MBP-stop plasmid 
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described above and using identical conditions for MBP-Tra1 except that it was only 
induced with IPTG for 3 h at 16 °C.  
 
Expression of Gal4(1-100) 
The GST-Gal4(1-100) or GST-Gal4(52-100) was transformed into chemically competent 
Rosetta2(DE3) pLysS E. coli (Novagen) and cells were plated onto LB-agar plates 
supplemented with ampicillin (100 µg/mL) and chloramphenicol (34µg/mL). Cultures 
(50 mL) from single colonies were grown overnight at 37 °C (300 rpm) in Select APS 
Super Broth (Difco) supplemented with ampicillin (100µg/mL) and chloramphenicol 
(34µg/mL) before addition to 1L of Select APS Super Broth supplemented with 
ampicillin (100µg/mL) and chloramphenicol (34 µg/mL). After an OD600 of 0.3 was 
reached (37 °C, 300 rpm), the cultures were cooled to 16 °C for 1 h (100 rpm), and 
expression was induced with IPTG (final concentration 0.1 mM) and 20 µM zinc sulfate 
(only for Gal4(1-100)) for 1.5 h (250 rpm). The frozen cell pellet was resuspended in 
Buffer A (100 mM PBS pH 7.4, 10% glycerol (v/v), 1 mM DTT, 0.2% NP-40 (w/v) and 
Roche Complete Protease Inhibitor Cocktail) lysed using sonication, and the GST-tagged 
protein was isolated using glutathione-sepharose beads (GE Healthcare). The protein was 
eluted from the beads overnight at 4 ºC using Elution buffer (50mM Tris pH 8.0 0.1%, 
NP-40 and 15mM Glutathione). The protein solution was then buffer exchanged to 
Storage buffer (10 mM PBS, pH 7.4, 1 mM DTT, 10% glycerol (v/v), and 0.01% NP-40) 
using a PD-10 column (GE Healthcare). Finally, the protein was concentrated to 10-50 
µM using a Vivascience 10K centrifugal filter device (polyethersulfone membrane). The 
protein solution was stored at –80 °C until needed. Cleavage of the GST tag was 
accomplished overnight at 4 °C using PreScission Protease (GE Healthcare) in Cleavage 
Buffer (50 mM Tris pH 7.0, 0.2% NP-40 (w/v), 1 mM DTT). The Gal4(1-100) solution 
thus obtained was concentrated using a Vivascience  10K centrifugal filter device and 
then loaded onto a gel filtration column (Superdex 75, GE Healthcare) to remove residual 
GST and to exchange the buffer to Storage Buffer. Fractions containing Gal4 (1-100) 
were pooled and concentrated using a Vivascience 10K centrifugal filter device.  The 
protein concentration was measured using a Bradford assay (Bio-Rad) with BSA as the 
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standard. The identity and purity of the fusion protein was verified by reducing SDS-
PAGE with appropriate molecular weight standards. 
 Expression of GST using the parental pGEX6p-1 plasmid was accomplished 
using an identical procedure as described above, except only 2 x 250 mL superbroth was 
used instead of 4 x 1L for GST-Gal4(1-100). 
 
Measurement of Dissociation Constants 
Dissociation constant measurements were carried out on a TECAN Genios Pro Plate 
reader (for Tra1 studies) and a Panvera Beacon 2000 (for Gal4 dimerization domain 
studies) at room temperature.  
Prior to each Tra1 binding experiment, fluorescein-labeled ligand was 
resuspended in 1 mL of Storage buffer (10mM PBS pH 7.0, 1 mM DTT, 10% glycerol 
(v/v), and 0.01% NP-40) and the concentration of the solution was determined by UV-
Vis using the absorbance of fluorescein, λ=495nm (ε 66,000 M-1 cm-1 for fluorescein 
NHS ester and ε 72,000 M-1 cm-1 for fluorescein maleimide). Two stock solutions were 
prepared, 50 nM labeled peptide solution in Storage buffer, and ~100 µM Tra1 in Storage 
buffer containing a final labeled peptide concentration of 50 nM. 20µL of ~100 µM 
Tra1+50 nM labeled peptide was added to the first well of a low volume 384-well plate 
(Corning). To each successive well, a certain amount of the two stock solutions were 
mixed to obtain a range of Tra1 concentrations from ~100 µM - 0.1 µM, keeping 
concentrations of the labeled ligand constant throughout the experiment. In each case, 20 
µL of mixture was added to the well. The plate was incubated for 10 min at room 
temperature and the fluorescence polarization at each Tra1 concentration was measured. 
The raw data was imported into Origin and fit to equation 1 using the Marquardt-




where a is maximum anisotropy – minimum anisotropy, x is protein concentration, b is 










( + c Equation 1 
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y is response. For each experiment, the R2 > 0.98 and each KD represents the average of 
three separate experiments. 
For binding experiments with Gal4(1-100) or Gal4(52-100), fluorescein-labeled 
ligand was resuspended in 1 mL of Storage buffer (10 mM PBS pH 7.4, 1 mM DTT, 10% 
glycerol (v/v), and 0.01% NP-40) as described above. A 100 µL solution of the highest 
Gal4 concentration was prepared with a final concentration of 50 nM fluorescein labeled 
peptide and added to a glass test tube. After a 10 minute incubation, the fluorescence 
polarization of this solution was measured. For each successive measurement, calculated 
amounts of Storage buffer + 50 nM labeled peptide were added to the test tube, keeping 
the concentrations of the labeled ligand constant throughout the experiment while the 
protein concentration was varied. The raw data was analyzed as described above.  
 
Competition experiments using fluorescence polarization 
Competition experiments were performed on the Beacon 2000. Prior to each experiment, 
~1 mg of purified unlabeled competitor peptide was weighed out and resuspended in 
DMSO (final concentration <10%) followed by ~1mL of Storage buffer to create a stock 
solution of unlabeled peptide (~500 µM - 2 mM). Peptide concentrations were 
determined using a spectrophotometer, λ = 280 or determined solely by weight in cases 
where their the extinction coefficient could not be determined due to the lack of 
tryptophans and tyrosines . A control solution with Storage buffer containing the exact 
amount of DMSO but no unlabeled competitor peptide was also prepared. Next, using the 
binding isotherm of the labeled peptide and protein, the concentration of protein that gave 
50% saturation of labeled peptide was determined. This concentration of protein was kept 
constant throughout the experiment. For each data point, solutions were prepared that 
contained the predetermined protein concentration, 25 nM fluorescein labeled peptide, 
variable amounts of competitor peptide and Storage buffer (with appropriate percentage 
of DMSO) bringing the solution to a total volume of 100 µL. All solutions were 





The ELISAs were carried out according to previously described protocols.64 The peptide 
library was synthesized on 0.5 mmole scale as described above. It was split into 4 Alltech 
tubes (12 mL).  Each tube was washed with MeOH (10 x 10 mL) using a vacuum 
manifold. The resin was then briefly dried under vacuum and allowed to swell in H2O (5 
mL) followed by washes with H2O (5 x 5 mL). The resin was then blocked with Blocking 
buffer (10 mM PBS pH 7.0, 0.1% gelatin, 0.2% Tween-20, 0.01% NP-40, 10% glycerol) 
for 1.5 h. After blocking, the resin was washed with Wash buffer (10 mM PBS, 0.2% 
tween-20) (2 x 10 mL). Subsequently, 1 µM MBP was added in Blocking buffer with 0.1 
mg/mL BSA (4 mL per tube) and incubated for 1 h followed by 5 x 5 mL washes with 
Wash buffer. To detect bound MBP, Anti-MBP-HRP (1:3000, New England Biolabs) 
was added in blocking buffer for 1 h. Unbound antibody was removed by washing with 
Wash buffer (3 x 10 mL), 100 mM PBS (3 x 10 mL) and water (1 x 5 mL). To visualize 
beads that bound MBP, 4 mL TMB substrate (Sigma) was added to each tube and 
allowed to incubate for 1 min, after which it was drained and the resin was resuspended 
into water and spread out into petri dishes to identify blue beads. No blue beads were 
isolated after 1 min incubation of the substrate. After 2 min incubation of the substrate, 2 
blue beads were isolated (the time was optimized based on control ELISA experiments 
with the positive control ligand VP2 and MBP-Tra1). The remaining resin was 
transferred back into the Alltech tubes and treated with 6M guanidine for 30 min 
followed by DMF overnight.  
To identify peptides that bind Tra1, the library was washed, and blocked as 
described above. After blocking, the resin was incubated for 1 h with MBP-Tra1(3092-
3524) at a final concentration of 0.25 µM in binding buffer followed by washing (5 x 5 
mL) with Wash buffer. The anti-MBP-HRP antibody was added for 1 hr as described 
above and after thoroughly washing, the TMB substrate was added. TMB was added to 
each alltech tube and incubated for 5 min after which the resin was resuspended in water 
and transferred into a petri dish to isolate the blue beads. Several beads (~1%) turned blue 
on the addition of TMB, however they lost their color when water was added. Only the 
beads that remained blue after washing with water were transferred into 1.5 mL 
microfuge tubes using a pipet tip. 500 µL of 6M guanidine was added to each tube 
containing a single bead and the beads were submitted for sequencing. Edman 
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Phage display was performed according to the Ph.D.-12 Phage Display Peptide Library 
Kit manual (New England Biolabs).  Selections against MBP-Tra1(3092-3524) were 
done in 96 well protein binding plates (Nunc). (Control experiments were initially 
performed using anti-MBP antibody to verify that MBP-Tra1 and MBP do indeed bind to 
the plate and the most stringent Wash buffer used does not strip them off the plate).   
200µL 1µM Tra1 in Storage buffer (10mM PBS pH 7.0, 10% glycerol, 0.0% NP-40) was 
incubated in 2 wells of the plate at 4 °C. Following an overnight incubation, the protein 
solution was poured off the plate. The plate was subsequently incubated with Blocking 
Buffer (10mM PBS pH 7.0, 10% glycerol, 0.01% NP-40, 0.1% gelatin, 0.2% tween-20, 
10 mg/mL BSA and 0.02% NaN3) for 2 h at 4 °C with shaking. After blocking, the wells 
were washed with Wash buffer (6 x 300µL) (10mM PBS, 0.1% Tween-20) and then 10 
µL of the phage library in 100 µL of Binding buffer (10 mM PBS pH 7.0, 10% glycerol, 
0.01% NP-49, 0.1% gelatin, 0.2% Tween-20, 100 µg/ml BSA) was added to each well. 
The phage were allowed to bind for 1 h at room temperature with shaking after which, 
the wells were washed (10 x 300µL) with Wash buffer. The phage were eluted by the 
addition of 150 mL Elution buffer (0.2M glycine-HCl pH 2.2). After a 10 min incubation, 
22.5 µL of Neutralizing buffer (1M Tris pH 9.0) was added. The eluted phage were 
amplified in ER2728 E. coli and precipitated using PEG/NaCl and used for subsequent 
pannings of selection. 
 The next round of panning consisting of a negative selection, was carried out to 
remove phage that bound MBP and/or the plate. For this purpose, 1µM MBP in Storage 
buffer was added to 2 wells of a plate as described above. 2 x 1011 amplified phage from 
the previous round were added to each well and in this case, after a 1 h incubation, phage 
that did not bind MBP or the plate were isolated and added to 2 wells that contained Tra1 
for the 2nd round of positive selection. The conditions for the 2nd panning were similar as 
described above, except in one well the Binding buffer used contained 500 µM VP2.   
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 The third round of positive panning was performed similar to the 2nd panning with 
the two different binding buffers except the stringency of the Wash buffer was increased 
to contain 0.5% Tween-20.  
To identify the peptide sequences encoded by each bound phage, after each 
panning, 15 individual phage were amplified to extract their DNA, which was sequenced 
at the University of Michigan Sequencing Core. Phage ELISAs were also performed as 
per the manual to identify phage that bound MBP-Tra1 over MBP or just the plate. 
Briefly, 109, 1010 and 1011 phage were incubated with a 96-well plate prebound with 0.1 
µM MBP-tra1 or MBP or a blank well. The bound phage were detected using a HRP-
conjuagted anti-phage antibody using the ABTS substrate and quantitated at 405 nm 
using an absorbance plate reader (Tecan Genios Pro). 
 
Competitive ELISA 
Phage expressing ENSPLWWPQPLA were amplified according to the New England 
Biolabs Phage display kit manual. Briefly, 10 µL of phage glycerol stock was used to 
infect 20 mL of LB (with tetracycline) inoculated with 200 µL of saturated culture of 
ER2728 and grown for 5 h at 37 °C. The cells were pelleted and the supernatant 
containing phage were precipitated with PEG/NaCl overnight at 4 °C. Subsequently, the 
phage was resuspended in PBS and re-precipitated with PEG/NaCl and finally dissolved 
in 10 mM PBS obtaining ~50 µL of 1010 phage/µL. 
 For the ELISA, 200 µL of 1 µM Tra1 or Med15 was added to each well of a 
NUNC maxisorp protein-binding 96 well plate and incubated overnight at 4 °C. The plate 
was blocked with Blocking buffer (10 mg/mL BSA in 10 mM PBS, 0.5% Tween-20) for 
1 hr. Subsequently, 200 µL of 1010 phage was added to each well in 10 mM PBS, 0.5% 
Tween-20 with varying amounts of VP2 and incubated for 1 h. After 6 washes with 10 
mM PBS, 0.5% Tween-20, 200 µL of anti-M13-hrp antibody (1:5000 dilution) was added 
in Blocking buffer to each well for 1 h. After 6 washes with 10 mM PBS, 0.5% Tween-20 
the phage were detected using 200 µL of ABTS solution in sodium citrate with hydrogen 
peroxide as per the NEB phage display manual. The substrate was incubated for 1 h and 
the absorbance at 405 nm measured using an absorbance plate reader (Tecan Genios Pro).  
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β-galactosidase assays  
The function of DBD+TAD fusions was examined in yeast by a quantitative liquid β-
galactosidase assay as described in Chapter 2. Briefly, the plasmids encoding the peptide 
fusions and the DBD plasmid (negative control) were transformed into yeast using the 
LiOAc method and transformed colonies were selected by growth on synthetic complete 
(SC) media containing 2% raffinose and lacking the appropriate amino acid(s) for 
selection. Freshly transformed colonies were used to inoculate 5 ml cultures of SC media 
containing 2% raffinose and lacking the appropriate amino acids. The cultures were 
incubated overnight at 30°C with agitation. Following incubation, these cultures were 
used to inoculate 5 ml cultures of SC media containing 2% raffinose, 2% galactose and 
lacking the appropriate amino acids that were subsequently incubated overnight at 30°C 
with agitation to an OD660 of 3–4. The yeast cells were harvested and resuspended in 
Breaking buffer (100 mM Tris-HCl (pH 8.0), 20% glycerol) containing the Complete 
Protease Inhibitors cocktail (Roche). The cells were lysed by vortexing with glass beads. 
A portion of the cell extract was used to measure β-galactosidase activity via incubation 
with o-nitrophenyl-β-D-galactopyranoside (1 mg/ml) in Z buffer (60 mM Na2HPO4, 40 
mM NaH2PO4, 10 mM KCl, 1 mM MgSO4•7H2O, and 50 mM 2-mercaptoethanol [pH 
7]). The reaction was stopped by adding 1 M Na2CO3 and the OD420 was measured on a 
Varian Cary 300 UV-vis spectrometer. The activity reported was normalized to the total 
protein concentration of the extract, measured using a Bradford assay kit (Bio-Rad) with 
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CHARACTERIZING ACTIVATOR-COACTIVATOR INTERACTIONS* 
 
A. Abstract 
Because of the central role that transcriptional activators play in gene regulation, 
significant effort has been devoted to developing a molecular-level picture of how they 
function in eukaryotes. It is generally accepted that activators are involved in two major 
types of binding events: DNA binding events and protein-protein interactions.3 
Experimental techniques such as ChIP-on-chip and in vivo footprinting have successfully 
been used to identify the DNA binding sites of activators within the genome, and in many 
cases these have been correlated with gene expression profiles.4-6 However, protein 
binding partners of activators, and more specifically, the transcriptional machinery 
binding partners (coactivators) have not conclusively been identified.7 For example, a 
number of genetic and biochemical studies have identified coactivator proteins that 
interact with activators directly or indirectly.8-13 Two recent crosslinking studies in 
reconstituted (cell-free) systems have implicated a small subset of these proteins as likely 
direct activator targets.2, 14 Although an important step forward, there are still many 
questions about the exact nature of activator-coactivator interactions and the relevance of 
these results in the context of the cellular environment. More specifically, given the 
importance of activator binding site on function (Chapter 2), not only is the identification 
of the in vivo activator targets important, but also determining the binding site(s) within a 
given coactivators.1, 2, 15, 16 In the long term, efforts to determine the identity of activator 
binding partners and the binding sites will establish screening targets for artificial 
activator and inhibitor design for therapeutic and biotechnology applications. 
                                                
* I performed experiments in Figures 4.4 – 4.7, 4.12 – 4.14. Mass spectrometry data for 
Figures 4.5 and 4.8 was obtained by Bo wang (Hakånsson group) and the Michigan 
Proteome Consortium facility. Jenifer Lum performed experiments in Figure 4.10. 
Experiments in Figure 4.15 were performed in collaboration with Anna Mapp. 
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In this Chapter, we use crosslinking coupled with mass spectrometry for the 
characterization of activator binding sites and, ultimately, for the identification of binding 
partners. In vitro crosslinking was used to identify the binding sites of the activators 
Gal4, Gcn4 and VP2 within a key coactivator Med15(Gal11) and coupled with genetic 
experiments, these studies suggest that the TADs function through distinct but 
overlapping binding profiles. To characterize these interactions in vivo, in parallel we 
developed a strategy for reliable incorporation of the photo-crosslinkable amino acid, p-
benzoylphenylalanine  (pBpa), into Gal4 in yeast using nonsense suppression. Finally, 
using crosslinker-containing Gal4, we have performed cellular crosslinking experiments, 
thus setting the stage to identify its functionally relevant targets in vivo. 
 
B. Introduction 
The protein-protein interactions between the amphipathic class of transcriptional 
activators and their interacting partners have been extensively studied. Much of what is 
known about these interactions comes from studies of the amphipathic activators Gal4, 
Gcn4 and VP16.1, 8, 10, 12, 17-23 Early on, chromatin immunoprecipitation (ChIP) studies 
showed that subsequent to activator-promoter binding, the chromatin-remodeling 
complex SAGA, the Mediator complex and the general transcriptional machinery are 
sequentially localized to the promoter.24 However, this study did not reveal if the 
recruitment process was initiated by direct binding interactions of activators with 
components of these complexes. In vitro crosslinking experiments with DNA bound 
Gcn4 and Gal4 subsequently revealed that both of these activators interact with Tra1 and 
Taf12 in the SAGA complex and Med15(Gal11) in Mediator.2, 14 However, whether or 
not these TADs target identical binding sites within these proteins was not elucidated. In 
addition, there was some question regarding the in vivo relevance of these results since 
the studies used non-native promoters and the DNA templates used were not 
chromatinized. There is, however additional data validating Tra1 as a target, in vivo 
FRET demonstrated an interaction between the Gal4 TAD and Tra1.25-27 This study 
examined eighteen other potential targets, including Med15(Gal11), and only Tra1 and 
the masking protein Gal80 gave a positive FRET signal.27 Although the negative results 
here are difficult to interpret given the reliance of FRET on the relative positioning of the 
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partner, they underscore the need for alternative approaches to define both the in vivo 
binding partners of activators and the binding sites with these partners. More recently, the 
Lehming group also used a similar approach where they attached half of the ubiquitin 
protein to Gal4, Gcn4 and probed for complementation with the other half of ubiquitin 
attached to different transcriptional machinery proteins in yeast.28 This study resulted in 
the identification of >10 proteins, including Med15(Gal11), that associate with Gal4 and 
it raises the possibility that some of these proteins are not direct targets of Gal4.29 Thus as 
outlined in this Chapter, we have focused on implementation of alternative in vitro and in 
vivo crosslinking strategies to address this unmet need. 
 
Table 4.1 Strategies to characterize activator-target interactions 




NMR spectroscopic and Crystallographic 
studies of free activators or activators in 
complex with target proteins 
Provides important information about the 
structure of activators and the residues 
of activators important for target binding. 
Can also provide information about the 
target binding site 
In vitro; free activators are often unstructured in solution and it is 
difficult to obtain structural information in these cases; high 
protein concentrations required and activators and their targets 





Activators or their targets are immobilized on a 
solid support often by tagging one of the 
partners with GST. The immobilized partner is 
incubated with extract containing a potential bait 
in solution and subsequently the solid support is 
probed for retainment of the bait proteins 
Convenient to perform experimentally; 
several examples of this techniques used 
to identify potential activator binding 
partners  
In vitro; often results in false positives since the experiments are 
performed at non-physiological concentrations of the interacting 
pair; GST dimerizes in solution and activator fusion to GST can 





Endogenous copies of potential coactivators are 
mutated or deleted and the effect of this 
perturbation is probed on the ability of an 
activator to function 
In vivo, can provide functional 
information about the relevance for the 
potential coactivator; low resolution 
information on binding sites by 
determining regions on coactivators that 
are important for activator function 
Often hard to interpret since they result in pleiotropic effects due 
to large-scale alteration of transcription protein complexes 





Incorporation of relatively small crosslinkers into 
a TAD results in a covalent bond between the 
crosslinker and the activator target when 
triggered by irradiation with light in the case of 
photo-crosslinkers or by the addition of other 
triggering molecules   
Identifies direct activator targets; creates 
a small perturbation in activator 
structure; can probe the role of different 
residues on an activator for target 
binding; can identify activator binding 
sites on targets 
In vitro, no direct physical evidence for these activator-target 
interactions in vivo, does not take in consideration the effects of 
chromatin, and covalent modifications on activators such as 





based in vivo 
crosslinking 
 
Use of formaldehyde as a crosslinking agent in 
live cells enables the rapid generation of 
protein-protein and protein-DNA crosslinks, 
creating a snapshot of cellular interactions at a 
given time point. Immunoprecipitation with an 
antibody for a particular target can indicate the 
association between the target and a DNA 
bound activator. 
In vivo, permits the ability to probe 
activator-target interactions in a time 
dependent manner; Using qPCR can 
quantitate the association between two 
interacting partners; formaldehyde 
freezes all cellular interaction preventing 
degradation of activator-target 
complexes by proteases and the 
proteasome that often results during 
cellular lysis 
Formaldehyde is a non-specific crosslinker that crosslinks two 
lysine residues on proteins that are in close proximity, an 
apparent protein-protein interaction in vivo could either represent 
a direct crosslink between the two proteins or it might be due to 
multiple crosslinks that indirectly connect the two proteins; the 
amount of formaldehyde crosslinking depends on the number 
and physical location of lysines within the interacting surfaces, 
parameters that vary among protein-protein interactions. For this 
reason, the failure to observe a crosslink between two proteins 




Two potential interacting partners are fused to 
different fluorophores that when in close contact 
display a FRET signal indicating an interaction 
between the two proteins 
 
In vitro and in vivo, validates interactions 
between an activator and targets in cells. 
All fluorophore fusions are not optimal to observe a FRET signal, 
there is a maximum separation distance that the fluorophores 
can be apart, the signal also depends on the orientation of the 
fluorophores; cannot be used to discover unknown interactions, 
require a priori knowledge of potential activator targets, so they 




B.1 Unnatural amino acids as protein interaction probes in cells 
Until recently, the state of the art in identifying protein-protein interactions and 
binding sites involved the use of in vitro approaches and the few cellular strategies that 
have been developed also have limitations (summarized in Table 4.1). Methods to 
incorporate a site-specific crosslinker in a protein in living cells would be extremely 
advantageous as any crosslinked protein discovered could be confidently assumed to be a 
direct binding partner.30-32 Historically the challenge to using this method has been 
technical; the selective incorporation of a photoactive group at a single site within a 
single protein in cells has been until recently an elusive goal. 
Current methods of incorporating crosslinking agents in cells involve the use of 
photo-Met and photo-Leu amino acids which substitute the endogenous Leu and Met in 
proteins.33-35 This strategy has been successfully used in mammalian cells to identify 
protein-protein interactions. We tried photo-Met and photo-Leu in yeast and found that 
yeast do not grow under these conditions, either due to problems incorporating them or 
poor transport cannot incorporate them and hence do not grow. Another approach 
involves the in vitro labeling of proteins with a crosslinker and assisting the cellular entry 
of the proteins by fusion to a cell-penetrating peptide such as TAT.36-40 However, this 
approach has seen only modest success in yeast.41-44 Moreover, the expression of well-
folded activators in bacteria is a longstanding challenge as these proteins typically 
aggregate quite extensively.  
B.1.a Nonsense suppression to incorporate site-specific unnatural amino acids into 
proteins  
 In a recent breakthrough, nonsense suppression methods have made it possible to 
incorporate unnatural amino acids conferring advantageous chemical functionality into 
proteins in cells. Using this strategy, the Schultz group has developed methods to 
incorporate unnatural amino acids in bacteria, yeast and mammalian cells at the amber 
stop codon.45-54 In order to incorporate unnatural amino acids into proteins in yeast, they 
used the orthogonal pair of the E. coli amber suppressor tyrosyl–tRNA synthetase and 
tRNACUA. The E. coli tyrosyl–tRNA synthetase (TyrRS) has previously been shown to 
efficiently aminoacylate E. coli tRNACUA when both are genetically encoded in S. 
cerevisiae (Figure 4.1c).55-58 To alter the amino acid specificity of the orthogonal TyrRS 
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so that it aminoacylates tRNACUA with a desired unnatural amino acid and none of the 
endogenous amino acids, they used a growth-based selection strategy in yeast with a 
library of TyrRS containing  5 random mutants in the active site. The selection was based 
on the ability of TyrRS to incorporate the unnatural amino acid into 2 amber positions 
producing an active Gal4, which enabled the yeast to survive. They also performed a 
number of controls to verify that the isolated TyrRS mutants were in fact functioning by 
incorporating a particular amino acid. Finally the unnatural amino acids of interest were 
inserted into the control protein superoxide dismutase (hSOD) and incorporation was 
verified by mass spectrometry.52, 53 
Using the synthetase-tRNA pairs developed by this approach, the Schultz and 
Wang groups have shown the incorporation of a variety of amino acids (>30) including 
the fluorescent amino acid dansyl alanine and amino acids that contain groups for 
photocrosslinking, p-Benzoyl phenyl alanine (pBpa) and p-Azido phenyl alanine (pAzpa) 
(Figure 4.1a).50, 59-63 Incorporation of pBpa and pAzpa into transcriptional activators in 
cells could lead to new methods for probing activator-coactivator interactions in a cellular 
context and to determine the binding sites of activators on coactivators using mass 
spectrometry.64-67   
Specifically, pBpa is well suited for this purpose because it is more stable than 
pAzpa and can be iradiated at 365 nm wavelengths that are less damaging to proteins and 
other biomolecules. Further, the diradicals formed when pBpa is excited to its triplet state 
reversibly relax back down to the ground state if there are no H-bond donors in close 
proximity.68-70 This feature enables the continuous irradiation of this molecule to increase 






Figure 4.1  Structure of unnatural amino acids. a) p-Benzoyl phenyl alanine (pBpa),  
p-Azido phenyl alanine (pAzpa) and dansyl alanine. pBpa and pAzpa contain 
functional groups that enable the formation of protein-protein crosslinks when 
irradiated with UV light. Dansyl alanine is a fluorescent amino acid and can be used 
for FRET studies. b) Mechanism of benzophenone crosslinking. Upon exposure to 
UV light (365 nm), benzophenone forms a diradical that abstracts a proton from 
adjacent backbone C-H bonds of proteins in close proximity followed by an 
insertion event to form a covalent C-C linkage between itself and the protein. c) 
Incorporation of unnatural amino acids in cells. Orthogonal suppressor tRNA is 
charged with an unnatural amino acid by its cognate synthetase and then it 




C.1 Determination of binding site(s) of activators within Med15(Gal11) 
 As outlined in Chapter 2, many lines of evidence suggest that the yeast Mediator 
component Med15(Gal11) is important for activated transcription, specifically as a 
binding target of endogenous and artificial TADs.2, 10, 13, 14, 71-74 For example, ligands that 
were screened to bind Med15(Gal11)(186-619) were able to specifically activate 
transcription in yeast (Chapter 2 and 3). It has been shown that the C-terminus of the 
protein is involved in transcriptional machinery interactions, with TFIIE.75-77 The N-
terminus and the middle portion of the protein have been shown to be important for 
activator contacts (residues 1-619).10, 17, 18, 71, 78 However, it is not known if there is a 
single, generally utilized TAD binding surface in this protein or a variety of sites (as 
suggested by experiments in Chapter 2) used by endogenous activators. 
As discussed in the final section of this Chapter, in vivo crosslinking will provide 
the most convincing evidence for physiologically relevant activator targets and binding 
sites on these targets. As we were adapting that technologically challenging strategy for 
our purposes, we simultaneously pursued in vitro crosslinking that would enable us to 
identify likely TAD binding sites to search for in vivo.  
To identify the binding site, we utilized mass spectrometry coupled with photo-
crosslinking methods resulting in a powerful strategy to determine activator-coactivator 
binding sites.79, 80 Using this approach, the identity and location of site-specific photo-
crosslinks generated can be identified by mass spectrometry, providing high resolution 
binding site information. More importantly, with the improvements in mass spectrometer 
sensitivity they require only small amounts of protein compared to structural studies that 
can also provide similar information but are less feasible due to the stability and 
solubility of several transcription proteins at high concentration.81-88  
We decided to identify the binding sites of the Gal4, Gcn4 and VP16 TADs 
within Med15(Gal11). These activators upregulate transcription to high levels in cells and 
several lines of evidence suggest that Med15(Gal11) is a target of these activators. 2, 10, 13, 
14, 71-74 Given the overall amphipathic nature of these TADs, we wanted to investigate if 
these TADs target the same binding site(s) on Med15(Gal11). For our initial studies, we 
envisioned that we would use isolated TADs from these activators and perform 
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crosslinking experiments with different fragments of Med15(Gal11) in vitro. Using 
western blots we could then narrow in on the regions that seemed to interact with these 
TADs. Once we identified the fragments of Med15(Gal11) that crosslink with TADs, we 
would repeat similar crosslinking experiments with those fragments and submit them for 
the more challenging mass spectrometry analysis for exact binding site(s) determination 
(Figure 4.2). This would provide, for the first time high resolution information about the 
location of the binding site. Subsequently, to investigate the physiological relevance of 
these results we could measure the activity of the various activators in Med15(Gal11) 
delete strains, since deletion of Med15(Gal11) does not result in large-scale 
reorganization of the transcriptional machinery.89 Future experiments with TADs fused to 
DBDs would probe the binding profile in the context of a DNA bound activator and 
finally crosslinking experiments in yeast with crosslinkers incorporated into activators 
would enable the identification of binding sites in a native context. 
 
Figure 4.2 Strategy to identify binding sites of activators using in vitro crosslinking. 
Irradiation of Med15(Gal11) fragments combined with TADs containing pBpa and 
biotin will form TAD-Med15 crosslinks. Western blots using a streptavidin-HRP 
conjugate can be used to qualitatively probe the fragments of Med15(Gal11) that are 
crosslinked. To identify binding sites, the crosslinked reaction is proteolytically 
digested (e.g. trypsin) and probed by mass spectrometry directly or it can be enriched 
specifically for crosslinked fragments (red+green arrow) over tryptic Med15 
fragments (green arrows) before being probed by mass spectrometry. 
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C.1.a Construction of TADs and expression of Med15(Gal11) fragments 
 Solid phase peptide synthesis was used to synthesize TADs from Gal4, Gcn4, and 
VP16 in which pBpa replaced particular phe residues. The sequences for each 
endogenous activator chosen have previously been shown to display a significant portion 
of the activity of the full-length proteins in yeast. Further, the importance of the particular 
Phe residue in interactions with targets and function has been well documented.1, 90-92 
Moreover, substitution of the particular Phe with other hydrophobic residues has shown 
to retain function and affinity for target proteins.1, 2, 14 Thus, the photactivatable amino 
acid p-Benzoyl phenyl alanine (pBpa) was used to replace positions that contained 
existing Phe residues, with the attempt of maintaining the hydrophobic character of the 
peptide (Figure 4.3a). The peptides were also labeled with a biotin handle at the N or C 
terminus for purification and qualitative detection of crosslinking by western blots. 
Since full-length Med15(Gal11) cannot be bacterially expressed well and with 
high enough purity due to its large size, in collaboration with the high throughput protein 
expression facility (LSI), we developed bacterial expression constructs that span the 
entire sequence of the protein. These constructs were designed on the basis of secondary 
structure predictions and produced Med15(Gal11) as fusions to the solubility and 
purification tags his-MBP and his-mOCR. Using this approach we were able to obtain 
constructs that span >90% the sequence of Med15(Gal11) (Figure 4.3b).  
 
Figure 4.3 Constructs for in vitro 
crosslinking. a) Structure of TADs used for 
in vitro crosslinking. pBpa is incorporated 
into the TADs in place of phe residues 
maintaining the hydrophobic character. A 
biotin handle is incorporated into each 
TAD to facilitate detection and 
purification. b) Med15 E. coli constructs. 
Bacterial expression constructs spanning 
the entire sequence of Med15 fused to 
MBP or mOCR were developed at the high 
throughput protein expression facility at 
LSI. Expression constructs that gave 
soluble protein >75% purity after a single 
affinity chromatography step are shown. 
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C.1.b Locating the TAD binding region  
 To localize the fragment of Med15(Gal11) that interacted with activators, we 
picked a series of fragments that spanned the entire sequence of Med15(Gal11) and 
performed crosslinking reactions with isolated TADs. For each crosslinking reaction, the 
pBpa containing-TAD was incubated with Med15(Gal11) and irradiated with 365 nm 
light for 30 min using a 6W handheld lamp at 4 °C. The presence of the crosslinked 
product was detected by western blots using streptavidin-horse raddish peroxidase (HRP) 
following resolution by PAGE. Satisfyingly, based on previous studies highlighting the 
importance of the N-terminus and the middle of the protein for activator contacts, we 
found that all the TADs interacted with Med15(Gal11)(1-357), and a smaller fragment 
within that region, Med15(Gal11)(107-255), also showed a strong signal when probed 
with streptavidin-hrp in a western blot (Figure 4.4).10, 17, 18, 71 This suggested that at least 
one binding site was contained within this region. Consistent with these results, 
fluorescence polarization binding experiments with this region revealed that the Gal4, 




Figure 4.4 Isolation of TAD binding 
region of Med15(Gal11). 
a) 1 mg/mL of MBP fusions spanning 
the sequence of Med15 (obtained from 
high throughput protein lab, LSI) were 
incubated with 24-32 µM TADs of 
each TAD individually and irradiated 
for 30 min. The detection of 
crosslinked products was performed 
using westerns blot probed with 
streptavidin-hrp. b) 20 µM Med15(1-
357) with no tag or MBP-Med15(107-
255) were incubated with 44 µM Gal4 
TAD and irradiated for 30 min. c) 
Dissociation constants for TADs and 
Med15(1-416) determined by 
fluorescence polarization. Error is 





C.1.c Mass spectrometric determination of binding sites 
To obtain binding site information we decided to use Med15(Gal11)(1-416) as 
Med15(Gal11)(345-416) also interacted with Gcn4 and VP2 (Figure 4.4b).  The mass 
spectrometry studies were performed by our collaborator Bo Wang in the Håkansson 
group. The determination of the binding site is achieved by performing a proteolytic 
digest of the TAD-Med15(Gal11) crosslinked complex and detection of a set of peaks 
that correspond to molecular weights of the TAD + a proteolytic Med15(Gal11) 
fragment. To eliminate false positives, a candidate crosslinked product was also 
confirmed using MS-MS to verify it contained residues of the TAD and of 
Med15(Gal11). 
C.1.c.i Determination of sequence coverage for Med15(Gal11)(1-357) 
Since the TAD could potentially crosslink at any region within Med15(Gal11), it 
was necessary to ensure that >80% sequence coverage of Med15(Gal11) itself could be 
obtained in terms of proteolytic peptides. Using FT-ICR mass spectrometry and 
optimizing various instrumental parameters, our collaborator Bo Wang was able to obtain 
>95% sequence coverage of the protein by using trypsin for proteolytic digestions 
(Figure 4.5). Similar experiments with chymotrypsin showed that it provided ~80% 
sequence coverage. 
 
C.1.c.ii TAD-Med15(Gal11) crosslinking 
 For each crosslinking reaction, the pBpa-containing TAD was incubated with 
Med15(Gal11) and irradiated with 365 nm light using a 6W handheld lamp at 4 °C. 
Evaluation of the time dependence of UV irradiation for the Gcn4 TAD revealed that 
Figure 4.5 Sequence coverage of Med15(1-357) using mass spectrometry. Med15(1-
357) was digested with trypsin and the proteolytic fragments were analyzed by ESI 
mass spectrometry. The residues that were contained in the proteolytic fragments are 
indicated in red. The amino acids SNA are not part of Med15(Gal11), but are left 
over after cleavage with TEV protease. 
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only 5 min of 365 nm light was sufficient to produce a crosslinked product detectable via 
Western blot analysis. At longer times (>2 h) we noticed that the TAD crosslinked to the 
minor impurities present in the Med15(Gal11) sample. A 2 h time point seemed to 
balance TAD-Med15(Gal11) crosslinked product yields with lower levels of crosslinking 
to the impurity (Figure 4.6). These were the conditions used for subsequent experiments. 
Initially, the reaction mixture containing uncrosslinked TAD, free Med15(Gal11) and 
crosslinked TAD-Med15(Gal11) was subjected to trypsin digest followed by mass 
spectrometric analysis directly without separating the individual components. Using this 
approach, however, only peaks corresponding to the free TAD and tryptic Med15(Gal11) 
fragments were observed. Thus the crosslinked products were likely of lower abundance 
relative to the other components and/or were less ionizable by the ion source perhaps due 
to ion suppression. 
 
C.1.c.iii Enriching for crosslinked products 
In order to specifically isolate the crosslinked products for mass spectrometric 
analysis, we incubated the tryptic digest reaction mixture with neutravidin beads. 
Theoretically, only the biotinylated compounds would bind to neutravidin, which would 
include the free TAD and any potential crosslinked products (the TADs were labeled at 
the N or C terminus depending on which position prevents the loss of biotin and pBpa 
after trypsin digest). After several washes of the neutravidin beads, the bound material 
was eluted using various elution conditions. It was found that the presence of detergent 
was required to elute the biotinylated material from the beads; heating the beads to 100 
°C, addition of organic solvents such as acetonitrile, DMF and DMSO and lowering the 
pH did not elute detectable amounts of material. Detergents are not compatible with mass 
spectrometry since they form clusters and prevent the ionization of the analyte. In an 
Figure 4.6 Time dependence of crosslinking.  45 µM 
Med15(1-416) was incubated with 70 µM Gcn4 TAD for the 
times indicated. The crosslinked products were visualized 
using a western blot with streptavidin-HRP. 
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effort to remove the detergent we moved to using LC/MS using a C18 column, which 
would resolve the tryptic peptides from the detergent. However, we had limited success 
with this approach, with the detergent clusters still being observed and no crosslinked 
fragment was found.  
C.1.c.iv Use of cleavable disulfide linked biotin-TAD conjugates 
 
In an effort to elute the biotinylated material from neutravidin using mass 
spectrometry compatible reagents, Gal4, Gcn4, and VP2 were linked to biotin via a 
disulfide bond, which on the addition of DTT results in the cleavage of biotin from the 
rest of the sequence, enabling its elution from neutravidin beads (Figure 4.7). Disulfide 
biotin-linked Gal4, Gcn4 or VP2 were combined with Med15(Gal11)(1-416) for 2 h and 
irradiated with a 150W 365 nm light source at 4 °C. At the end of this time, a 30K MW 
cut-off concentrator was used to remove any free TAD from the solution and the semi-
purified mixture was digested with trypsin. After the trypsin was heat inactivated, the 
material was purified using neutravidin agarose and eluted with 100 mM DTT at 65 °C 
and subsequently analyzed by mass spectrometry.  
C.1.c.v Location of binding sites 
The TADs were observed to crosslink to Med15(Gal11) (207-217) and to 
Med15(Gal11) (161-174) by MS and the result was confirmed by obtaining MS-MS 
spectra. This was not unexpected since in Figure 4.4, Med15(Gal11)(107-255) also 
crosslinks with these TADs. Interestingly, recent work by Kim et. al identified homology 
between residues 116-255 of Med15(Gal11) and the Qr of human steroid receptor 
coactivator (SRC) proteins.93 Specifically, they align two characteristic nuclear receptor 
binding motifs, an A and B box, to lie within this region. They also found that the 
mammalian glucocorticoid receptor (GR) TAD (known as tau1, GR(77-262)) was able to 
interact with the 116-255 fragment. In particular, they found that mutations in the B box 
(residues 196-202) abolished Med15(Gal11) binding and the cellular activity of the GR 
Figure 4.7 Structure of TAD 
linked to cleavable biotin. 
TADs containing pBpa and a 
Cys (in red) were linked to a 




TAD in yeast. Given the close proximity of the potential B box to the 
Med15(Gal11)(207-217) crosslinked fragment, it is likely that this region has evolved to 
interact with multiple activators (Figure 4.8).  
 Crosslinking experiments with Gal4, Gcn4, VP2 and Med15(Gal11)(1-416) also 
resulted in another crosslinked fragment, Med15(Gal11)(74-84). This binding site lies in 
helix 3 of the Med15(Gal11) GACKIX domain, an evolutionary conserved activator 
binding motif.78, 94-98 The GACKIX domain has been found in mammalian coactivators 
CBP, ARC105 and SREBP. Comparison of the different activators binding sites across 
species reveals an overlapping region in helix 3 of the GACKIX domain (Figure 4.9). 
While these results highlight the Med15(Gal11) binding sites that are targeted by VP2 
and Gcn4 in vitro, it is conceivable and indeed likely that in vivo, at physiological 
conditions, all or a subset of the interactions control the function of these TADs. 
Figure 4.8 Summary of binding sites on Med15(1-416). Binding sites on 
Med15(1-416) as determined by mass spectrometry are indicated in red. 
Conserved domains are indicated in green. The Gal4 TAD used in these 
experiments consisted of residues 854-874 instead of the larger 840-881. This 
shorter peptide sequence still retains the ability to bind Med15 as shown in Figure 




C.1.c.vi.Independent confirmation of mass spectrometry results 
The binding sites within Med15(Gal11) determined by photo-crosslinking in the 
previous section were performed in vitro and it is conceivable that only a subset of these 
are physiologically relevant. To probe the significance of the interaction in cells, 
functional assays were performed in yeast in collaboration with Dr. Jenifer Lum. The 
ability of these TADs to activate transcription in reporter gene assays as Gal4 DBD 
fusions in various Med15(Gal11) mutant yeast strains was investigated. Interestingly, 
Jenifer Lum found that deletion of Med15(Gal11)(1-186) resulted only in the reduction of 
activity for Gal4-VP2. On the other hand, the Med15(Gal11)(1-345) deletion mutant 
resulted in reduction of activity of all the TADs. These studies show that in cells, VP2 
most likely targets all three binding sites, while Gcn4 and Gcn4 only utilize the 
Med15(Gal11)(207-217) binding site for function (Figure 4.10). Additional studies with 
other Med15(Gal11) deletions are in progress to completely delineate the functional role 
of each individual binding site. 
Figure 4.9 Comparison of binding of sites of activators in the GACKIX domain. The 
binding sites of different activators in homologous GACKIX domains are indicated in 
red. The solution structures of the GACKIX domains are taken from the PDB ,2KON 
(Med15 KIX), 2GUT (ARC105 KIX), 1KDX (CBP KIX-CREB), 1SBO (CBP KIX-c-
Myb) and 2AGH (CBP KIX-MLL). 
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These results show that multiple activators seem to target the same binding sites 
on coactivators. Further these binding sites seem to be conserved between different 
coactivators, with the GACKIX, A and B boxes being found in many coactivators. 
However, the three activators investigated in this study had a different functional 
dependence, highlighting that in cells only a subset of binding sites are functionally 
relevant. Furthermore from the studies with VP2 we observe that multiple binding 
interactions to Med15(Gal11) are required to obtain maximal activation.  
 
In the future, the crosslinking combined with proteomics approaches can be 
extended to study other activator-coactivator interactions, to map out the critical residues 
important for their interactions. For example, elucidating all the physiologically relevant 
binding sites of the mammalian transcriptional activator (Elf1)ESX on Med23(Sur2), will 
assist in developing inhibitors of this interaction to treat breast cancer that results from an 
over expression of (Elf1)ESX regulated genes.99   
C.2 Incorporation of unnatural amino acids in cells for in vivo crosslinking 
Extension of the in vitro crosslinking strategy of determining activator binding 
sites to cellular approaches will not only confirm the binding sites of TADs on 
Med15(Gal11) but also lead to the identification of other bonafide coactivators 
supplementing those that have been determined using previous in vivo approaches.27 In 
particular, in contrast to previous in vitro crosslinking approaches, incorporation of 
crosslinking amino acids pBpa and pAzpa into the TAD of activators in yeast will 
Figure 4.10 Functional 
evaluation of TADs in 
yeast. β-galactosidase 
assays were performed 
in Med15(Gal11) 
mutant strains 
containing deletions of 2 
or 3 of the TAD binding 
sites. The TADs were 
fused to the Gal4(1-100) 
DBD. The experiments 
were performed in 
triplicate and the error is 
reported as SDOM.  
 
 117 
facilitate the identification of cellular activator-coactivator interactions. When irradiated 
with UV light, pBpa and pAzpa form radicals that insert into adjacent C-H bonds of 
proteins, forming stable covalent crosslinks with potential direct-binding partners. For 
our initial experiments, we decided to incorporate pBpa and pAzpa amino acids into the 
well-characterized minimal Gal4 TAD comprising residues (840-881).1 We envisioned 
that using western blot analysis of a Gal4 TAD-containing activator, we could visualize 
the incorporation of unnatural amino acids in the Gal4 TAD. Subsequently, we could use 
western blots and mass spectrometry to determine the identity and location of the 
covalent crosslinks generated by the crosslinker-incorporated activators when yeast cells 
are irradiated by UV light. 
 Several hydrophobic and acidic residues in the Gal4 TAD have been shown to be 
important in vitro for contact with potential coactivators and also for activity (Figure 
4.11).1, 2, 22, 100 However, replacement of a subset of these residues with other 
hydrophobic groups has shown to have limited impact on coactivator binding and for 
Gal4 function. Thus, we hypothesized that replacing residues F849, F856, F869 and 
D873 with pBpa or pAzpa will have minimal structural perturbation and should retain the 
function of the Gal4 TAD in yeast. 
 
Figure 4.11 Residues in the Gal4 TAD important for function. Cys or ala mutants of the 
Gal4 TAD have been previously evaluated for in vitro binding and activity in yeast. + 
indicates the residue when mutated retains >75% function +  indicates ~50-70% of wild 
type function and – indicates loss of function. Residues in red will be replaced with pBpa 
for crosslinking.1, 2  
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C.2.a Incorporating pBpa and pAzpa in yeast 
 Using the non-sense suppression methodology, incorporation of unnatural amino 
acids is controlled by the amber codon.57 Yeast expression plasmids were constructed 
with the Gal4 TAD (840-881) fused to the Gal4 DBD (1-147) or the LexA DBD (1-202). 
Site-directed mutagenesis was used to encode the amber stop codon at a specific residue. 
Thus, when used in cells with the appropriate tRNA/synthetase we should either see a full 
length product with incorporated unnatural amino acid, or we would see truncated 
products. 
 To investigate these possibilities, plasmids encoding the LexA+Gal4(840-
881)F849TAG were introduced into yeast strain DSY-5 together with the cognate 
tRNA/synthetase (tRNAx1) encoding for pBpa or pAzpa (obtained from Dr. Peter 
Schultz ).52, 53 Five mL yeast cultures with and without 1 mM unnatural amino acid were 
grown in selective media to late-log phase, pelleted, and the contents resolved by SDS-
PAGE followed by probing with a LexA antibody. Unfortunately, it was found that 
majority of the protein terminated at position of the TAG codon instead of incorporating 
any unnatural amino acid (Figure 4.12a).  
C.2.a.i Optimization of incorporation efficiency 
 In order to increase the yield of protein that contained pBpa we decided to 
investigate the tRNA and synthetase expression. Previous studies by Schimmel and 
coworkers have demonstrated that the E. coli tRNACUA is not expressed to high levels in 
yeast and the use of multiple tRNAs resulted in greater yields of full length protein 
product with the desired amino acid incorporated.56, 57 Towards this end, we made 
expression plasmids that encoded for 2 and 3 copies of the E. coli tRNACUA (tRNAx2 and 
tRNAx3) and investigated their ability to produce full length Gal4 TAD containing the 
unnatural amino acid. We only saw marginal improvements of yield when these tRNAs 
were used in combination with LexA+Gal4(840-881)F849TAG (Figure 4.12a). Another 
feature that affects the yield of the tRNA is the promoter it is expressed from. The 
original promoter used by Schultz and coworkers driving the tRNA expression has been 
reported to give poor yields of the tRNA as it lacks a yeast polIII promoter. Hahn and 
coworkers tested strong, medium and weak promoters to investigate the affect on tRNA 
yield.101 They found that the medium-strength N(GTT)PR promoter allowed expression 
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of nearly normal levels of several proteins with pBpa incorporated. We created a plasmid 
based on their results, with the N(GTT)PR driving expression of a single copy of E. coli 
tRNACUA. Contrary to what they observed, we found that this promoter did not provide 
us with any higher yield (N(GTT) promoter tRNAx1). In their studies they integrated the 
plasmids encoding the tRNA/synthetase and their gene of interest using plasmid 
shuffling, perhaps improving their yields. 
Recently, Chen et. al performed a similar study, where they increased the number 
of tRNAs to 3 and introduced a strong Pol III promoter, pPGK1, normally used for 
mRNA transcription to drive expression of these tRNAs.102 They found that this construct 
gave >50 fold increase in tRNA production compared to the original plasmid. 
Correspondingly this translated to increased yield of protein containing the unnatural 
amino acid. Unfortunately, the increased yield comes at a price as the fidelity of the 
system seems to decrease. They show that incorporation of pBpa at a particular amber 
codon is only 61% while ~30% Trp is incorporated at this position. In the case of pAzpa, 
90% is incorporated, but ~6% and 2% of Trp and Leu respectively are also incorporated.  
 
Figure 4.12 Incorporation of photo-crosslinking amino acids in the Gal4 TAD in 
yeast. a) Dependence of incorporation on tRNA. DSY-5 yeast expressing LexA(1-
202)+Gal4(840-881)849TAG with the indicated tRNA plasmid were grown in 
media with and without 1 mM pBpa. 3 ODs of late log phase growing cells were 
probed using a LexA antibody in a western blot. b) LS41 yeast expressing 
LexA(1-202)+Gal4(840-881)849TAG with the indicated tRNA plasmid were 
probed as described in a). 
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We obtained the plasmids encoding three tRNAs driven by the PGK1 promoter ( 
PGK1 promoter + tRNAx3) and evaluated their ability to incorporate pAzpa and pBpa in 
LexA+Gal4(840-881)F849TAG. Satisfyingly, we found that these incorporating 
conditions gave higher yield of full length product (Figure 4.12a). However, there was a 
significant amount of misincorporation (~50%), possibly Trp and/or Leu leading to full 
length product when no unnatural amino acid was added. However, for our purposes, 
these levels of misincorporated products most likely will not interfere with the 
crosslinking reaction by effectively competing for coactivator binding; based on related 
in vitro competition binding experiments it would require >10 fold excess of 
misincorporated protein compared to incorporated protein to completely prevent 
crosslinking. More recently, alleviating this concern, we have determined conditions 
where we observe no full-length misincorporated products in the absence of unnatural 
amino acids (vide infra).   
Wang and coworkers also developed an optimized system for tRNA and 
synthetase expression.103 They have shown that using the Pol III SNR promoter (derived 
from the snoRNA encoding gene SNR52) to drive tRNA expression and GDH promoter 
to express the synthetase, yielded ~9 fold higher levels of a control protein incorporated 
with tyrosine at the amber codon compared to the first generation Schultz plasmids 
(tRNAx1). Interestingly, they show using northern blots that the tRNA produced by the 
SNR promoter is in fact 100 fold lower than the tRNA produced by tRNAx1. These 
results suggest that the tRNA produced by the tRNAx1 plasmid is not correctly processed 
or modified. Based on these promising results, we developed plasmids using the SNR and 
GDH promoters for the incorporation of pBpa. We found that these conditions (pSNR 
promoter + tRNAx1) yielded the highest amount of incorporated LexA-Gal4 product, ~2 
fold higher than the PGK1 promoter driving the expression of 3 tRNAs (Figure 4.12b). 
Further, we have also found that the incorporation levels of pBpa and pAzpa into the 





C.2.b Crosslinking in live yeast 
 Using the optimized conditions for expression of LexA-Gal4 constructs 
incorporating pBpa and pAzpa, we exposed the yeast cells to UV irradiation in order to 
form crosslinks between the Gal4 TAD and its binding partners. Satisfyingly, we find 
additional higher molecular weight protein bands in a western blot only for the samples 
that contained unnatural amino acid and were UV treated (Figure 4.14). Consistent with 
previous work showing the importance of multiple protein complexes involved in 
transcription we see at least three crosslinked products.  One crosslinked product is at 
~150 kD, potentially corresponding to a crosslink to Med15(Gal11), while another 
product potentially matches the a Gal80 crosslink (~80 kD). These results are indicative 
of functionally relevant crosslinked products and we are currently in the process of 
identifying them using proteomic approaches at the Michigan Proteome Consortium 
facility. Moreover, we will use the binding site information determined from the in vitro 
crosslinking studies in the previous section to assist in determining the binding site(s) of 
Gal4 within Med15(Gal11) in cells. 
Figure 4.13 
Dependence of incorporation on 
unnatural amino acid. DSY-5 yeast 
expressing LexA(1-202) + Gal4(840-
881)849TAG and a plasmid expressing 3 
tRNAs under the control of the PGK1 
promoter and the appropriate synthetase 
were grown in media with and without 1 
mM Azpa or pBpa. 3 OD of late log 
phase growing cells were probed using a 






More recently, we have also extended this approach to express pBpa incorporated 
at a variety of positions in constructs that contain the Gal4 DBD and the Gal4 TAD. In 
contrast to the Lex DBD+Gal4 TAD incorporation results, we find that the fidelity of 
incorporation is extremely high for the Gal4 DBD+TAD constructs; there is no visible 
misincorporated full length product when pBpa is absent from the media (Figure 4.15). 
One of the differences between the two DBDs used, apart from sequence composition, is 
that the LexA constructs were expressed on a high copy plasmid driven by the ADH 
promoter, while the Gal4 constructs were expressed on a low copy plasmid driven by the 
β-actin promoter. It is, however, not clear why these differences so significantly affect 
incorporation fidelity. 
Figure 4.14 In vivo crosslinking with LexA+Gal4 constructs. LS41 yeast 
expressing LexA(1-202)+Gal4(840-881)849TAG and pSNR pBpa tRNA 
plasmids were grown in media with and without pBpa and differentially 
irradiated by a 365 nm light source. The activator constructs also contain a C-
terminal Flag epitope tag to facilitate detection. 60 ODs of late log phase yeast 
were harvested and immunoprecipitated using a LexA antibody followed by 
western blots in which they were probed with a) a LexA antibody or b) Flag 





The Gal4 constructs developed here will be valuable tools to determine the 
coactivator targets in a cellular context. For example, the yeast can be grown in different 
sugars and the binding profile of Gal4 can be investigated in each individual case. The 
effect of the location of DNA binding site in the promoter on the binding profile can also 
be probed. Further, the effect of chromatinized DNA templates versus non-chromatinized 
templates can be investigated and the presence of activator DNA binding sites in general 
can also be investigated. Finally, the ability to incorporate the crosslinker at different 
positions in the TAD, facilitates the investigation of activator-specific residues important 
for coactivator binding. 
 
D. Conclusions and future directions 
Using photo-crosslinking and mass spectrometry we were able to develop 
methods to identify activator binding sites on Med15(Gal11). Verification of these results 
using binding and activity assays validates this technique for the future discovery of 
activator binding sites. Supplementary ChIP-based studies in yeast can be used to verify 
the recruitment of Med15(Gal11) by these activators at endogenous promoters in various 
Med15(Gal11) mutant strains. Somewhat unexpectedly, we found multiple overlapping 
activator binding sites on Med15(Gal11) for the three different TADs VP2 and Gcn4. 
Further, we have found the artificial TAD XLY to also interact with Med15(Gal11)(1-
416) and binding site determination for this peptide is also underway. Moreover, several 
other activators have been found to interact with structurally conserved/similar binding 
4.15 Incorporation of pBpa in 
Gal4 DBD+TAD constructs. 
LS41 yeast expressing 
Gal4(1-147+840-881) with 
select amber mutations and  
pSNR pBpa tRNA plasmid 
were grown in media with and 
without pBpa. 3 ODs of mid 
log phase cells were harvested 
and probed in a western blot 
with a Gal4 antibody. The 
lower molecular weight band 
in each lane represents the 
amber truncated product. 
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regions using NMR spectroscopy and mutational analysis. These findings indicate that 
activator binding surfaces are evolutionary conserved and predict the presence of certain 
binding sites on coactivator surfaces that are probably important for activation. Thus, we 
can rationalize our earlier studies (Chapter 2), where only a subset of ligands that targeted 
Med15(Gal11) activated transcription, although they had similar binding affinities. 
Further, the existence of conserved binding sites on different coactivators can explain 
how activators are able to activate transcription across species. 
In the long term, the identification of activator binding sites in combination with 
structural studies on Med15(Gal11) and similar approaches with other coactivators, will 
lead to excellent screening targets for novel artificial activator discovery and also for 
therapeutically useful inhibitor design. 
We have also shown here that unnatural amino acids can be incorporated in a 
TAD in yeast. More importantly, we have found that irradiation of live yeast expressing 
crosslinker containing activators leads to crosslinked products between activators and 
their binding partners. Although, the identification of the binding partners is currently 
underway, we find that at least three crosslinked products indicating that Gal4 most likely 
interacts with more than one protein in a cellular context. 
In the future, studies with different activators such as Gcn4, VP2, Rap1 and Pdr1 
can assess the conservation of coactivators among different classes of activators. Further 
incorporation of crosslinkers in the TAD and the DBD can circumvent the need for 
formaldehyde in ChIP to study coactivator promoter localization. In contrast to 
formaldehyde, the use of pBpa or pAzpa will investigate the direct binding of 
transcription proteins to DNA bound activators. Finally, given the recent success in using 
non-natural amino acids in mammalian cells, analogous crosslinking experiments with 
Gal4, Gcn4, VP2 in combination with mammalian activators such p53, Hif1α, ESX and 
p65 should be feasible in metazoan systems and would provide an explanation as to how 
activators from diverse species are able to activate transcription in different contexts.45, 104  
Lastly, activator-coactivator interactions are one of first interaction pathways in 
transcriptional networks and determining these are a great stride forward towards 
mapping the network of protein-protein interactions involved in transcription. Once 
coactivators are identified, using unnatural amino acid mutagenesis it should be 
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straightforward to extend a similar approach to incorporate crosslinkers into coactivators 
and subsequently other transcriptional machinery proteins in efforts to map out the entire 
transcriptional network. A complete understanding of the interactions necessary for 
transcription will be useful for not only therapeutic purposes and biomanufacturing, but 






Fmoc-based solid phase peptide synthesis was used to synthesize  
VP2 DFDLDMLGD(pBpa)DLDMLGC,  
Gal4(840-881) 
CWTDQTAYNAFGITTGMFNTTTMDDVYNYL(pBpa)DDEDTPPNPKKE or 
Gal4(854-874) GMFNTTTMDDVYNYL(pBpa)DDEDT and Gcn4 
TPMFEYENLEDNSKEWTSL(pBpa)DNDIPVTTDDC.  FMOC-pBpa was purchased 
from Bachem and Chem-Impex International. The peptides were synthesized using an 
ABI 433A peptide synthesizer on clear amide resin (0.4 mmol/g, Peptides International) 
at 0.1 mmole scale using manufacturer recommended conditions, except for forced 
double coupling of all residues in the synthesis of Gal4 and Gcn4 after the first proline in 
the sequence was encountered. 
To facilate labeling of the peptides with biotin, ~10 mg of peptides were dissolved 
in ~500 µL DMF and 100 µL CH3CN followed by 500µL 0.1% TFA. To this a ~10 fold 
excess of Biotin-HPDP (N-(6-(Biotinamido)hexyl)-3'-(2'-pyridyldithio)-propionamide  
(Pierce) dissolved in 100µL DMF, 100 µL CH3CN was added and the reaction was 
carried out at 37 ºC overnight. The products were characterized and purified to 
homogeneity using reversed-phase HPLC on a C18 column with a gradient solvent 
system (Buffer A: 0.1% TFA, buffer B: CH3CN) and stored at -80 ºC.  
 
Med15(Gal11) bacterial expression plasmids 
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 Bacterial expression constructs expressing different fragments of Med15(Gal11) 
fused to the mutated OCR protein (for increasing solubility) and a His tag (for 
purification) were created by the High-Throughput protein lab (LSI). The plasmids also 
contained a cleavable TEV protease site to separate the tags from Med15(Gal11) after 
expression/purification. Ligation independent cloning (LIC) was used to insert the 




 To identify the Med15(Gal11), fragment(s) that interact with TADs, all the His-
MBP-Med15(Gal11) constructs generated by ligation independent cloning were 
expressed and purified at the LSI using high-throughput methods using a Biomek FX 
liquid handling system. The analysis of the concentration and purity of each sample was 
determined using a Caliper Labchip90 instrument. Samples of each protein construct 
were obtained in 100 mM PBS pH 7.2 with 250 mM imidazole and used without further 
purification for crosslinking with Gal4, Gcn4 and VP2 followed by detection by 
streptavidin-HRP in a western blot. 
For larger scale isolations, the His-mOCR-Med15(1-416), His-mOCR-Med15(1-
357) and His-MBP-Med15(107-255) plasmids were grown individually. For these 
purposes, plasmids encoding each construct were transformed into chemically competent 
Rosetta2(DE3) pLysS E. coli (Novagen) and cells were plated onto LB-agar plates 
supplemented with ampicillin (100 µg/mL) and chloramphenicol (34µg/mL). Cultures 
(50 mL) from single colonies were grown overnight at 37 °C (300 rpm) in Select APS 
Super Broth (Difco) supplemented with ampicillin (100µg/mL) and chloramphenicol 
(34µg/mL) before addition to 1L of Select APS Super Broth supplemented with 
ampicillin (100µg/mL). After an OD600 of 0.3 was reached (300 rpm, 37 °C), the cultures 
were cooled to 20 °C for 1 h (100 rpm), and expression was induced with IPTG (final 
concentration 0.1 mM) for ~12 h (250 rpm). The cell pellet was resuspended in Buffer A 
(100 mM Tris pH 7.5 at 4 °C, 10% glycerol (v/v), 150 mM NaCl, 10 mM β-ME and 
Roche Complete Protease Inhibitor Cocktail) lysed using sonication, pelleted, and the 
His-tagged protein was isolated from the supernatant using Ni NTA-Agarose (Qiagen). 
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The Ni beads were washed 6 times with Wash buffer (100 mM Tris pH 7.5 at 4 °C, 10% 
glycerol (v/v), 150 mM NaCl, 10 mM β-ME, 30 mM Imidazole). The protein was eluted 
from the beads at 4 ºC 3 times using Elution buffer (100 mM Tris pH 7.5 at 4 °C, 10% 
glycerol (v/v), 150 mM NaCl, 10 mM β-ME, 300 mM Imidazole).  
 For His-mOCR-Med15(1-416) and His-mOCR-Med15(1-357), the His-mOCR 
tag was cleaved using TEV protease by incubating 0.25 mg TEV for every liter of 
Med15(Gal11) lysed.  The eluted protein and TEV were combined in dialysis tubing 
(Pierce) and the buffer exchange to Storage Buffer (50 mM Tris pH 7.5 at 4 °C, 10% 
glycerol (v/v), 150 mM NaCl, 10 mM β-ME) overnight at 4 °C. The Med15(1-416) 
solution thus obtained was concentrated using a Vivascience  30K centrifugal filter 
device and then loaded onto a gel filtration column (Superdex 75, GE Healthcare), pre-
equilibrated with Storage buffer, to remove His-mOCR. Fractions containing Med15(1-
416) were pooled and concentrated using a Vivascience 10K centrifugal filter device 
(Vivaspin 15).  The protein concentration was measured using absorbance at 280 nm. The 
identity and purity of the fusion protein was verified by reducing SDS-PAGE with 
appropriate molecular weight standards. 
 His-MBP-Med15(107-255) were purified similarly using gel filtration except the 
His-MBP tag was not cleaved as it helped stabilize the protein. 
 For mass spectrometry experiments the single cysteine in Med15(Gal11)(1-416) 
was acetylated to prevent it from reacting with the biotinylated TAD. To acetylate 
cysteine 306 in Med15(Gal11), Med15(1-416) was treated with 10 mM DTT for 1 h. 
After reducing any disufides, 40 mM iodoacetamide (1M stock in 100 mM NaHCO3) 
was added and the protein solution was incubated in the dark for 45 min. Excess 
iodoacetamide and any reducing agent were removed using a PD-10 column (GE 
Healthcare) pre-equilibrated with Storage buffer that did not contain any reducing agents. 
 
In vitro Crosslinking 
Biotinylated TADs were resuspended in DMSO followed by 100 mM PBS 
ensuring the final DMSO concentration was <10%. The concentration of the peptides 
were determined by measuring absorbance at 280 nm. The extinction coefficient for pBpa 
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was calculated to be 16,000 M-1 cm-1 (based on a titration curve with pBpa as a standard) 
and used to calculate the overall extinction coefficients of the peptides. 
100 µL of biotinylated TAD (~100-300 µM) was mixed with 100 µL Med15 
(~100-300 µM) and irradiated with a 150W 365 nm UV lamp (BIB-150P, Spectroline) at 
a distance of 20 cm at 4 °C for 2 h. The irradiated sample was then buffer exchanged with 
a 1 mL 30K MW cutoff concentrator (Millipore) with 100 mM PBS to remove free TAD 
(4 x 1mL). This solution was subsequently incubated with 10 µg sequencing grade 
trypsin (Promega) for 5 h at 37 °C. After digesting the sample, trypsin was inactivated by 
vortexing and incubating at 65 °C for 10 min. Next the sample was added to 100 µL of 
neutravidin beads (Pierce) prewashed with 100 mM PBS and incubated for 1 hr at 4 °C 
with shaking. To remove bound unbound tryptic Med15 fragments, the neutravidin beads 
were washed (6 x 1 mL) with 100 mM PBS. To elute the biotinylated products the beads 
were incubated 2x with 100 µL Elution buffer (100 mM PBS, 100mM DTT) for 1 h at 65 
°C. The eluted samples were stored at -80 °C until mass spectrometry analysis was 
performed.  
For mass spectrometry analysis, the samples were purified using a ZIP tip 
(Millipore) and exchanged to 0.1% formic acid, 70% acetonitrile or 70% methanol and a 
combination of MALDI and FT-ICR was performed. MALDI analysis was performed at 
the Michigan Proteome Consortium facility. FT-ICR electro-spray analysis was 
performed in the Håkansson Laboratory. 
 
Plasmid construction  
Gal4(1-147+840-881) Constructs 
A low copy plasmid expressing Gal4(1-147+840-881) containing a C-terminal 
cysteine driven by the strong β-actin promoter was obtained from Jenifer Lum. This 
plasmid has a His marker for growth in yeast and an ampicillin selection in E. coli. TAG 
mutations at amino acids 849, 856, 869, and 873 were inserted as described below.  
 
LexA(1-202)+Gal4(840-881) Constructs 
A high copy plasmid expressing LexA(1-202)+Gal4(840-881)+flag peptide under 
the control of the ADH promoter was created from pNlexA (Origene). Amberlyn Wands 
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mutated the existing EcoRI and BamHI at the N terminus of LexA. Subsequently, she 
inserted these sites at the C-terminus of LexA to enable the creation of C terminal LexA 
fusions. Primers (5’-TTAC gaattc TGGACGGACCAAACTG -3’) and (5’- AGT GGA 
TCC TTA TTT GTC GTC GTC GTC TTT ATA GTC CTC TTT TTT TGG G -3’) were 
used to amplify Gal4 (840-881) from a plasmid expressing Gal4(1-147)+(840-881). Pfu 
turbo (Stratagene) was used to amplify the product with 200 nM of each primer and 4.5 
mM MgCl2 and 5 ng of template plasmid per 50 µL reaction. The amplification 
conditions are [94 °C 2’, 9x (94 °C 15”, 52 °C 30”, 68 °C 2’), 24x (94 °C 15”, 59 °C 30”, 
68 ° C 2’), 68 °C 7’, 4 °C hold]. A total of 4, 50 µL PCRs were performed. The PCR 
products were purified using a Qiagen PCR purification kit and subsequently double 
digested with BamHI and EcoRI. The digestion reaction was purified using the Qiagen 
PCR purification kit and ligated with T4 DNA ligase into pCLexA (predigested with 
BamHI/EcoRI and treated with calf intestinal phosphatase). The resulting plasmids were 
amplified in Smart E. coli cells (Genlantis), selected on LB-agar plates containing 100 
µg/ml ampicillin, and isolated from cultures using a QIAprep Spin Miniprep Kit 
(Qiagen). The sequences of the isolated plasmids were verified by sequencing at the 
University of Michigan Core Facility. 
 
TAG mutations 
Site-directed mutagenesis was used to insert the TAG codon at various positions in Gal4. 
In general primers were designed to have ~15 bases of homology on either side of the 
TAG mutation. Pfu turbo polymerase (Stratagene) was used to incorporate the TAG 
mutants with 200 nM of each primer and 4.5mM MgCl2 and 5ng of template plasmid per 
50 mL reaction. The amplification conditions were [95 °C 30’’, 17x (95 °C 30”, 55 °C 1, 
68 °C 11’), 68 °C 7’, 4 °C hold]. The PCR products were digested with 2 µL Dpn1 at 37 
°C for 1.5 h. 5 µL of the digest was transformed in Smart E. coli cells (Genlantis), 
selected on LB-agar plates containing 100 µg/ml ampicillin, and isolated from cultures 
using a QIAprep Spin Miniprep Kit (Qiagen). The sequences of the isolated plasmids 







pESC bp-2 encodes a single amber tRNA and the synthetase incorporating pBpa. 
pESC Az-3 encodes a single amber tRNA and the synthetase incorporating pAzpa. pESC 
WT encodes a single amber tRNA and the WT synthetase that incorporated tyrosine. 
These plasmids were obtained from Dr. Peter Schultz. They are ampicillin selectable in 
E. coli and have a Trp marker for yeast and are high copy. 
 
tRNAx2 and tRNAx3 plasmids 
Additional amber tRNAs were added by inserting NcoI and NdeI sites after the 
first tRNA. For this purpose, a new tRNA fragment was amplified from pESC bp-2 using 
primers (5’ – G GG TCG ACC GGT AAG CTT CCC GAT AAG GGA GCA G -3’) and 
(5’ - CAA AAG TCC CTG AAC TTC CCC CAT GGC CTA CAT ATG TGC TGC TAG 
CGC CG – 3’) that contained NdeI and NcoI sites after the tRNA. The PCR conditions 
were similar to the ones above with Pfu Turbo. The PCR product was digested with AgeI 
and NheI and ligated into pESC bp-2 predigested with AgeI/NheI and treated with CIP. 
The resulting plasmid, ptRNAx1-bp was amplified and characterized as described above.  
 Primers (5’ - GGG TCG CCA TGG AAG CTT CCC GAT AAG GGA GCA G – 
3’) and (5’ - CAA AAG TCC CTG AAC TTC CCC ATA TGG CCG – 3’) were used to 
amplify the second tRNA using PCR. The PCR product was digested with NcoI and NdeI 
and ligated in ptRNAx1-bp predigested with NcoI/NdeI and treated with CIP. The 
resulting plasmid, ptRNAx2-bp was amplified and characterized as described above. 
Primers (5’ - GGG TCG CAT ATG AAG CTT CCC GAT AAG GGA GCA G – 
3’) and (5’ - CAA AAG TCC CTG AAC TTC CCG CTA GCC GAC CC – 3’) were used 
to amplify the third tRNA using PCR. The PCR product was digested with NdeI and 
NheI and ligated in ptRNAx2-bp predigested with NdeI/NheI and treated with CIP. The 
resulting plasmid, ptRNAx3-bp was amplified and characterized as described above. 
 
N(GTT)PR promoter plasmid 
To change the promoter 5’ of the tRNA, DNA oligos were designed that 
contained the sequence of the N(GTT)PR followed by the amber tRNA and terminated 
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with the 3’ tRNA flanking sequence. Complementary oligo set 1 (5’ - CCG GTA ATA 
AAT ACC GGA GAT ATG ATT CAG ATG TGG AAG CGG TTT TAA AGT CCC 
AAT TCA TCA TTA TTT GCG TGG GGT TCC CGA G -3’), (5’ - CCC TTT GGC 
CGC TCG GGA ACC CCA CGC AAA TAA TGA TGA ATT GGG ACT TTA AAA 
CCG CTT CCA CAT CTG AAT CAT ATC TCC GGT ATT TAT TA -3’) and set 2 (5’ - 
CGG CCA AAG GGA GCA GAC TCT AAA TCT GCC GTC ATC GAC TTC GAA 
GGT TCG AAT CCT TCC CCC ACC ACC ATT TTT TTC AAA AGT CCC TGA ACT 
TCC CG – 3’), (5’ - CTA GCG GGA AGT TCA GGG ACT TTT GAA AAA AAT GGT 
GGT GGG GGA AGG ATT CGA ACC TTC GAA GTC GAT GAC GGC AGA TTT 
AGA GTC TGC T -3’) were annealed and phosphorylated using T4 polynucleotide 
kinase. Both sets of oligos were then ligated simultaneously into Age/NheI digested and 
CIP treated pESC bp-2. The resulting plasmid, pN(GTT)PR-bp was amplified and 
characterized as described above. 
 
pPR1-pGK1+3SUP4-tRNACUA plasmids 
pPR1-pGK1+3SUP4-tRNACUA-pBpa and pPR1-pGK1+3SUP4-tRNACUA-pAzpa 
expressing 3 tRNAs driven by the pGK1 promoter were obtained from Dr. Peter Schultz. 
They are ampicillin selectable in E. coli and have a Trp marker for yeast. 
 
pSNR plasmids 
pSNR WT plasmid incorporating tyrosine at the amber position was obtained from Dr. 
Lei Wang. pSNR pBpa and pSNR pAzpa were generated by insertion of the appropriate 
E. coli tyrosyl synthetase (amplified from pPR1-pGK1+3SUP4-tRNACUA-pBpa or pPR1-
pGK1+3SUP4-tRNACUA-pAzpa) using primers 5’- AGT TCA ACT AGT ATG GCA 
AGC AGT AAC TTG ATT -3’ and 5’-TCG ATC TCG AGT TAT TTC CAG CAA ATC 
AGA CA-3’ followed by a SpeI/XhoI  digest) into SpeI and XhoI sequentially digested 
and calf intestinal phosphate treated pSNR WT. 
 
Binding experiments 
The dissociation constants of fluorescence labeled TADs to Med15(Gal11) were 





Western blots were performed to verify the incorporation of unnatural amino acids in the 
Gal4(1-147+840-881) or LexA(1-202)+Gal4(840-881) amber mutant constructs. Freshly 
transformed yeast colonies were used to inoculate 5 ml cultures of SC media containing 
2% glucose but lacking the appropriate amino acids for selection. The cultures were 
incubated overnight at 30°C and agitated at 250 rpm. Following incubation, these 
cultures were used to inoculate 5 mL cultures of SC media containing 2% glucose with or 
without 1 mM unnatural amino acid (dissolved in 1M NaOH) and were subsequently 
incubated overnight at 30 °C with agitation to an OD660 of 3-4. To each 5 mL culture 
containing unnatural amino acids, ~1 mg of pBpa or pAzpa dissolved in 50 µL 1 M 
NaOH was added followed by an equal volume of 1 M HCl. 3 ODs of cells were 
harvested, washed with water and quick-frozen in liquid nitrogen. The pellets were lysed 
by heating in SDS lysis buffer (50 mM TrisOAc pH 7.9, 150 mM KOAc, 20% glycerol 
(v/v), 0.02% Tween, 1 mM β-mercaptoethanol, 2 mM Mg(OAc)2) at 90 oC for 10 
minutes. Crude lysates were centrifuged at 14000 rpm for 2 minutes and the supernatant 
was resolved on NuPAGE 12% Bis-Tris gels using MES electrophoresis buffer 
(Invitrogen). Gal4 fusions were detected using an antibody for Gal4 (1:2000, SC-577, 
Santa Cruz Biotechnologies). LexA fusions were detected using an antibody for LexA (1: 
1000, SC-1725, Santa Cruz Biotechnologies). Blots were developed using a horseradish 
peroxidase-conjugated secondary antibody (1: 5000, Santa Cruz Biotechnologies) and 
visualized by chemiluminescence (ECL, ECL plus or ECL advance, GE Healthcare). 
 
In vivo crosslinking 
Freshly transformed LS41 yeast colonies expressing LexA(1-202)+Gal4(840-881) 849 
TAG + flag and the pSNR tRNA plasmid for pBpa or pAzpa were used to inoculate 5 ml 
cultures of SC media containing 2% glucose but lacking histadine and tryptophan for 
selection. The cultures were incubated overnight at 30°C and agitated at 250 rpm. 
Following incubation, these cultures were used to inoculate 50 mL cultures of SC media 
containing 2% glucose, with or without 1 mM unnatural amino acid (dissolved in 1M 
NaOH) and were subsequently incubated overnight at 30 °C with agitation to an OD660 of 
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3-4. 60 ODs of cells were isolated, washed with water and resuspended in 2 mL water 
and irradiated for 1 h with 365 nm light at 4 °C (Rayonet photo-reactor). Following 
irradiation, the cells were pelleted and stored at -80 °C until lysis. Cells were resuspended 
in 700 µL Lysis buffer (50 mM Hepes-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% 
Triton X-100, 0.1% Na-Deoxycholate and 2X Complete protease inhibitor (Roche)) and 
lysed using glass beads by vortexing at 4 °C using the following cycle: 30 min vortex, 10 
min break, 15 min vortex. The lysate was isolated by piercing a hole in the microfuge 
tube and collection by centrifugation. Subsequently, the lysate was pelleted and the 
supernatant incubated with 10 µL of LexA antibody (D-19 or N-19, Santa Cruz 
Biotechnologies) for 5 h at 4 °C for immunoprecipitation. The protein bound to the 
antibody was isolated by incubation for 1 h with ~100 µL of prewashed protein G 
magnetic beads (Dynal Corporation) at 4 oC. The beads were washed 4X with 1 mL 
Wash Buffer (10 mM Tris-HCl pH 8.0, 250 mM LiCl, 0.5% NP-40, 1% Na-
Deoxycholate and 1 mM EDTA) and stored dry at -20 oC. The protein was eluted from 
the beads by heating at 90 oC for 10 min in NuPAGE SDS gel loading buffer (Invitrogen) 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
A. Introduction 
Regulated gene expression is essential for the appropriate development and the 
continued existence of all organisms. Transcriptional activators play a critical role in this 
process, precisely controlling the transcriptional response of their cognate genes based 
upon environmental needs. Given their importance in transcription, it is not surprising 
that many diseases arise due to malfunctioning transcriptional activators. Thus, activator 
artificial transcription factors (activator ATFs), molecules that mimic the function of 
natural activator proteins, have been proposed as effective replacements for 
malfunctioning activators to treat diseases ranging from cancer to diabetes.1, 2 One of the 
major long-term goals of our research is to develop more drug-like small molecule 
activator ATFs for these purposes.3-5 Activator ATFs that precisely control gene 
expression are also in demand for synthetic biology applications to modulate biological 
circuits to develop cell-based devices.6 One of the biggest hurdles, however, is that the 
features endogenous activators use for function are not well defined, making it difficult to 
design activator ATFs that work in an analogous manner.7  
As outlined in this dissertation, we have investigated the mechanism of 
endogenous transcriptional activators to determine the features they utilize to activate 
transcription to high levels. In the process, we have also developed new generations of 
activator ATFs with advantageous specificity and stability properties. Incorporation of all 
these factors into future generations of non-biopolymer and small molecule activator 
ATFs will serve to develop molecules with enhanced utility for a variety of applications. 
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B. Multiple interactions are required for potent function 
A key observation arising from this work is that we have found that multiple 
interactions inside and outside the transcriptional machinery are required for enhanced 
cellular function of an activator. In Chapter 2, we screened a synthetic peptide library and 
isolated ligands that target the yeast Mediator component Med15(Gal11). We found that 
the ligands that functioned by targeting a single transcriptional machinery component, 
specifically recruiting the coactivator Med15(Gal11), were only able to activate 
transcription to moderate levels. While activator ATFs developed using these ligands can 
be useful to specifically target diseased cells and tissues, they do not function with levels 
of activity that resemble natural activators and other features are required for these 




In Chapter 3 we isolated ligands that target the coactivator Tra1 and we found that 
the ligand that functioned with the highest activity did so by targeting multiple 
coactivators. These findings were further substantiated when we showed that 
combination of the Med15(Gal11)-specific ligands with Tra1 ligands resulted in a 
synergistic increase in activity. 
Figure 5.1 Multiple TAD interactions inside and outside the transcriptional 
machinery. Masking interactions with masking proteins (mp) greatly enhance 
activator function, presumably by increasing the amount of activator available for 
productive transcriptional machinery interactions. Recruiting multiple coactivator 
proteins, involved in different processes required for transcriptional activation, 
results in a synergistic increase in activation. 
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Interactions outside the transcriptional machinery also seem to enhance activator 
function. Also in Chapter 3, we found that incorporating a masking interaction leads to a 
large increase in transcriptional activation compared to activators that do not incorporate 
a masking interaction. Although in this case the enhanced function is most likely not due 
to interactions that directly involve contacts with the transcriptional machinery, we 
hypothesized that the masking interactions positively affecting the stability of an 
activator, leading to effective coactivator recruitment. 
Finally, in Chapter 4, we investigated the binding partners of natural activators 
using in vitro and in vivo crosslinking experiments. Consistent with our findings in 
Chapters 2 and 3 that multiple interactions enhance the function of activator ATFs, we 
find that the potent yeast activator Gal4 interacts with at least three different proteins, 
suggesting that natural activators use multiple interactions to activate transcription to 
high levels. 
C. Existence of privileged activator binding sites on coactivators 
We have found that interactions with certain activator binding sites on 
coactivators are more amenable to high levels of transcriptional activation than others. In 
Chapter 2, we found that ligands that in vitro target different surfaces of the coactivator 
Med15(Gal11) with similar affinities to activate transcription to varying levels in yeast. 
The differences in activity levels was contributed to the different binding sites on 
Med15(Gal11) that the ligands targeted, illustrating for the first time that binding site(s) 




In Chapter 3, we found that the Tra1 ligand that activated transcription to the 
highest levels targeted a binding site shared with the natural activator VP2. Moreover, the 
Figure 5.2 Interaction with privileged 
binding sites. Certain binding sites 
(shown in red) within coactivators are 
more accessible to transcriptional 
activators and they are conserved 
across different coactivators. Targeting 
these binding sites enables the 
recruiting of multiple coactivators 
using the same TAD surface, resulting 




ligand was also able to target another coactivator Med15(Gal11), at an overlapping 
binging site with VP2. These findings suggest that natural activators have evolved to 
target certain privileged binding sites on coactivators that are conserved between 
coactivators, despite presumed differences in function. 
To further strength the idea of the existence of a set of privileged binding sites, in 
Chapter 4, we found using in vitro crosslinking followed by functional evaluation in cells 
that three different activators with varying sequence compositions, target one overlapping 
binding site on the coactivator Med15(Gal11). Further, BLAST searches of these binding 
sites indicates homology to a variety of transcription proteins across species, although the 
full-length proteins are not significantly homologous. These finding illustrate that natural 
activators target similar binding sites that have evolved to exist on multiple coactivators. 
Finally, the results also highlight how natural activators are able to target multiple, 
different proteins using the same small set of amino acid residues and activate across 
species. 
 
D. Future directions  
D.1 Conformation 
Activators are predicted to be unstructured in solution and adopt a particular 
conformation upon binding. Thus investigating the structure of activators in complex 
with different target proteins will assist in elucidating the role of structural changes in 
transcription. Further structures of activator-coactivator complexes will assist in the 
design of small molecules to functionally mimic activators. 
In Chapter 4, we determined that Med15(Gal11)(1-357) contains binding sites for 
the yeast activator Gal4. Several studies have shown that amphipathic activators adopt a 
helical conformation on target binding. However, a study by Johnston and coworkers on 
the Gal4 TAD has predicted it forms a β-sheet in solution.8, 9 The Ptashne group has 
shown that certain proline mutations in the Gal4 TAD prevent an interaction with its 
masking protein Gal80, but permit an interaction with the transcriptional machinery.10 
Taken together, these results suggest that the interaction with Gal80 induces formation of 
some ordered structure incompatible with the presence of proline residues; in contrast, to 
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interact with the transcriptional machinery such a structure is not required. Thus it is 
likely that Gal4 may obtain a different structure depending on the target it is bound to.  
To investigate the conformational preference of Gal4, in collaboration with the 
Ansari and Markely groups (U. of Wisconsin) we are using NMR spectroscopy to 
investigate the conformational changes in the solution structure of Gal4 when complexed 
with the inhibitor Gal80 or the coactivator Med15(Gal11)(1-357). Thus far we have 
found that the Gal4 TAD is unstructured (based on 13C chemical shifts obtained for 
13C,15N labeled Gal4 TAD) under the experimental conditions investigated. Currently, we 
are in the process of performing NMR experiments with Gal4 complexed to 
Med15(Gal11). 
D.2 Solid state characterization 
 The identification of three binding sites on Med15(Gal11) for VP2 raises the 
question if these binding sites are structurally similar and whether VP2 uses a similar 
interaction to target these sites. Further, the exact function of Med15(Gal11) is unknown 
and it has long poly-glutamine stretches suggesting it might have unique structural 
features compared to other coactivators. To get further insight into Med15(Gal11)-
activator interactions, in collaboration with the LSI protein crystallography facility and 
the Matzger group we are investigating the use of polymer-induced crystals to crystallize 
Med15(Gal11)(1-357) in complex with VP2 and other TADs. Currently, we are in the 
process of optimizing screening conditions to grow larger, diffractable crystals of 
Med15(Gal11)(1-357) complexed to VP2.   
D.3 Kinetics 
We have found three factors that contribute to the high levels of natural activator 
function: targeting specific binding sites, recruiting multiple transcriptional machinery 
proteins and incorporation of masking lead to increased activity levels. However, other 
factors may also contribute to function. For example, the kinetics of formation and 
dissociation of TAD-coactivator complexes are likely to be significant contributors to 
transcriptional output. 11-15. Since initiation of transcription includes a series of coupled 
binding events including a number of activator-target interactions that result in PIC 
formation and transcription, the rates of association and dissociation could potentially 
control activator function. FRET studies can be used to probe these association and 
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dissociation kinetics. Using the Med15(Gal11) binding sites for VP2, Gcn4 and Gal4 
TADs determined in Chapter 4, we can site specifically incorporate one FRET pair in 
close proximity to the activator binding site(s) on Med15(Gal11) and another in the TAD 
to measure the kinetics. These studies can be performed in vitro or in cells using 
unnatural amino acid incorporation or by labeling Med15(Gal11) with a fluorophore. 
D.4 Long term goal of developing therapeutic small molecule ATFs 
 In the efforts described here we have primarily focused on developing design 
principles to create synthetic transcriptional activators that upregulate gene expression. 
We have found that targeting a single protein in the transcriptional machinery, in absence 
of any other interactions, does not yield high levels of activity. On the other hand, 
multiple interactions with the transcriptional machinery and at transcriptionally relevant 
binding sites yields high levels of activation. Further, incorporation of a masking 
interaction that shields the TAD from aggregation and/or premature degradation can have 
a profound impact on transcriptional output.  
Thus, in the future the molecules that display a promiscuous binding profile in the 
transcriptional machinery, but also incorporate a masking interaction that controls the 
promiscuity to target particular privileged binding sites on coactivators will lead to 
molecules with greatly enhanced function. For instance, one might consider performing a 
small molecule screen to identify molecules that disrupt an endogenous activator-
coactivator interaction thereby targeting the same binding site as the endogenous 
activator. Another approach could involve the design of molecules to display functional 
groups important for endogenous activator function on an effective scaffold. 
Subsequently, fusion of the prospective TAD via a flexible linker to an appropriate DBD 
that also incorporates a masking feature should result in molecules that rival the cell-
based activity of natural activators. Such molecules will be of great benefit for 
biomanufacturing fermentations where, for instance, the expression of an enzyme needs 
to be increased to a desired level to increase product yields.   
 However, in order for activator ATFs to be therapeutically useful, several other 
criteria need to be fulfilled. For example, activator ATFs will need to integrate with 
cellular signals and respond to a number of physiological cues for temporal control of 
their function. Not only would they have to respond to external stimuli, but also traffic to 
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the nucleus and once they have finished activating there needs to be a mechanism to turn 
them off. Further complicating matters, when administered in humans, there are also non-
functional considerations such as toxicity and immunogenicity that will have to be 
addressed. There has been some recent progress on these front, for example, small 
molecule responsive activators have been developed and peptidic sequences 
corresponding to nuclear localization signals have also been identified.16-18  
Despite all the challenges to develop a therapeutically useful activator ATF, a 
biopolymer-based activator ATFs is currently undergoing clinical trials for the treatment 
of diabetic neuropathy (Sangamo Biosciences). Thus, the first generation of transcription-
based therapeutics are at the horizon and the tools described here will assist in fulfilling 
the biggest limitations of small molecule activator ATFs, robust cellular activity, 
generating a new class of therapeutics that will be proteolytically more stable, less 
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